A Multicenter, Randomized, Double -Blind, Placebo- Controlled Phase  3 Study 
of Rucaparib as Switch Maintenance Following Platinum -Based 
Chemotherapy in Patients with Platinum -Sensitive,  High -Grade  Serous or 
Endometrioid Epithelial  Ovarian, Primary Peritoneal or 
Fallopian Tube  Cancer 
Protocol Number:  CO-338-014 
Investigational Product: Rucaparib (CO -338) 
Eudra CT Number :  
IND Number:   
Development Phase:  Phase  3 
Indication s Studied:  Platinum- sensitive, high-grade serous and endometrioid 
epithelial ovarian, primary peritoneal , and fallopian tube 
cancer  
Sponsor Name and Address:  Clovis Oncology, Inc. 
 
 
  
Responsible Medical Officer:    
Compliance Statement:  This study will be conducted in accordance with the ethical 
principles that have their origin in the Declaration of 
Helsinki, clinical research guidelines established by the 
Code of Federal Regulations (Title 21, CFR Parts 50, 56, and 312), and International Council for Harmonization (ICH) Good Clinical Practice  (GCP ) Guidelines ICH 
E6(R2). Essential study documents will be archived in accordance with applicable regulations.  
Protocol D ate: 
  
 
  
  
  
Amendment 5 Date:  06 July 2020 
CONFIDENTIALITY STATEMENT  
The information in this document contains commercial information and trade secrets that are privileged or 
confidential and may not be disclosed unless such disclosure is required by applicable laws and regulations. In any 
event, persons to whom the information is disclosed must be informed that the information is privileged or 
confidential and may not  be further disclosed by them. These restrictions on disclosure will apply equally to all 
future information supplied to you which is indicated as privileged or confidential.  

Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  2 
 Coordinating Investigators for the Study  
Coordinating Investigator for North America : 
 
 
 
  
Coordinating Investigator for Europe, Middle East , and Asia Pacific : 
 
 
 
 
 
 
 
 
 
 

CloYil ODcoloaY, Inc. 
Oral rucapml, (co-338) 
Protocol ApproVII Signature Page Cliaical l'lotocol C0-33S,,Ol4 
06July2020 
Protocol: 
Title: C0-338-014 
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 
Study of Rw:apanb as Switch Maintenance Following Platinum-Based 
Chemotherapy in Patients with Platinum-Sensitive. High-Glade Serous or 
Endometrioid Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube 
Cancer · 
Date: 06July2020 
Amendment: s 
Amendmmt S 3 

Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  4 
 Protocol Acceptance Form  
Protocol:  CO-338-014 
Title:  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Phase  3 
Study of Rucaparib as Switch Maintenance Following Platinum -Based 
Chemotherapy in Patients w ith Platinum- Sensitive,  High -Grade  Serous or 
Endometrioid Epithelial Ovarian, Primary Per itoneal or Fallopian Tube 
Cancer  
Date : 06 July 2020  
Amendment:  5 
 
 
I have carefully read this protocol and agree that it contains all of the necessary information 
required to conduct this study. I agree to conduct this study as described and according t o the 
Declaration of Helsinki, ICH Guidelines for GCP, and all applicable regulatory requirements.  
  
   
Investigator’s Signature   Date  
dd Month yyyy 
  
   
Name (printed)    
   
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  5 
 TABLE OF CONTENTS 
Description  Page 
Table  of Contents  ......................................................................................................................... 5  
List of Tables  .............................................................................................................................. 10  
List of Figures  ............................................................................................................................. 10  
1 SYNOPSIS  ............................................................................................................................ 11  
2 LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS  .................................. 22  
3 INTRODUCTION ................................................................................................................ 26  
3.1 Ovarian Cancer  ............................................................................................................ 26  
3.1.1  General Overview  ................................................................................................... 26  
3.1.2  Treatment of Ovarian Cancer  ................................................................................. 26  
3.1.3  Homologous Recombination Deficiency ................................................................ 27  
3.1.4  Role of HRD in Ovarian Cancer  ............................................................................. 28  
3.2 PARP Inhibitors  ........................................................................................................... 29  
3.3 Rucaparib  ..................................................................................................................... 30  
3.3.1  Nonclinical Experience  ........................................................................................... 30  
3.3.1.1  Rucaparib Absorption, Distribution, Metabolism, and Excretion ............... 30  
3.3.1.2  Multiple -Dose Toxicity Studies  .................................................................. 32  
3.3.1.3  Additional Observations  .............................................................................. 33  
3.3.2  Clinical Experience  ................................................................................................. 34  
3.3.2.1  Rucaparib Monotherapy .............................................................................. 34  
3.3.2.1.1  Study CO-338-010 ......................................................................... 34  
3.3.2.1.2  Study CO-338-017 ......................................................................... 36  
3.3.2.1.3  Study A4991002, A4991005, and A4991014 ................................ 37  
3.3.2.1.4  Safety: Events of Special Interest  .................................................. 37  
3.4 Rationale for Study  ...................................................................................................... 37  
4 STUDY OBJECTIVES  ........................................................................................................ 39  
4.1 Objectives and Endpoints ............................................................................................ 39  
5 STUDY DESIGN .................................................................................................................. 41  
5.1 Overall Study Design and Plan .................................................................................... 41  
5.1.1  Screening Phase  ...................................................................................................... 41  
5.1.2  Randomization ........................................................................................................ 43  
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  6 
 5.1.3  Double-B lind Treatment Phase ............................................................................... 43  
5.1.4  Treatment Discontinuation ..................................................................................... 44  
5.1.5  Follow-Up Phase .................................................................................................... 44  
5.2 Study Schema .............................................................................................................. 44  
5.3 End of Study ................................................................................................................ 46  
5.4 Discussion of Study Design ......................................................................................... 46  
6 STUDY POPULATION ...................................................................................................... 47  
6.1 Number of Patients and Sites ....................................................................................... 47  
6.2 Inclusion Criteria  ......................................................................................................... 47  
6.3 Exclusion Criteria  ........................................................................................................ 49  
6.4 Patients or Partners of Patients of Reproductive Potential  .......................................... 50  
6.5 Waivers of Inclusion/Exclusion Criteria  ..................................................................... 51  
7 DESCRIPTION OF STUDY TREATMENTS AND DOSE MODIFICATIONS  .......... 52  
7.1 Description of Investigational Product ........................................................................ 52  
7.2 Method of Assigning Patients to Treatment Groups ................................................... 52  
7.3 Preparation and Administration of Protocol- Specified Treatment  .............................. 53  
7.3.1  Dietary Restrictions  ................................................................................................ 53  
7.4 Starting Dose and Dose Modifications of Protocol- Specified Treatment  ................... 53  
7.4.1  Starting Dose .......................................................................................................... 53  
7.4.2  Dose Modification Criteria  ..................................................................................... 54  
7.4.3  Criteria for Re -Treatment  ....................................................................................... 55  
7.5 Accountability of Protocol- Specified Treatment  ......................................................... 56  
7.6 Blinding/Masking of Treatment .................................................................................. 56  
7.7 Treatment Compliance  ................................................................................................ 56  
8 PRIOR AND CONCOMITANT THERAPIES ................................................................. 57  
8.1 Anticancer or Experimental Therapy  .......................................................................... 57  
8.2 Hematopoietic Growth Factors and Blood Products ................................................... 57  
8.3 CYP450 Isoenzyme Inhibitors, Inducers, and Substrates ............................................ 57  
8.4 Bisphosphonates .......................................................................................................... 57  
8.5 Anticoagulants ............................................................................................................. 58  
8.6 Other Concomitant Medications .................................................................................. 58  
8.7 General Restrictions  .................................................................................................... 58  
9 STUDY PROCEDURES  ..................................................................................................... 59  
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  7 
 9.1 Schedule of Assessments  ............................................................................................. 59  
9.2 Screening Phase  ........................................................................................................... 62  
9.3 Treatment Phase  .......................................................................................................... 63  
9.3.1  Day 1 of Cycles 1 and 2 .......................................................................................... 63  
9.3.2  Day 15 of Cycles 1 and 2 ........................................................................................ 64  
9.3.3  Cycles 3 and Beyond .............................................................................................. 64  
9.4 Post-Treatment Phase  .................................................................................................. 65  
9.4.1  Treatment Discontinuation ..................................................................................... 65  
9.4.2  28-day Follow-up .................................................................................................... 66  
9.4.3  Long- term Follow -up .............................................................................................. 66  
9.5 Methods of Data Collection ......................................................................................... 67  
9.5.1  Pharmacokinetic Evaluations and AAG Measurement  .......................................... 67  
9.5.2  Biomarker Analysis – FFPE Tumor Tissue  ............................................................ 67  
9.5.3  Biomarker Analysis – Blood................................................................................... 67  
9.5.4  Safety Evaluations .................................................................................................. 67  
9.5.4.1  Adverse Event Assessment  ......................................................................... 67  
9.5.4.2  Prior and concomitant medications ............................................................. 67  
9.5.4.3  Clinical Laboratory Investigations  .............................................................. 68  
9.5.4.4  Vital Signs  ................................................................................................... 68  
9.5.4.5  12-Lead Electrocardiograms  ....................................................................... 68  
9.5.4.6  Body Weight and Height ............................................................................. 68  
9.5.4.7  Physical Examinations  ................................................................................ 68  
9.5.4.8  ECOG Performance Status  .......................................................................... 68  
9.5.5  Efficacy Evaluations  ............................................................................................... 69  
9.5.5.1  Disease Assessments  ................................................................................... 69  
9.5.5.2  Tumor Markers ............................................................................................ 69  
9.5.6  Patient -Reported Outcomes  .................................................................................... 69  
9.5.7  Appropriateness of Measurements  .......................................................................... 70  
10 ADVERSE EVENT MANAGEMENT  .............................................................................. 71  
10.1  Definition of an Adverse Event ................................................................................... 71  
10.2  Definition of a Serious Adverse Event ........................................................................ 71  
10.3  Definition of an Adverse Event of Special Interest ..................................................... 71  
10.4  Exceptions to Serious Adverse Event Reporting ......................................................... 72  
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  8 
 10.5  Clinical Laboratory Assessments and Other Abnormal Assessments as Adverse 
Events and Serious Adverse Events  ............................................................................ 72  
10.6  Pregnancy or Drug Exposure during Pregnancy ......................................................... 73  
10.7  Recording of Adverse Events, Serious Adverse Events, and Adverse Events of Special Interest  ............................................................................................................ 73
 
10.7.1  Intensity of Adverse Events .................................................................................... 74  
10.7.2  Causal Relationship of Adverse Events to Study Drug .......................................... 74  
10.7.3  Outcome .................................................................................................................. 75  
10.7.4  Follow-up of Adverse Events, Serious Adverse Events, and Adverse Events of Special Interest  ....................................................................................... 75
 
10.8  Regulatory Aspects of Adverse Event Reporting ........................................................ 75  
10.9  Independent Data Monitoring Committee ................................................................... 76  
11 STATISTICAL METHODS  ............................................................................................... 77  
11.1  Analysis Populations ................................................................................................... 77  
11.2  Statistical Methods  ...................................................................................................... 77  
11.2.1  General Considerations  ........................................................................................... 77  
11.2.2  Patient Disposition  .................................................................................................. 78  
11.2.3  Baseline Characteristics  .......................................................................................... 78  
11.2.4  Efficacy Analyses  ................................................................................................... 78  
11.2.4.1  Primary Efficacy Analysis  .......................................................................... 78  
11.2.4.2  Secondary Efficacy Analyses  ...................................................................... 79  
11.2.5  Safety Analyses ....................................................................................................... 79  
11.2.5.1  Adverse Events ............................................................................................ 80  
11.2.5.2  Clinical Laboratory Evaluations  ................................................................. 80  
11.2.5.3  Vital Sign Measurements  ............................................................................ 81  
11.2.6  Population PK Analysis  .......................................................................................... 81  
11.2.7  Exploratory Analyses  .............................................................................................. 81  
11.2.7.1  Change from Baseline in CA -125 ............................................................... 82  
11.2.7.2  Progression Free Survival 2 (PFS2) ............................................................ 82  
11.2.7.3  Overall Response Rate  ................................................................................ 82  
11.2.7.4  Duration of Response  .................................................................................. 82  
11.2.7.5  Patient Reported Outcome EQ -5D .............................................................. 82  
11.2.7.6  Relationship between Rucaparib Exposure and Efficacy and Safety  ......... 83  
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  9 
 11.3  Interim Analysis  .......................................................................................................... 83  
11.4  Sample Size Considerations ........................................................................................ 83  
12 PATIENT DISPOSITION................................................................................................... 85  
12.1  Remov al of patients from therapy or assessment  ........................................................ 85  
12.2  Procedures for discontinuation  .................................................................................... 85  
13 STUDY ADMINISTRATION............................................................................................. 86  
13.1  Regulatory and Ethical Considerations  ....................................................................... 86  
13.2  Regulatory Authority Approvals  ................................................................................. 86  
13.2.1  Institutional Review Board or Independent Ethics Committee Approval .............. 87  
13.3  Patient Information and Informed Consent ................................................................. 87  
13.3.1  General Aspects of Informed Consent  .................................................................... 87  
13.3.2  Informed Consent Process ...................................................................................... 88  
13.3.3  Additional Informed Consent Documentation ........................................................ 88  
13.4  Patient Confidentiality  ................................................................................................. 88  
13.5  Study Monitoring ......................................................................................................... 88  
13.6  Case Report Form  ........................................................................................................ 89  
13.7  Study Termination and Site Closure ............................................................................ 90  
13.8  Study Protocol Amendments ....................................................................................... 91  
13.9  Retention of Study Documents .................................................................................... 91  
13.10  Quality Control and Assurance.................................................................................... 92  
13.10.1  Protocol Deviations................................................................................................. 92  
13.10.2  Study Site Training  ................................................................................................. 92  
13.10.3  Quality Assurance Audits and Inspections ............................................................. 92  
13.10.4  Direct Access to Source Data/Documents for Audits and Inspections  ................... 92  
13.11  Clinical Study Report  .................................................................................................. 93  
13.12  Study Publication and Disclosure Policy..................................................................... 93  
13.13  Investigator Oversight  ................................................................................................. 93  
14 REFERENCES  ..................................................................................................................... 94  
15 APPENDICES  ...................................................................................................................... 99  
15.1  Appendix A................................................................................................................ 100  
15.2  Appendix B ................................................................................................................ 101  
15.3  Appendix C ................................................................................................................ 105  
15.4  Appendix D................................................................................................................ 106  
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  10 
 15.5  Appendix E ................................................................................................................ 108  
15.6  Appendix F ................................................................................................................ 113  
 
LIST OF TABLES  
Description  Page 
Table  1. Primary, Secondary, and Exploratory Objectives and Endpoints ........................ 39  
Table 2.  Dose Reduction Steps .......................................................................................... 55  
Table  3. Schedule of Assessments After Implementation of Amendment 5  ..................... 60  
Table  4. Estimated Sample Sizes and Power Calculations  ................................................ 84  
 
LIST OF FIGURES  
Description  Page 
Figure 1  Best Response in Target Lesions – Phase 2 Portion of Study 
CO-338-010 ......................................................................................................... 36  
Figure 2  Study Schema....................................................................................................... 45  
 
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  11 
 1 SYNOPSIS  
Protocol Number  CO-338-014 
Title  A Multicenter, Randomized, Double -Blind, Placebo -Controlled Phase  3 Study of 
Rucaparib as Switch Maintenance Following Platinum -Based Chemotherapy in 
Patients wi th Platinum -Sensitive, High -Grade Serous or Endometrioid Epithelial 
Ovarian, Primary Peritoneal, or Fallopian Tube Cancer 
Study Phase  Phase  3 
Introduction  
 Rucaparib is an orally available, small molecule inhibitor of poly (adenosine 
diphosphate [ADP] -ribose) polymerase (PARP) -1, PARP-2, and PARP-3 and is  
being developed for treatment of ovarian cancer associated with homologous 
recombination deoxyribonucleic acid (DNA) repair deficiency. The safety and 
efficacy of rucaparib has been evaluated in several Phase 1 , Phase 2 , and Phase 3 
studies.  Rucaparib (Ru braca®) is approved in the United States (US) as 
monotherapy treatment for adult patients with deleterious breast cancer gene 
(BRCA) mutation (germline and/or somatic) -associated epithelial ovarian (EOC), 
fallopian tube (FTC), or primary peritoneal (PPC) c ancer who have been treated 
with 2 or more prior chemotherapies, and for the maintenance treatment of adult 
patients with recurrent EOC, FTC, or PPC who have a complete or partial 
response to platinum -based chemotherapy.1 Rucaparib is also approved in the 
European Union (EU) as monotherapy treatment of  adult patients with platinum -
sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade EOC, FTC, or PPC who have been treated with 2 or more prior lines 
of platinum -based chemotherapy, and who are unable to tolerate further pl atinum -
based chemotherapy, and for maintenance treatment of adult patients with 
platinum -sensitive recurrent EOC, FTC, or PPC who are in response (complete or 
partial) to platinum -based chemotherapy.
2 
Normal  cells repair single-strand breaks (SSBs) in DNA primarily through base 
excision repair (BER). While there are several variations of BER, all pathways rely on PARP enzymes, of which PARP -1 is the best characterized . SSBs that are 
not repaired result in stalled replication forks and the development of double -
strand breaks (DSBs), which are in turn primarily repaired  by homologous 
recombination DNA repair, a complex process involving multiple proteins, including those encoded by breast cancer gene 1 and 2 ( BRCA1  and BRCA2 ), as 
well as many others.  
Homologous recombination pathway defects, either as an initiating event or late 
event in the carcinogenetic process, may be responsible for the genetic instabi lity 
observed in many cancers. An analysis of the Cancer Genome Atlas (TCGA), 
which examined molecular changes in high -grade serous ovarian cancer 
(HGSOC), estimated that approximately 50% of patients with HGSOC have 
homologous recombination deficiency (HRD) .
3 Drivers of HRD include:  
1. Germline mutations in the BRCA1 and BRCA2 genes ( gBRCA ). The se are 
the strongest known hereditary factors for EOC, accounting for up to 15% of all EOC.
4, 5 These patients carry heterozygous deleterious mutations in their 
germline DNA and develop tumors when the remaining wild-type functi onal 
allele is inactivated (i.e. “second hit”).  
2. Somatic BRCA1/2 mutations ( sBRCA ) (6 – 8% of HGSOC patients)3, 6 
3. Mutation in a homologous recombination gene other than BRCA1/2 
(approximately 16% of HGSOC patients).3 Nonclini cal studies by several 
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  12 
 groups have identified RAD proteins (eg , RAD51, RAD51C, RAD52, 
RAD54L) ,7-10 Fanconi Anemia proteins (eg , FANCA, FANCC, FANCD2 ),11-
13 and many others (eg , ATM, ATR, CHEK1, CHEK2)14-17 as being involved 
in homologous recombination. 
4. Functional s ilencing of homologous recombination genes, such as through 
BRCA1 promoter methylation (approximately 10% of HGSOC patients )3 or 
other mechanism s 
Inhibition of DNA damage repair in cancer cells, which are intrinsically 
genetically unstable, represents an attractive opportunity for the  development of 
new therapies. Given the overlap in various DNA repair pathways, inhibition of a single pathway is unlikely to have a significant effect, whereas i nhibition of 
multiple DNA repair pathways may lead to cell death, a concept known as 
synthetic lethality. Normal cells, with  only one DNA  repair pathway affected  by 
inhibition of PARP, still have an intact DNA repair pathway that can compensate, whereas cancer cells with pre-existing HRD that are treated with a PARP inhibitor develop critically DNA repair deficiency and enter apoptosis. This concept of synthetic lethality has been demonstrated in landmark in  vitro and 
in vivo studies
18, 19 as well as in several clinical trials that evaluated a single agent 
PARP inhibitor for the treatment of relapsed ovarian cance r and metastatic breast 
cancer with or without an associated germline BRCA mutation.20-26 In vitro 
studies have also shown that cells deficient in or depleted of homologous recombination proteins other than BRCA1/2 have been associated with PARP inhibitor sensitivity.
27-30 It is possible that the 24 % overall response rate (ORR ) 
observed in olaparib-treated ovarian cancer patients without evidence of a gBRCA1/2 mutation
23 was due to HRD driven by a sBRCA1/2 mutation or by an 
alteration in another key homologous recombination gene.  
Clinical activity in HGSOC has also been observed with switch maintenance PARP inhibitor therapy following response to platinum -based chemotherapy. 
Patients with platinum -sensitive relapsed ovarian cancer who achieved a response 
to another regimen of platinum -based chemotherapy followed by olaparib as 
switch maintenance treatment experienced a statistically significant improvement in median progression -free survival ( PFS) (8.3 months) compared to patients who 
received placebo as maintenance therapy (4.8 months); hazard ratio (HR) of 0.35 (95% confidence interval [CI], 0.25 – 0.49).
31 Patients with a BRCA mutation 
derived the most benefit (median PFS 11.2 vs 4.3 months; HR=0.18; 95% CI 0.11- 0.31; P<0.00001).
32 It should be noted that the outcomes of sBRCA 
+ gBRCA mutant patients were the same as gBRCA mutant patients alone, 
suggesting that, for strat ification and analysis purposes in the present study, it is 
appropriate to not differentiate between germline and somatic mutations. Patients without a BRCA mutation also experienced significant benefit from treatment 
with olaparib (HR=0.53; 95% CI 0.33-0.84; P=0.007), suggesting that patients 
with DNA repair defects in genes other than BRCA are likely contributing to the 
overall PFS result.
32  
The purpose of this study is to evaluate PFS of patients with platinum -sensitive, 
relapsed high -grade EOC , FTC , or PPC  who receive rucaparib or placebo as 
switch maintenance therapy following a response to platinum -based 
chemotherapy. Prior to final analysis, patients will be placed into molecularly defined subgroups of HRD based on the Final Clinical Trial Assay (FCTA). I t is 
anticipated that rucaparib will provide therapeutic benefit and increase PFS in patients with HRD.  
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  13 
 Study Overview   This is a randomized, international, double -blind, placebo -controlled Phase  3 
study evaluating rucaparib maintenance therapy in advanc ed ovarian cancer. The 
primary endpoint is PFS by Response Evaluation Criteria in Solid Tumors 
(RECIST) version ( v)1.133 as assessed by the investigator. Risk/benefit will be 
assessed regularly by an Independent Data Monitoring Committee (IDMC) that 
will have access to unblinded datasets.  
This study will enroll patients with platinum -sensitive, high -grade serous or 
endometrioid epithelial ovarian, primary peritoneal, or FTC who achieved either a 
complete response (CR) by RECIST v1.1 or a partial response (PR), defined as 
either a RECIST v1.1 PR or a cancer antigen 125 (CA-125) response by 
Gynecologic Cancer Intergroup (GCIG) criteria,34 to their last platinum -based 
regimen. All responses will require CA-125 that is within the  
upper limit of normal (ULN). During the screening phase, each patient will have 
archival tumor tissue analyzed for mutations in homologous recombination pathway genes. Genes of interest will be sequenced using Foundation Medicine’s 
next generation sequencing (NGS) test, which examines a panel of cancer -related 
genes, including BRCA 1/2 and other homologous recombination pathway genes. 
Patients will be stratified into one of three HRD subgroups ( BRCA1/2 mutation in 
tumor tissue [ tBRCA ], HRD due to mutation in a homologous recombination 
gene other than BRCA1/2 [nonBRCA HRD (nbHRD)], or biomarker negative) 
for randomization based on the results obtained with Foundation Medicine’s 
Initial Clinical Trial Assay (ICTA) ( Appendix A ). Enrol lment of patients known a 
priori  to harbor a gBRCA  mutation classified as deleterious (pathogenic), 
suspected deleterious, or equivalent, on the most recent assessment, will be limited to 150. Enrollment of patients with a BRCA gene mutation detected in 
tumor tissue (tBRCA), including those known to harbor a gBRCA mutation, will 
be limited to 200. Once this cap is reached, newly screened patients identified as having a BRCA mutation in tumor tissue will be offered treatment in another 
study.  
The complete results of the Foundation Medicine NGS test, which examines 
exons of 287 genes as well as introns of 19 genes, will be provided to all patients 
who opt to receive this information and provide appropriate consent. Tumor tissue results for the BRCA genes will be provided to patients who consent to receive 
this information upon availability. Results for the remainder of the gene panel will be provided to consenting patients upon study treatment discontinuation. Results are to be disclosed to consenting patients by the study physician as part of an overall clinical discussion. In the event a mutation associated with hereditary 
cancer or other syndrome is detected in tumor tissue, the patient will be referred 
by the investigator for genetic counseling and potential germline testing per institutional guidelines. If the patient chooses to have germline BRCA testing, this 
result will be entered into the clinical trial database.  
Mutations detected in tumor tissue may be somatic or germline; however, the 
NGS test will not distinguish between the two. A blood sample will therefore be 
collected for all patients and stored. Prior to final efficacy analysis, genomic DNA may be subjected to exploratory analysis in order to determine whether any mutation identified is of germline or somatic origin.  
Tumor DNA will also be assessed by the NGS test to detect the presence of 
genomic scars.
35-38 Analysis of specific genomic scarring patterns may identify 
tumors with HRD regardless of the underlying mechanism(s). The extent of 
genomic scarring and its utility in predicting clinical outcome with rucaparib will 
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  14 
 be assessed in a Phase  2 study (CO -338-017) that will be initiated in parallel with 
this Phase 3 study, but will be completed earlier. The insights from study 
CO-338-017 will be applied prospectively to the analysis of this Phase  3 study.  
The FCTA analysis plan (gene mutation and/or genomic scarring) and 
classification of HRD subgroups will be finalized and locked down prior to the 
completion of the Phase  3 study and applied prospectively to the primary efficacy 
analysis. The s ponsor will remain blinde d to all tumor tissue and germline test 
results until the primary efficacy analysis is conducted.  
Number of 
Patients  Approximately 5 40 patients  will be enrolled . A minimum of 18 0 and a maximum 
of 200 patients with a deleterious t BRCA  mutation will be enroll ed. Enrollment of 
patients with a known deleterious  gBRCA  mutation documented in their medical 
record will not exceed 150.  There is no minimum number of patients required for 
each of the nbHRD and biomarker negative subgroups ; however, no more than 
360 total patients will be randomized for stratification into these subgroups 
combined.  
Number of Sites  This is a multicenter, multinational study. Patients will be enrolled from 
approximately 90 – 100 study sites.  
Study Duration  Q4 2013 – Q2 2022 (estimated last patient, last visit [ LPLV ]) 
Study Objectives  The primary objective of this study is:  
• To evaluate PFS  by RECIST , as assessed by the investigator, in 
molecularly -defined HRD subgroups  
The secondary objectives of this study are:  
• To evaluate patient -reported outcome (PRO) of disease-related symptoms 
utilizing the disease -related symptoms –  physic al (DRS –P) subscale of 
the National Comprehensive Cancer Network -Functional Assessment of 
Cancer Therapy (NCCN -FACT) FACT -Ovarian Symptom Index 18 
(FOSI -18)  
• To evaluate PRO utilizing the complete FOSI -18 
• To evaluate survival benefit  
• To evaluate PFS by RECIST , as assessed by independent radiology 
review (IRR), in molecula rly-defined HRD subgroups   
• To evaluate safety  
• To determine the population pharmacokinetics (PK) of rucaparib 
The exploratory objectives of this study are:  
• To evaluate the relationshi p between CA-125 levels and disease 
progression as assessed by investigator ( invPFS)  
• To evaluate PFS2 (PFS on the subsequent line of treatment)  
• To evaluate ORR  
• To evaluate duration of response (DOR)  
• To evaluate PRO utilizing the Euro -Quality of Life 5D (EQ -5D)  
• To explore the relationship between rucaparib exposure, efficacy, and safety  
Study Population  
  
 Inclusion Criteria  
All patients enrolling into the study must meet all of the following inclusion 
criteria:  
1. Have signed an Institutional Review Board  (IRB)/Independent Ethics 
Committee  (IEC) -approved informed consent form prior to any study -specific 
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  15 
 evaluation  
2. Be ≥18 years of age at the time the informed consent form is signed  
3. Have a histologically confirmed diagnosis of high- grade ( Grade 2 or 3) serous 
or endometrioid epithelial ovarian, fallopian tube, or primary peritoneal 
cancer  
− For mixed histology, >50% of the primary tumor must be confirmed to be 
high-grade serous or endometrioid  
− Grade 2 tumors classified under a 3 -tier system should be re-reviewed by 
local pathology and confirmed as high-grade under the 2-tier system  
4. Received prior platinum -based therapy and have platinum -sensitive disease 
(i.e. documented radiologic disease progression >6 months following the last 
dose of the penultimate platinum administered)  
− Received ≥2  prior platinum -based treatment  regimens, including platinum -
based regimen that must have been administered  immediately prior to 
maintenance therapy in this trial . In addition, up to 1 non-platinum 
chemotherapy regimen  is permitted. Prior hormonal therapy is permitted; 
this treatment will not  be counted as a non-platinum regimen.  
− There is no upper limit on the number of prior platinum -based regimens 
that may have been received, but the patient must have been sensitive to 
the penultimate platinum -based regimen administered.  
− If both neoadjuvant and adjuvant treatment were administered pre/post any 
debulking surgery, this will be considered 1 treatment regimen  
− Prior maintenance therapy following a prior treatment regimen is 
permitted, with the exception of the regimen received immediately prior to 
maintenance in this study. No anticancer therapy is permitted to be 
administered as maintenance treatment in the interval period between 
completion of the most recent platinum -based therapy and initiation of 
study drug in this trial. 
5. Achieved  best response of either  CR or PR to the most recent platinum -based 
regimen administered and is randomized to study treatment within 8 w eeks 
of the last dose of platinum received.  
− The most recent platinum -based regimen must have been a chemotherapy 
doublet . The choice of the platinum and the 2nd chemotherapy agent is per 
investigator’s discretion.  
− A minimum of 4 cycles of platinum chemotherapy must have been 
administered. There is no cap on the maximum number of cycles; however, 
additional cycles of treatment administered following completion of 
therapy for the specific purpose of enabling patient eligibility and 
randomization within 8 wee ks of the last platinum dose is not  permitted. 
− A CR is defined as a complete radiologic response per RECIST  v1.1, i.e. 
absence of any detectable disease and CA-125 <ULN. * 
− A PR is defined as either a partial response per RECIST v1.1 (if disease was measurab le prior to chemotherapy) or a serologic response per GCIG 
CA-125 response criteria (if disease was not measurable according to 
RECIST  v1.1) .* 
o CA-125 must also be <ULN for all responses classified as a PR  
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  16 
 − R0 surgery (no visible tumor) or R1 surgery (residual disease <1  cm) as a 
component of the most recent treatment regimen is not  permitted. The 
response assessment must be determined solely in relation to the 
chemotherapy regimen administered. The presence of measurable disease 
or CA -125 > 2 x ULN im mediately  prior to the chemotherapy regimen is 
required.  
− Responses must have been maintained through the completion of 
chemotherapy and during the interval period between completion of 
chemotherapy and entry in the study.  
− All disease assessments performed prior to and during this chemotherapy 
regimen must be adequately documented in the patient’s medical record  
6. Have sufficient archival formalin -fixed paraffin -embedded ( FFPE ) tumor 
tissue ( 1 x 4 µm section for hematoxylin and eosin [H&E] stain and 
approximately 8 to 12 x 10  µm sections, or equivalent ) available for planned 
analyses.  
− The most recently  collected tumor tissue should be provided, if available  
− Submission of a tumor block is preferred; if sections are provided, the se 
must all be from the same tumor sample.  
− Sample must be received at the central laboratory at least 3 weeks prior 
to start of treatment in order to enable stratification for randomization 
7. Have CA-125 measurement that is < ULN 
8. Have Eastern Cooperative Oncology Group ( ECOG) performance status of 0 
to 1 
9. Have adequate organ function confirmed by the following laboratory values obtained within 14 days of the first dose of study drug:  
− Bone Marrow Function  
o Absolute neutrophil count  (ANC ) ≥ 1.5 × 10
9/L 
o Platelets >  100 × 109/L  
o Hemoglobin ≥ 9 g/dL  
− Hepatic Function  
o Aspartate aminotransferase (AST) and alanine aminotransferase 
(ALT) ≤ 3 × ULN; if liver metastases, then ≤  5 × ULN 
o Bilirubin ≤ 1.5 × ULN (< 2 x ULN if hyperbilirubinemia is due to 
Gilbert’s synd rome)  
− Renal Function  
o Serum creatinine ≤  1.5 × ULN or estimated glomerular filtration rate 
(GFR) ≥  45 mL/min using the Cockcroft Gault formula  
* Note: It is acceptable for sites to utilize local and contemporaneous clinical 
imaging reports to record lesion measurement history and define a burden of 
disease according to RECIST; it is not a requirement to re -read radiological 
scans to collect this data.  
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  17 
 Exclusion Criteria  
Patients will be excluded from participation if any of the following criteria apply:  
1. History of a prior malignancy except:  
− Curatively treated non-melanoma skin cancer  
− Breast cancer treated curatively > 3 years ago, or other solid tumor treated 
curatively > 5 years ago, without evidence of recurrence  
− Synchronous endometrioid endometrial cancer (Stage 1A G1/G2)  
2. Prior treatment with any PARP inhibitor, including oral or intravenous 
rucaparib. Patients who previously received iniparib are eligible.  
3. Required drainage of ascites during the final 2 cycles of their last platinum -
based regimen and/or during the period between the last dose of chemotherapy of that regimen and randomization to maintenance treatment in this study  
4. Symptomatic and/or untreated central nervous system (CNS) metastases. Patients with asymptomatic previously treated CNS metastases are eligible provided they have been clinically stable for at least 4 weeks.  
5. Pre-existing duodenal stent and/or any gastrointestinal disorder or defect that would, in the opinion of the investigator, interfere with absorpt ion of study 
drug 
6. Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) -related illness, or history of chronic hepatitis B or C  
7. Pregnant or breast feeding. Women of child-bearing potential must have a negative serum pregnanc y test ≤  3 days prior to first dose of study drug. 
8. Received treatment with chemotherapy, radiation, antibody therapy or other 
immunotherapy, gene therapy, vaccine therapy, angiogenesis inhibitors, or 
experimental drugs ≤14 days prior to first dose of study drug and/or ongoing 
adverse effects from such treatment > NCI -CTCAE Grade 1, with the 
exception of Grade 2 non- hematologic toxicity such as alopecia, peripheral 
neuropathy and related effects of prior chemotherapy that are unlikely to be 
exacerbated by treatment with study drug  
− Ongoing hormonal treatment for previously treated breast cancer is permitted  
− Refer also to inclusion criteria #4 for guidelines pertaining to prior maintenance therapy  
9. Received administration of strong CYP1A2 or CYP3A4 inhibitors ≤  7 days 
prior to first dose of study drug or have on-going requirements for these medications (Appendix F ) 
10. Non-study related minor surgical procedure ≤ 5 days, or major surgical 
procedure ≤21 days, prior to first dose of study drug; in all cases, the patient must be sufficiently recovered and stable before treatment administration 
11. Presence of any other conditi on that may increase the risk associated with 
study participation or may interfere with the interpretation of study results, and, in the opinion of the investigator, would make the patient inappropriate for entry into the study  
Pregnancy is an exclusion criterion and women of child-bearing potential must 
not be considering getting pregnant during the study.  
Female p atients of reproductive potential must practice a  highly  effective method 
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  18 
 of contraception (failure rate <  1% per year) with their male partners  during 
treatm ent and for 6 months following the last study drug dose.  
 No waivers of these inclusion or exclusion criteria will be granted by the 
investigator and the s ponsor or its designee for any patient enrolled into the study.  
Study Treatment   Eligible  patients will be randomized 2:1 to receive rucaparib (600  mg twice a day  
[BID]) or placebo. Randomization will occur by a central randomization procedure using an Interactive Voice Response System/Interactive Web Response System (IVRS/IWRS). The following will be included as randomization 
stratification factors at study entry to ensure treatment groups are balanced:  
• HRD classification (tBRCA, nbHRD, or biomarker negative) by the ICTA 
(Appendi x A). 
• Interval between completion of the penultimate platinum -based regimen and 
disease progression (6 to 12 or >12 months) by radiologic assessment  
• Best response to the most recent platinu m-based regimen (CR [defined as 
complete radiologic response by RECIST or PR [defined as partial response by RECIST and/or a GCIG CA-125 response]). All responses require that CA-125 be <ULN. 
Randomization to study treatment must occur within 8 weeks following a patient’s last dose of platinum -based chemotherapy. Study drug will be taken 
orally twice  daily (12 hours  apart) with at least 8 oz (240  mL) of water. Study 
drug may be taken with an empty stomach or with food.  
Patients will take study drug twice da ily for continuous 28-day  cycles until 
disease progression by RECIST as assessed by the investigator, or other reason for discontinuation. Treatment interruptions and/or dose  reductions are permitted 
in the event of unacceptable toxicity.
 
Withdrawal 
Criteria  A patient must be discontinued from treatment with study drug if any of the 
following apply:  
• Consent withdrawal at the patient’s own request or at the request of their legally authorized representative 
• Progression of patient’s underlying disease by RECIST as assessed by the 
investigator  
• Any event, adverse or otherwise, that, in the opinion of the investigator, would pose an unacceptable safety risk to the patient 
• An intercurrent illness that, in the opinion of the investigator, would aff ect 
assessments of the clinical status to a significant degree and requires discontinuation of therapy  
• A positive pregnancy test at any time during the study 
Disease 
Assessments for 
Efficacy Efficacy measures will include clinical examination, CA-125 measurement, and 
appropriate imaging (CT scans of the chest, abdomen, and pelvis with appropriate slice thickness per RECIST); other studies (magnetic resonance imaging [MRI], X ray, positron emission tomography [PET], and ultrasound) may be perform ed if 
required. Disease assessment will be performed at screening, at the end of every 12 calendar weeks after start of treatment on Day 1 of Cycle 1, at discontinuation of treatment, and as clinically indicated  
Disease progression will be determined by RE CIST (Appendix  B). Patients with a 
CR at study entry will only be considered to have disease progression if a new 
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  19 
 lesion is identified. Patients who m eet GCIG CA -125 criteria (Appendix  C) for 
disease progression should have a radiologic assessment by RECIST. If the 
radiologic assessment does not confirm disease progression, patients should continue on treatment and be assessed  by RECIST per the protocol schedule.  
Patients who discontinued treatment for reason other than disease progression or 
death should continue to have tumor scans performed at 12 -week  intervals (up to 
1 week prior is permitted) until disease progression, as assessed by the 
investigator. 
Patients who have been on study at least 18 months may 
decrease the frequency of disease assessments to every 16 (±2) weeks. 
Investigator should consult with sponsor’s medical monitor before decreasing frequency.
   
Safety 
Assessments  Safety assessments may include adverse events (AEs), hematology, serum 
chemistry, vital signs, body weight, concomitant medications/procedures, ECOG 
performance status ( Appendix D ), and study drug modifications. As of 
implementation of Protocol Amendment  5, AEs will be monitored but only 
serious adverse events ( SAEs )/adverse events of special interest (AESIs ) will be  
recorded in the eCRF . Ongoing SAEs and AESIs will be followed until 
resolution, stabilization, or lost to follow -up. 
Statistical 
Procedures  Sample Size Justification  
The total enrollment planned is 5 40 patients. A minimum of 1 80 and a maximum 
of 200 patients with a deleterious tBRCA mutation will be enrolled. Enrollment 
of patients with a known deleterious gBRCA mutation documented in their 
medical record will not exceed 150. There is no minimum number of patients 
required for each of the nbHRD and biomarker negative subgroups; however, no 
more than 360 total patients will be randomized for stratification into these 
subgroups combined.  Prior to final efficacy analysis, HRD classification will be 
determined by the FCTA that will ev aluate homologous recombination gene 
mutations and/or extent of genomic scarring in tumor tissue.  
The table below provides estimated sample sizes and power calculations.  
Group  Hazard 
Ratio  Cumulative 
N  Minimum 
Number of 
Events 
(70%)  Median 
PFS 
Placebo vs 
Rucaparib 
(months)  Power  One-
sided 
Alpha  
tBRCA  0.50 180 126 6 vs 12  90% 0.025  
All HRD 
(tBRCA + nbHRD) 0.60 300 210 6 vs 10  90% 0.025 
ITT 
Population 
(tBRCA + 
nbHRD + 
Biomarker 
Negative)  0.70 540 378 6 vs 8.5  90% 0.025 
Analysis Populations  
Safety: The safety population will consist of all patients who received at least one 
dose of protocol -specified treatment. 
Intent -to-treat (ITT): The ITT population will consist of all randomized patients.  
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  20 
 Response  evaluable : The response eval uable  population will consist of all patients 
who have measurable or evaluable disease at study entry, received at least one 
dose of study drug, and who had at least one post -baseline disease assessment.  
General Statistical Considerations  
Quantitative variables will be summarized using descriptive statistics. For 
variables registered on a continuous scale, the following will be presented: N, 
mean, standard deviation, median, minimum and maximum. Categorical variables will be presented using  frequencies and percentages. The Kaplan -Meier 
methodology will be used to summarize time -to-event variables. The stratified 
hazard ratio from the Cox proportional hazards model will be used to estimate the HR between the randomized treatment groups.  The p rimary and key secondary 
endpoints will be tested among the  tBRCA  subgroup , all HRD subgroup, and all 
randomized patients, using an ordered step-down multiple comparisons 
procedure.  
Investigator -determined PFS (invPFS) in the tBRCA  subgroup will be tested  first 
at a one-sided 0.025 significance level. If invPFS in the tBRCA  subgroup is 
statistically significant, then  invPFS will be tested in the all HRD subgroup 
followed by invPFS in all randomized patients. Continuing in an ordered step-
down manner, the P RO of disease symptoms utilizing the DRS -P subscale of the 
FOSI -18 will be tested at the one-sided 0.025 significance level in the tBRCA , all 
HRD,  and all randomized patients subgroups and then for the remaining key 
secondary endpoints of PRO  utilizing the  FOSI -18 total score and OS. Once 
statistical significance is not achieved for one test the statistical significance will 
not be declared for all subsequent analyses in the ordered step -down procedure.  
PFS by IRR will be evaluated as a stand -alone secondar y endpoint.  
Primary Efficacy Analysis  
The primary efficacy analysis for the study is investigator -determined PFS 
(invPFS) by RECIST. Investigator -determined PFS is defined as the time 
from randomization to disease progression, according to RECIST  v1.1 
criteria as assessed by the investigator, or death due to any cause, 
whichever occurs first. The stratification factors included in the primary analysis of invPFS will be HRD  
classification ( tBRCA , nbHRD or biomarker 
negative), interval between completion of penultimate platinum regimen and 
disease progression (6 to 12 months or >12 months) by radiologic assessment, 
and best response to the most recent platinum -based regimen ( either CR [defined 
as complete radiologic response by RECIST] or PR [de fined as partial response 
by RECIST and/or a GCIG CA -125 response]).  All responses require that 
CA-125 be <ULN.  
Tumor HRD status by the FCTA will  be determined after randomization, but 
before the final efficacy analysis, so that the primary endpoint (PFS i n 
molecularly defined subgroups) can be assessed prospectively.  
Secondary Efficacy Analyses  
Secondary efficacy endpoints include:  
• PRO of disease-related symptoms as measured by the DRS -P 
subscale score of the FOSI -18 
• PRO as measured by the total score of t he FOSI -18 
• Overall survival ( OS) 
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  21 
 • PFS by  RECIST  v1.1 as assessed by IRR  
The time to an event in PRO  of worsening of disease symptoms will be defined as 
the time from randomization to a 4- point reduction in the FOSI -18 DRS−P 
subscale score. Similarly, an eve nt in worsening of PRO utilizing the  FOSI -18 
total score will be defined as the time from randomization to an 8- point reduction 
in the total score.  
OS, time to death from any cause, is defined as the number of days from the date 
of randomization to the dat e of death (due to any cause). Patients without a 
known date of death will be censored on the date the patient was last known to be 
alive.  
PFS for secondary efficacy analysis is defined as the time from randomization to disease progression, according to RE CIST v1.1 criteria as assessed  by IRR, or 
death due to any cause, whichever occurs first.   
Safety Analysis  
Data from all patients who receive at least one dose of study drug will be included 
in the safety analyses. AEs, clinical laboratory information, vital signs, ECOG 
performance status, body weight, and concomitant medications /procedures will be 
tabulated and summarized.  
AEs will be summarized overall, with separate summaries for S AEs, AEs leading 
to treatment discontinuation or death, an d CTCAE Grade 3 or higher AEs.  
Independent Data Monitoring Committee (IDMC)  
No formal efficacy interim analyses for early stopping are planned.  
An IDMC  will meet regularly to review the efficacy and safety data from this 
study. The IDMC will: 
• Review efficacy and safety of rucaparib compared to placebo to ensure 
the study is beneficial to patients;   
• Ensure the study is conducted in a high quality manner; and  
• Monitor the size of the tBRCA subgroup and known gBRCA  subgroup  
 
The IDMC will hold meetings an d continue to review data until the protocol -
specified primary endpoint collection is complete (i .e., 70% of the patients in the 
tBRCA subgroup have an event of PFS) and the IDMC recommend the sponsor to 
unblind the treatment assignments for assessment of primary efficacy. The 
treatment assignment was unblinded in June 2017 for the primary efficacy 
analysis and thus no further IDMC meetings are planned.  
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  22 
 2 LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS  
AAG  alpha -1 acid glycoprotein  
ADP  adenosine diphosphate  
AE adverse event  
AESI  adverse event of special interest  
AIDS  acquired immunodeficiency syndrome  
ALCOA+  attributable, legible, contemporaneous, original, and accurate  
ALP  alkaline phosphatase  
ALT  alanine aminotransferase  
AML  acute myeloid leukemia  
ANC  absolute neutrophil count  
AST  aspartate aminotransferase  
AUC  area under the plasma concentration curve  
AUCR  ratio of the area under the curve  
BCRP  breast cancer resistance protein  
BER  base excision repair  
BID twice a day  
BRCA  breast cancer gene 
BRCA1  breast cancer gene 1  
BRCA2  breast cancer gene 2  
BUN  blood urea nitrogen  
CA-125 cancer antigen 125  
CFR  Code of Federal Regulations  
CI confidence interval  
Cmax maximum concentration  
CNS  central nervous system  
CR complete response  
CRO  contract research organization  
CSR  clinical study report  
CT computed tomography  
CTCAE  Common Terminology Criteria for Adverse Events (version 4.0 3) 
CYP  cytochrome P450  
DDI drug-drug interaction  
DLT  dose-limiting toxicity  
DNA  deoxyribonucleic acid  
DOR  duration of response  
DSB  double -strand break  
DRS−P disease-related symptoms −physical  
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  23 
 ECG  electrocardiogram  
ECOG  Eastern Cooperative Oncology Group  
eCRF  electronic case report form  
EDC  electronic data capture  
EMA  European Medicines Agency  
EOC  epithelial ovarian cancer  
EQ-5D Euro -Quality of Life 5D 
EU European Union  
FCTA  Final Clinical Trial Assay  
FDA  Food and Drug Administration  
FFPE formalin -fixed paraffin -embedded  
FOSI -18 FACT -Ovarian Symptom Index 18  
FSH follicle -stimulating hormone  
FTC fallopian tube cancer  
GALT  gut-associated lymphoid tissue  
gBRCA  germline BRCA  
gBRCAmut deleterious germline BRCA mutation  
BRCAwt wild-type BRCA  
GCIG  Gynecologic Cancer InterGroup  
GCP  Good Clinical Practice  
GDPR  General Data Protection Regulation  
GFR  glomerular filtration rate  
h Hour  
Hct Hematocrit  
HDL  high-density lipoprotein  
H&E  hematoxylin and eosin  
hERG  human ether -a-go-go-related gene 
Hgb hemoglobin  
HGSOC  high grade serous ovarian cancer  
HIPAA  Health Information Portability and Accountability Act  
HIV human immunodeficiency virus  
HNSTD  highest non -severely toxic dose  
HR hazard ratio  
HRD  homologous recombination deficiency 
IB Investigat or’s Brochure  
ICF informed consent form  
ICH International Conference on Harmonization  
ICTA  Initial Clinical Trial Assay  
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  24 
 ICxx concentration where maximum response is inhibited by XX%  
IDMC  Independent Data Monitoring Committee  
IEC Independent Ethics Committee  
INR international normalized ratio  
invPFS  disease progression according to RECIST v1.1 as assessed by the investigator, or 
death from any cause  
IRB Institutional Review Board  
IRR independent radiology review  
irrPFS disease progression according to RECIST v1.1 as assessed by independent radiology review, or death from any cause  
ITT Intent -to-treat  
IV intravenous  
IVRS/IWRS  Interactive Voice Response System/Interactive Web Response System  
LDL  low-density lipoprotein  
LOH  loss of heterozygosity  
LPLV  last patient, last visit 
MATE  multidrug and toxin extrusion transporter  
MCV  mean corpuscular volume  
MCH  mean corpuscular hemoglobin  
MCHC  mean corpuscular hemoglobin concentration  
MDS  Myelodysplastic Syndrome  
MedDRA  Medical Dictionary for Drug Regulatory Activities  
Min minute  
MRI magnetic resonance imaging  
mut mutant  
nbHRD  non-BRCA homologous recombination deficiency 
NCCN -FACT  National Comprehensive Cancer Network -Functional Assessment of Cancer  
NCI National Cancer Institute 
NGS  next generation sequencing  
NOAEL  no-observed -adverse-effect level  
OCT  organic cation transporter  
ORR  overall response rate  
OS overall su rvival  
PARP  poly (adenosine diphosphate [ADP] -ribose) polymerase  
PD progressive disease  
PET positron emission tomography  
PLD  PEGylated liposomal doxorubicin  
PFS progression -free survival  
PFS2  second event of progression-free survival  
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  25 
 P-gp P-glycoprotein  
PID poly (adenosine diphosphate [ADP] -ribose) polymerase inhibiting dose  
PIS patient information sheet  
PK pharmacokinetic(s)  
PPC primary peritoneal cancer  
PR partial response  
PRO  patient -reported outcome  
PS performance status  
QD once a day  
QoL quality of life  
RBC  red blood cell  
RECIST  Response Evaluation Criteria in Solid Tumors  
SAE  serious adverse event  
SAS statistical analysis software  
sBRCA  somatic breast cancer gene  1 or 2 mutation  
SD stable disease  
SNP single -nucleotide polymorphism  
SOC  system organ class  
SOP Standard operating procedure  
SSB single -strand break  
SUSAR  suspected unexpected serious adverse reaction  
tBRCA  tumor tissue alteration in BRCA1 or BRCA2, includes gBRCA and sBRCA  
TCGA  The Cancer Genome Atlas 
TEAE treatment -emergent adverse events  
Tmax time to maximum concentration 
UGT  uridinediphosphate -glucuronosyletransferase  
ULN  upper limit of normal  
unk unknown  
UV ultraviolet  
US United States  
v version  
VEGF  Vascular endothelial growth factor  
WBC  white blood cell  
WOCBP  women of child-bearing potential  
WT wild type  
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  26 
 3 INTRODUCTION  
3.1 Ovarian Cancer  
3.1.1 General Overview  
Ovarian cancer is the second most common gynecologic malignancy worldwide and the leading 
cause of death attributed to gynecological cancer .39, 40 After initial therapy, most women will 
have a progression -free interval of approximately 1.5 to 2 years, depending on the extent of post-
operative residual disease and response to chemotherapy .41 Relapse still occurs, however, in the 
majority of cases, and only 10− 30% of women experience long-term survival.41 Advanced stage 
disease is associat ed with a 5-year survival rate of only 30− 40%.39  
Approximately 90% of ovarian tumors are surface epithelial in origin, and the papillary serous histology subtype accounts for approximately 75%, of which the large majority (70%) is high- grade .
41 The site of or igin of epithelial ovarian cancer (EOC) remains unclear. Some studies 
suggest that serous EOC and primary peritoneal cancer (PPC) arise from the fallopian tube epithelium;
42, 43 however, other studies suggest an origin within stem cells of the ovarian surf ace 
epithelium.41, 44 EOC, PPC and fallopian tube cancer ( FTC) behave very similarly, and are 
therefore treated in the same way.  
The median age at presentation of EOC is 60 years. Many women present with advanced disease and therefore have a poor prognosis. 
3.1.2  Treatment  of Ovarian Cancer  
The standard approach to treatment of advanced ovarian cancer is cytoreductive surgery (either at time of diagnosis or interval debulking following 2 – 3 cycles of neoadjuvant chemotherapy ), 
with the goal of minimizing residual tumor to no visible residual disease, a major prognostic indicator for improved survival. Six to eight cycles of platinum- and taxane -based chemotherapy 
is the global standard of care.  If initial cytoreduction is not performed, interval de bulking surgery 
is considered. This surgery m ay be carried out after three or four cycles of primary 
chemotherapy, followed by three further cycles of chemotherapy.  Platinum analogues, such as 
carboplatin and cisplatin, are the most active agents, mediating their effects through the formation of inte r- and intra -strand cross-links with deoxyribonucleic acid (DNA).
45, 46  
The choice of treatment for relapsed disease is based on the treatment -free interval relative to last 
therapy administere d and chemotherapy agent s used.  As many patients experience multiple 
relapses, pr ognosis and response to therapy decreases as the interval between last chemotherapy 
exposure and disease relapse shortens. The treatment -free, or specifically the platinum -free 
interval, provides further prognostic information for patients, as therapeutic options lessen and survival shortens as a patient’s tumor becomes less responsive to platinum- based therapy.  
Platinum-based regimens dominate ovarian cancer therapy and de fine treatment groups.
46 In 
general, patients whose disease progresses dur ing treatment with a platinum- based regimen are 
considered to have platinum- refractory disease; patients whose disease relapses within 6 months 
after the last platinum agent was administered are considered to have platinum -resistant disease; 
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  27 
 and patients w hose disease relapses more than 6 months after the last platinum- based therapy 
was administered are considered to have platinum -sensitive disease. These classifications are 
clinical, and not based on a mechanistic definition of platinum sensitivity or resistance.  
PARP inhibitor monotherapy has elicited objective responses in patients with platinum -sensitive 
disease as well as in patients with platinum -resistant disease, although response rates are higher 
in the former population.23-25 This indicates that using platinum- sensitivity alone as a selection 
marker for PARP inhibitor the rapy is not a very effective tool, although it is a reasonable place to 
begin predictive biomarker development.  
Maintenance therapy following a response to standard treatment provides an opportunity to  
extend the disease -free period. Maintenance strategies evaluated to date for ovarian cancer have 
focused on the prolonged use of single-agent chemotherapy, antiangiogenesis agents, hormonal 
therapy, vaccines, and intraperitoneal chemotherapy. The  OCEANS study evaluated carboplatin 
and gemcitabine with or without bevacizumab as part of the initial treatment and then as maintenance in women with platinum-sensitive ovarian, primary peritoneal, or FTC  who were in 
their first relapse following primary chemothera py. The addition of bevacizumab resulted in a 
statistically sign ificant improvement in progression- free survival (PFS) (median 12.4 vs 8.4 
months; HR=0.484 [95% CI, 0.388 to 0.605; log-rank P <0.00001]).
47 The PFS benefit of 
bevacizumab administered together with chemotherapy followed by single agent bevacizumab maintenance treatment compared to chemotherapy alone and placebo maintenance was further 
established in two front- line Phase 3 studies, GOG -218 (HR=0.717 [95% CI, 0.625 to 0.824; log-
rank P <0.001])
48 and ICON-7 (HR=0.81 [95% CI, 0.70 to 0.94; log-rank P<0.04]).49 Based on 
these trials, the European Medicines Agency (EMA) approved bevacizumab , in combination 
with carboplatin and paclitaxel,  for front- line treatment of advanced (International Federation of 
Gynecology and Obstetrics [ FIGO] stages III B, III C and IV) epithelial ovarian, fallopian -tube, 
or primary peritoneal cancer, and, in combination with carboplatin and gemcitabine,  for 
treatment of first recurrence of platinum- sensitive epithelial ovarian, fallopian -tube or primary 
peritoneal cancer in women who have not received prior therapy with bevacizumab or other vascular -endothelial- growth -factor (VEGF) inhibitors  or VEGF -receptor -targeted agents.  
3.1.3 Homologous Recombination Deficiency  
DNA is constantly damaged by both endogenous and exogenous (environmental) assaults.  A 
common type of DNA damage is the formation of D NA single -strand breaks (SSBs).  During 
normal cell cycling, DNA is replicated and replication forks are eventually stalled by persistent 
SSBs. If stalled replication forks are not rapidly repaired, they can often degenerate and form DNA double- strand breaks (DSBs), which are highly likely to be lethal to the cell.  
Normal cells repair SSBs in DNA primarily through base excision repai r (BER). While there are 
several variations of BER, all pathways rely  on PARP enzymes, of which PARP1 is the best 
characterized. SSBs that are not repaired result in stalled rep lication forks and the development 
of DSBs, which are in turn primarily repaired  by homologous recombination DNA repair, a 
complex process involving multiple proteins, including those encoded by breast cancer gene 1 and 2 ( BRCA1  and BRCA2 ), among others. 
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  28 
 If either the BER or homologous recombination pathway is rendered non- functional, the 
remaining functional pathway can compensate to ensure ongoing DNA repair and cell cycling. 
For example, when the BRCA- associated homologous recombination pathway is lost or 
dysfunctional, repair shifts towards the BER repair pathway that is dependent on PARP enzymes. In contrast, in the setting in which both repair pathways (BER and homologous 
recombination) are rendered non-functional, the cell dies. This  concept, where a defect in either 
of two pathways can be withstood by a cell , but defects in both are lethal, is referred to as 
synthetic lethality. This type of lethality can arise from a variety of different interactions. In the case of DNA damage repai r, dual non-functionality can be achieved by enzymatic inhibition of 
PARP in the context of a genetic mutation in the BRCA1  or BRCA2  genes.  
Synthetic lethality has been demonstrated in landmark in vitro  and in  vivo  studies as well as in 
several clinical tr ials that evaluated a single agent PARP inhibitor for the treatment of relapsed 
ovarian cancer and metastatic breast cancer . Bryant and colleagues showed that cell lines and a 
tumor xenograft deficient in homologous recombination (via a defect in a BRCA or other 
homologous recombination gene) were highly sensitive to PARP inhibition.
18 This study also 
showed that synthetic lethality could be achieved regardless of whether the mutation was in BRCA1  or BRCA2 . In a parallel set of experiments, Farmer and colleagues illustrated that 
chemical inhibition of PARP1 was more potent in homozygous BRCA- deficient cell lines than in 
heterozygous mutant or wild -type cell l ines.
19 These finding s were also supported by a 
BRCA2 -deficient murine model. Taken together, these studies provided support for the treatment 
of patients with a BRCA- deficient tumor with a PARP inhibitor.  
3.1.4 Role of HRD in Ovarian Cancer  
Homologous recombination pathway defects, either as an initiating event or late event in the carcinogenetic process, may be responsible for the genetic instabi lity observed in many cancers. 
An analysis of the Cancer Genome Atlas (TCGA), which examined molecular changes 
associated with  high-grade serous ovarian cancer (HGSOC), estimated that approximately 50% 
of patient with HGSOC have homologous rec ombination deficiency (HRD).
3 Drivers of HRD  in 
ovarian cancer  include: 
1. Germline mutations in the BRCA1  and BRCA2  genes ( gBRCA).  These are the strongest 
known hereditary factors for EOC, accounting for up to 15% of all EOC.4, 5 These 
patients carry heterozygous deleterious mutations in their germline DNA and develop tumors when the remaining wild -type functional allele is inactivated ( i.e. “second hit”). 
2. Somatic BRCA1/2  mutations ( sBRCA) (approximately 6 – 8% of HGSOC patients)
3, 6  
3. Mutation in a homologous recombination gene other than BRCA1/2  (approximately 16% 
of HGSOC patients).3 Nonclinical studies by several groups have identified RAD 
proteins (eg , RAD51, RAD51C, RAD52, RAD54L) ,7-10 Fanconi Anemia proteins (eg , 
FANCA, FANCC, FANCD2) ,11-13 and many others (eg, ATM, ATR, CHEK1, CHEK2)14-
17 as being involved in homologous recombination. 
4. Functional silencing of homologous recombination genes, such as through BRCA1 promoter methylation (approximately 10% of HGSOC patients)
3 or other mechanisms  
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  29 
 Mutations in the BRCA genes in the tumor can be detected through next-generation sequencing 
(NGS). A possible approach to  identify  non- BRCA patients with HRD is to detect genomic scars 
within the tumor, which arise from the use of error-prone DNA repair pathways when HRR is compromised.  Through a series of experiments and data analyses, the sponsor has determined 
that a potential method for identifying patients who may be sensitive to rucaparib is to assess genomic scarring by quantifying the extent of loss of heterozygosity across the tumor genome (tumor genomic loss of heterozygosity [ LOH]). One of the main advantages of detecting tumor 
genomic LOH is that it can identify HRD tumors regardless of the underlying mechanisms, which include both known (i.e. BRCA mutations ) and unknown genomic mechanisms.
35, 38  
3.2 PARP Inhibitors  
Please refer to the current Investigator’s Brochure for comprehensive information on 
rucaparib.  
PARP inhibitors have been evaluated in the clinic for the past decade. Olaparib (AZD -2281), the 
most advanced investigational PARP inhibitor, has demonstrated compelling Phase 2 clinical activity, both in treatment and maintenance settings, in relapsed , HGSOC patients (both germline 
BRCA mutant and wild -type) and in metastatic breast cancer patients with a gBRCA mutation . 
The concept of synthetic lethality was exploited in two proof-of-concept clinical studies with olaparib in patients with BRCA- associated tumor types.  These studies evaluated the efficacy and 
safety of continuous oral dosing with olaparib in women with either relapsed ovarian cancer or advanced bre ast cancer and a gBRCA mutation.
21, 22 In these patients, who had received a 
median of three prior chemotherapy regimens, encouraging overall response rates of 33% and 41%, were observed, in gBRCA ovarian and gBRCA breast cancer, respectively. In a third study, 
olaparib treatment was associated with a greater overall response rate (ORR) in patients with gBRCA- associated ovarian cancer compared w ith the patients in the non- gBRCA associated 
cohort (41% vs 24%, respectively).
23 In a fourth study that evaluated olaparib versus PEGylated 
liposomal doxorubicin (PLD) in patients with a gBRCA mutation and relapsed ovarian cancer, the efficacy of olaparib was consistent with tha t observed in previous studies.
24  
Activity in HGSOC has also been observed with PARP inhibitor switch maintenance therapy following response to platinum-based chemotherapy.
31, 32 Patients with platinum- sensitive 
relapsed ovarian cancer who achieved a response to another regimen of platinum- based 
chemotherapy followed by olaparib as switch maintenance treatment experienced a statistically 
significant improvement in median PFS (8.3 months) compared to pati ents who received placebo 
as maintenance therapy (4.8 months); hazard ratio of 0.35 (95% CI, 0.25 – 0.49).31 Patients with 
a BRCA mutation derived the most benefit (med ian PFS 11.2 vs 4.3 months; HR=0.18; 95% CI 
0.11-0.31; P <0.00001).32 It should be noted that the outcomes of sBRCA + gBRCA mutant 
patients were the same as gBRCA mutant patients alone, suggesting that, for stratification and analysis purposes in the present study, it is appropriate to not differentiate between germline and somatic mutations. Patients without a BRCA mutation also experienced significant benefit from 
treatment with olaparib (HR=0.53; 95% CI 0.33-0.84; P =0.007).
32  
Niraparib (MK -4827) has exhibited clinical activity in a Phase  1 study in both BRCA -mutated 
ovarian cancer ( 8 RECIST PRs) and sporadic ovarian canc er (5 RECIST PRs  and/or GCIG 
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  30 
 CA-125 responses ).25 In a Phase 1 evaluation of BMN 673, 11 of 17 BRCA- mutated ovarian 
cancer patients treated  at doses ≥100 µg/day exhibited a RECIST and/or CA-125 response.26  
Taken together, these data support the potential role for the PARP inhibitor rucaparib in the 
treatment of patients with BRCA- associated ovarian cancer. Furthermore, the 24% ORR and HR 
of 0.53 in the non- BRCA cohorts described above23, 32 suggests that the clinical utility of PARP 
inhibitors can be extended to a larger patient group. Pat ients with HRD due to defects in 
homologous recombination genes other than BRCA, i.e. nbHRD, may be part of this larger group. 
3.3 Rucaparib  
Rucaparib (formerly known as AG-014447 and PF-01367338) refers to the free base. The 
camphorsulfonic acid salt form (also referred to as camsylate salt) CO -338 (formerly known as 
PF-01367338- BW) will be used in this clinical trial.  
Rucaparib (Rubraca®) is a small molecule inhibitor of PARP -1, PARP -2, and PARP-3 approved 
in the United States (US) as monotherapy treatment for adult patients with deleterious BRCA mutation (germline and/or somatic)- associated EOC, FTC, or PPC cancer who have been treated 
with 2 or more prior chemotherapies, and for the maintenance treatment of adult patients with recurrent EOC, FTC, or PPC w ho have a complete or partial response to platinum -based 
chemotherapy.
1 Rucaparib is also approved in the European Union (EU) as monotherapy 
treatment of adult patients with platinum-sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high -grade EOC, FTC, or PPC who have been treated with 2 or more 
prior lines of platinum -based chemotherapy, and who are unable to tolerate further platinum-
based chemotherapy, and for maintenance treatment of adult patients with platinum -sensitive 
recurrent EOC, FTC, or PPC who are in response (complete or partial) to platinum- based 
chemotherapy.
2 
Nonclinical evaluation has demonstrated exquisite sensitivity of BRCA1  and BRCA2  
homozygous mutant cell lines to rucaparib and provides a rationale for the clinical assessment of 
rucaparib as monotherapy in patients with hereditary deficiencies of BRCA1  and/or BRCA2 . 
Rucaparib has also shown antitumor activity as a single agent in the MDA -MB-436 ( BRCA1  
mutant) xenograft mouse model. The activity of rucaparib in these nonclinical experiments was 
similar to that of olaparib.  
Comprehensive nonclinical and clinical information for rucaparib  is available in the current 
Investigator’s Brochure. 
3.3.1 Nonclinical Experience  
3.3.1.1 Rucaparib Absorption, Distribution, Metabolism, and Excretion  
The pharmacokinetics (PK) and toxicokinetics of rucaparib (as camsylate  salt)  following oral 
administration, the intended route of administration in humans, was evaluated in the mouse, rat, and dog. The time at which the peak plasma concentrations were observed (T
max) occurred at 1 –
3 hours post dose in the mouse and dog, with the rat generally exhibiting a later T max (4–8 hours ). 
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  31 
 The oral bioavailability was 17%, 36%, and 62%, respectively, in the mouse (50 mg /kg), rat 
(100 mg /kg), and dog (20 mg /kg). In the rat and dog, there were no marked gender- related 
differences and no accumulation after repeat oral administration. A less than dose -proportional 
increase in exposure was observed in the rat and dog when rucaparib was administered as a 
suspension in 0.5% methylcellulose; however, a greater than dose -proportional increase in 
exposure was observed in the 1-month dog toxicity study when rucaparib was administered in capsules.  
In vitro plasma protein binding studies in mouse, rat, and dog plasma showed moderate binding and ranged from 49.5% to 73%. Plasma protein binding in humans ranged from 55% to 75%.  
Recombinant cytochrome P450 (CYP) studies indicated that CYP2D6, and to a lesser extent, 
CYP1A2 and CYP3A4, have the ab ility to metabolize rucaparib.  
In vitro studies indicated that rucaparib reversibly inhibited (in order of decreasing potency) CYP1A2, CYP2C19, CYP2C9, CYP3A, CYP2C8, and CYP2D6. Rucaparib demonstrated concentration -dependent induction of CYP1A2 and down-regulation of CYP3A4 and CYP2B6 at 
clinically relevant concentrations in a hepatocyte incubation study. No time-dependent CYP inhibition was observed. Rucaparib also moderately inhibited uridinediphosphate-glucuronosyletransferase (UGT)1A1. Based on in vitro CYP interaction data, the drug-drug interaction (DDI) potential of rucaparib as a CYP inhibitor and /or inducer was assessed by 
calculating the ratio of AUC (AUCR) of CYP substrate drugs in the presence and absence of rucaparib at target clini cal exposures (600 mg twice a day [ BID] ) using the mechanistic static 
modeling.
50, 51 AUCR allows a conservative estimation of the magnitude of DDIs. Based on this 
analysis, the DDI potential for rucaparib was estimated to be moderate (AUCR 2 to 5) for CYP3A (AUCR=5.0), CYP1A2 (AUCR=2.9), CYP2C8 (AUCR=2.6), and CYP2D6 (AUCR=2.3); but appear ed to be strong (AUCR > 5) for CYP2C19 (AUCR=11) and CYP2C9 
(AUCR=5.2). Clinical implication of CYP3A downregulation was unknown and thus not 
considered in the modeling; however, downregulation could  further increase AUCR for CYP3A 
and result in elevated exposures of drugs that are CYP3A substrates.  
Rucaparib is a substrate for both P-glycoprotein (P-gp) and breast cancer resistance protein 
(BCRP ). In vitro data indicate rucaparib is a potent inhibitor of multidrug and toxin extrusion 
transporter ( MATE )-1 and MATE2 -K (efflux transporters on renal tubule cells), and moderate 
inhibitor of organic cation transporter ( OCT )1, BCRP, and P-gp.  
Quantitative whole body autoradiography studies in Long Evans rats showed [
14C] rucaparib 
radioequivalents were rapidly a nd widely distributed to tissues following IV administration, 
consistent with a large volume of distribution. At 2  minutes after dosing, highest concentrations 
were found in kidney, lung, thyroid gland, heart, stomach mucosa, liver adrenal glands, spleen, and blood. Little radioactivity was present in brain; levels were undetectable at 15 minutes  after 
dosing. Activity was undetectable in most tissues by 96 hours after dosing, however levels in the choroid/retina declined more slowly, and persistent radioac tivity was also found in hair follicles 
through 192 hours, indicating that drug equivalents have high affinity and long half- life in 
pigmented tissues. High levels of radioactivity were observed in ureters, bladder, and bile ducts, indicating both renal and biliary routes eliminated drug equivalents.  
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  32 
 3.3.1.2 Multiple -Dose Toxicity Studies  
Rucaparib was evaluated in both rat and dog in oral and IV infusion toxicity studies. Only the 
multiple -dose toxicity studies utilizing the oral for mulation are summarized below. Details of all 
other toxicity studies are provided in the Investigator’s Brochure.  
Target organs identified in studies where rucaparib was administered orally include the hematopoietic syst em and gastrointestinal tract. No cardiovascular findings were not ed in any of 
the oral toxicity studies.  
Multiple -Dose Oral Toxicity in Rats  
Administration of rucaparib camsylate salt via oral gavage was generally well- tolerated in the rat 
up to 1000 mg /kg/day for 7 days and up to 150 mg /kg/day for 28 days. Decreases in body weight 
gain and food consumpti on were noted in both studies. In the 7- day study, target organs 
identified microscopically were bone marrow, spleen, and thymus. Minimal to mild bone marrow hypocellularity  was noted in all dose groups. The  no-observed- adverse- effect -level 
(NOAEL) was established at 500  mg/kg/day.  
In the 28- day study, there were 3 rucaparib -related deaths at 500 mg /kg/day immediately after 
blood collection on Day  28 (n=1) or Day 29 (first day of recovery phase (n=2). These deaths 
likely resulted from the marked anemia identified hematologically. Other rucaparib -related 
clinical signs at 500  mg/kg/day included thinning haircoat and pale eyes. Identified target organs 
included bone marrow, spleen, lymphoid tissue (thymus, gut -associated -lymphoid tissue 
[GALT], and lymph nodes), and cecum (at 500 mg/kg/day only). Following cessation of 
rucaparib dosing, most findings reversed. In this study, the severe toxic dose in 10% of the animals (STD10) was 500 mg /kg/day and the NOAEL was 50  mg/kg/day.  
Rucaparib camsylate in capsules was also given orally to rats at doses of 10, 40, and 100 mg /kg/day for 91 consecutive days with a 28 -day recovery period. Decreased body weight 
and body weight gain were observed for animals given ≥40 mg /kg/day. At the end of the 
recovery phase, mean body weight was still lower for males given 100 mg /kg/day and females 
given ≥40 mg /kg/day. Hematological findings included decreases in red blood cell mass 
parameters in animals given ≥40 mg /kg/day (which correlated with decreased bone marrow 
hypocellularity), and decreases in reticulocytes, white blood cells (WBC) and absolute lymphocytes at ≥40 mg /kg/day. The latter changes correlated with the microscopic findings of 
decreased lymphocytes in the mandibular lymph nodes and gut -associated lymphoid tissue. All 
effects were reversible. Microscopically, bone marrow hypocellularity at 100 mg /kg/day and 
minimally decreased lymphocytes in lymphoid tissues at ≥40 mg /kg/day were noted and were 
completely reversed at the end o f the recovery period. The NOAEL was established to be 
100 mg /kg/day. 
Multiple -Dose Oral Toxicity in Dogs  
Oral gavage administration of the camsylate salt form of rucaparib to dogs for 7 days resulted in gastrointestinal clinical signs at the 80  mg/kg/day high- dose group. Hematopoietic effects of 
decreased reticulocytes were noted in mid - to high- dose groups and leukopenia was exhibited in 
all treatment groups. Lymphoid atrophy occurred in both sexes and in all treatment groups. 
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  33 
 Decreased bone marrow  cellularity was seen in both sexes (males at all doses; females at 
80 mg /kg/day). A 7- day repeat -dose toxicity study using oral capsules in dogs was repeated in 
order to characterize the toxicity of a new lot of rucaparib camsylate. Similar to the results  of the 
prior 7 -day study in dog, gastrointestinal clinical findings were noted at 80 mg /kg/day.  Vomiting 
was observed throughout the dosing phase for males as well as liquid and/or mucoid feces in 
both genders. Decreased food consumption was observed at 80 mg /kg/day that correlated with 
the body weight loss that was considered adverse. Decreases in erythroid, platelet, and leukocyte parameters were observed primarily at 80  mg/kg/day and occasionally at 20 or 5 mg /kg/day. 
These data indicated that the drug targeted multiple bone marrow lineages in a dose -related 
pattern.  
Rucaparib camsylate salt in capsules was administered orally to dogs for 30 consecutive days with a 29- day recovery. Gastrointestinal clinical signs were noted at ≥5 mg /kg/day, with 
decrease in food consumption at 75 mg/kg/day. Adverse hematological changes (decrease in 
erythroid, myeloid, and megokaryocytic lineages) occurred at ≥20 mg /kg/day. Effects were fully 
reversible. The NOAEL in this study was 5 mg /kg/day.  
Rucaparib camsylate in capsules was also given orally to dogs at doses of 3, 15/10, 40/30/20 mg /kg/day for 91 consecutive days with a 29- day recovery period. Body weight losses 
and inappetance observed at the high dose in both sexes during the first quarter of the dosing phase were considered adverse and resulted in dose reductions (40 to 30 to 20 mg /kg/day for 
toxicity and 15 to 10 mg /kg day in order to maintain multiples of exposures for optimal testing of 
dose response) for the remainder of the study. Clinical pathology findings w ere indicative of 
bone marrow toxicity; these changes were non- progressive over time suggesting potential 
adaptation to these initial effects. Hematological findings at 40/30/20  mg/kg/day correlated with 
erythroid atrophy of the bone marrow detected micros copically. By Day  29 of recovery, most 
effects reversed. The highest non -severely toxic dose (HNSTD) for this study was 20  mg/kg/day 
for male dogs. No HNSTD was established for female dogs. The NOAEL was 10 and 20 mg /kg/day for male and female dogs, respec tively.  
3.3.1.3 Additional Observations  
In vitro genetic toxicology assays demonstrated oral rucaparib  to be clastogenic. Bacterial 
mutagenicity data for rucaparib  were clearly negative in four  microbial tester strains , both with 
and without metabolic activation, and equivocal in a fifth tester strain.   
In an in vitro assay for human ether -a-go-go-related gene (hERG) activity, the IC
50 and IC 20 for 
the inhibitory effects of rucaparib (50% inhibitory concentration and 20%  inhibitory 
concentration) on hERG potassium currents were 24 µ M (7761 ng/ mL) and 7  µM (2264 ng/ mL), 
respectively. These values are 9- fold and 2.6- fold higher, respectively, than the mean unbound 
steady state plasma concentration (858 ng/ mL) observed to da te in humans at a dose of 600 mg  
BID rucaparib administered orally.  
Effects on appearance and behavior, motor activity, body temperature, and a number of neurofunctional tests and reflexes were evaluated in rats. A dose of 50 mg /kg of rucaparib 
administere d via IV infusion (mean maximum concentration [ C
max]=13629 ng/ mL) resulted in a 
significant reduction in motor activity compared with vehicle -treated animals; however, there 
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  34 
 were no effects on neurofunctional or reflex testing at this dose. The plasma conc entration 
measured at this dose is 4.7- fold above the mean  steady state plasma concentration (2880 ng/ mL) 
observed to date in humans at a dose of 600 mg  BID rucaparib administered orally.  
Administration of rucaparib to Long -Evans rats orally at doses up to 750 mg/kg/dose, followed 
by a single exposure to solar -simulated ultraviolet radiation approximately 4  hours  after the final 
dose elicited no skin or ocular reaction s indicative of phototoxicity. The no -observed -effect -level 
(NOEL) for phototoxicity was >750 mg /kg/day.  
3.3.2 Clinical Experience  
The early clinical program assessed safety and efficacy of rucaparib in patients with 
malignancies commonly treated with chemotherapeutic agents . Initially,  the IV  formulation of 
rucaparib was administe red in combination wi th a variety of chemotherapies; later , the oral 
formulation of rucaparib was administered in combination with chemotherapy and as a 
monotherapy. The oral formulation as monotherapy is the focus of current development efforts.  
Information regarding clinical studies with rucaparib is available in the Investigator’s Brochure.  
3.3.2.1 Rucaparib Monotherapy  
3.3.2.1.1 Study CO -338-010 
Clovis -sponsored study CO -338-010 is a 2- part, open- label, safety, PK, and preliminary efficacy 
study of oral rucaparib adminis tered daily for continuous 21- day cycles.  Part 1 is a Phase 1 
portion in patients with any solid tumor, including lymphoma, who have pr ogressed on standard 
treatment.  The primary objective of Part  1 is to determine the optimal monotherapy dose for 
orally a dministered rucaparib.  Part 2 is a Phase 2 portion in patients with platinum- sensitive 
relapsed ovarian cancer with evidence of a gBRCA mutation who have received at least 2, but no 
more than 4, prior regimens. The primary objective of Part  2 is to assess the overall objective 
response rate by Response Evaluation Criteria  in Solid Tumors ( RECIST)  v1.1. 
Study CO -338-010 was  initiated in Q4 2011. As of 27 June 2014, 56 patients (median age 50 yrs 
[range 21 −71]; 51 female; 27 breast cancer, 20 ov arian/peritoneal cancer, 9 other tumor) were  
treated at dose levels of 40, 80, 160, 300, and 500 mg  once daily ( QD), and 240, 360, 480, 600, 
and 840 mg  BID rucaparib administered continuously in the Phase 1 portion of the study. A total 
of 50 patients discontinued rucaparib ; n=46 due to disease progression ; n=2 due to a n adverse 
event  (AE) (unrelated to rucaparib) ; n=1 due to consent withdrawal ; and n=1 due to an eligibility 
criteria violation. One of 6 patients treated with 360 m g BID rucaparib experienced a dose-
limiting toxicity (DLT) of Common Terminology Criteria for Adverse Events (CTCAE) Grade  3 
nausea despite maximal intervention in Cycle 1 of treatment. No DLTs were observed during Cycle 1 in the 480 (n=9) , 600 (n=5) , and  840 mg  BID (n=3) cohort s; however, similar to other 
PARP inhibitors, non- DLT myelosuppression was observed beyond Cycle 1. The  dose of 
600 mg  BID rucaparib was selected as the recommended dose for Phase 2 and Phase 3 studies  
based on the overall safety & t olerability, PK, and clinical activity profile . As of June 27, 2014, 
15 patients (median age= 58 [range= 45-84]; 9 ECOG PS=0) with platinum- sensitive, relapsed 
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  35 
 ovarian cancer associated with a deleterious BRCA1/2  mutation have been enrolled in the 
Phase 2 portion of the study. One patient has discontinued rucaparib due to disease progression. 
Treatment -related AE s (all grades ) reported in ≥15% of  patients treated with 600 mg  BID 
rucaparib include gastrointestinal and relate d symptoms ( nausea, vomiting, dysgeusia, diarrhea, 
abdominal pain, and decreased appetite ), anemia, fatigue/asthenia, and headache. E levations of  
alanine amino transferase ( ALT ) and/or AST have been reported. The ALT/AST elevations occur 
early (within first 2 -4 weeks of treatment), were generally mild to moderate (Gr 1 -2), not 
accompanied by any changes in bilirubin levels, and often transient and resolved to within 
normal ranges, or stabilize. No patient met the laboratory criteria for Hy’s Law.52 As has been 
observed with rucaparib and other PARP inhibitors, myelosuppression may be delayed and observed after a period of continuous dosing. All treatment- related AE s were successfully 
managed with concomitant medication, supportive care, treatment interruption and/or dose reduction. No patient discontinued rucaparib treatment due to a treatment- related AE . A total of 
five patients have died on study or within 30 days of last dose of rucaparib ; all deaths were due 
to disease progression and were assessed as not related to rucaparib. 
Extensive centrally -reviewed electrocardiogram (ECG) monitoring was conducted in the Phase I 
portion of Study CO-338- 010. ECG results (as triplicate reads) are available for all 56 treated 
patients. No patient had a QTcF measurement ≥500 msec at any ti me d uring study participation. 
Only one patient had a QTcF measurement ≥480 msec. This measurement occurred in a patient 
receiving 480 mg  BID rucaparib and concomitant administration of citalopram, a medication 
with known potential to cause QT prolongation. This patient has continued to receive monotherapy rucaparib at a dose of 480 mg  BID with no further QTcF measurement ≥480 msec. 
No patient experienced a ≥60 msec increase in QTcF over baseline. The data suggest no relationship between QTcF increase and dose or exposure. In addition, there were no AEs 
suggestive of cardiac arrhythmia (eg , presyncope, syncope, sudden death) in any patient. ECG 
and AE  data as of the cutoff date in patients receiving monotherapy rucaparib at doses up to 
840 mg  BID suggest there i s a minimal risk of QTc prolongation. 
In the Phase  1 portion, 2 patients (1 breast cancer, 1 ovarian cancer, both gBRCA
mut) achieved a 
RECIST CR and 7 patients (2 ovarian cancer, 4 breast cancer, 1 pancreatic cancer; all gBRCA
mut) achieved a RECIST PR (n=2  at 300 mg  QD; n=2 at 360 mg  BID; n=3 at 480 mg  
BID; and n=2 at 600 mg  BID). In addition, 3 patients with ovarian cancer achieved a cancer 
antigen 125 (CA -125) response as defined by Gynecologic Canc er InterGroup (GCIG) criteria. 
The disease control rate ( CR, PR, or SD>12 wks at doses ≥360 mg  BID in evaluable ovarian 
cancer patients is 92% (11/12). Responses have been durable across tumor types.  
Preliminary efficacy data are available for 1 6 patients in the Phase 2 portion of Study 
CO-338-010. Currently, 12 of 16 (75 %) patients have achieved a RECIST PR . Response to 
treatment occurs rapidly; the majority of these  patients achieved a PR by the first disease 
assessment (week 6). All responses are ongoing, with several patients in Cycle 5 of treatm ent or 
beyond. The vast majority of patients had some level of target lesion measurement reduction as shown in Figure 1. 
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  36 
 Figure  1 Best Response in Target Lesions –  Phase  2 Portion of Study CO -338-010 
 
After once daily oral administration of rucaparib for 15 days, steady state C max and AUC 0-24 
generally increased dose proportionally. T max and t 1/2 were independent of dose. Steady state 
exposure increased by an average of 89%, consistent with accumulation expected for a 
compound exhibiting a t 1/2 of approximately 17 hours  administered once daily. Following BID 
oral administration of rucaparib for 15 days, steady state C max and AUC 0-24 generally increased 
dose proportionally. Moreover, BID dosing delivered a lower C max with a low peak to trough 
plasma concentration variation. The target trough level of 2 µ M was achieved in 100% of 
patients (n=14) at ≥240 mg BID with low inter- patient variability (<4 -fold) within each dose 
group. Steady state trough levels also exhibited low intra -patient variability (24% coefficient of 
variation ). No sporadically high exposures were observed. The effect of food on rucaparib PK 
was evaluated at 4 0 mg  (n=3) and 300 mg  (n=6) doses administered once daily. There was no 
food effect; patients may take rucaparib on an empty stomach or with food.  
Updates of  study information may be found in the Investigator’s Brochure. 
3.3.2.1.2 Study CO -338-017 
Study CO -338-017 (ARIEL2)  is a Phase 2 study of rucaparib as monotherapy treatment for 
relapsed, platinum -sensitive high -grade ovarian, fallopian tube or primary peritoneal cancer . The 
purpose of this study is to define a tumor -based molecular signature of HRD in ovarian c ancer 
that correlates with response to rucaparib and enables selection of appropriate ovarian cancer 

Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  37 
 patients for treatment with rucaparib. The trial is enrolling patients with and without a BRCA1/2  
mutation in order to enable identification of this response signature, which will then be 
prospectively applied to the primary analysis of study CO -338-014 (ARIEL3) . Tumor HRD 
status is assessed using next generation sequencing, with an algorithm for HRD status based on the presence of a BRCA mutation (germline  or somatic) and/or degree of tumor genomic LOH, a 
phenotypic consequence of HRD.  
All patients enrolled into Clinical Study CO -338- 017 (ARIEL2) must have received at least 1 
prior platinum- based treatment regimen, received a platinum -based regimen as thei r last course 
of treatment and have platinum- sensitive disease, defined as disease progression >6  months after 
the last dose of platinum. In addition, all patients must have disease that can be biopsied and is 
measurable by RECIST v1.1. Rucaparib 600 mg BID is administered continuously until disease 
progression. 
Clinical Study CO -338-017 (ARIEL2) was initiated in October 2013. As of 27 June 2014, 72 of 
180 planned patients have been enrolled. The median age is 65.5 years (range 44 – 83) and the 
majority of patients (n= 54, 75%) had Eastern Cooperative Oncology Group (ECOG) performance status of 0.  
The most frequent (reported in ≥ 15% of patients treatment -related AE s (all grades) as of 27 June 
2014 are gastrointestinal- related toxicities (nausea, constipation, vomiting, diarrhea, and 
abdominal pain), fatigue, elevations in ALT/AST , decreased appetite, and dysgeusia.  
Transaminase elevations occur early in treatment and are generally transient and resolve or 
stabilize. All patients who experienced AE s related to rucaparib , including those with Grade  3 
transaminase elevation,  were successfully managed by treatment interruption and/or a dose 
reduction. No patient has discontinued rucaparib due to a t reatment- related AE . No patients have 
died on study or within 30 days of last dose of rucaparib . 
Response data are preliminary , yet indicate that rucaparib has activity in BRCA
wt patients with 
high level of LOH as well as in BRCAmut patients.  
Updates of study information may be found in the Investigator’s Brochure. 
3.3.2.1.3 Study A4991002, A4991005, and A4991014 
Further details of these studies are provided in the Investigator’s Brochure.  
3.3.2.1.4 Safety : Events of Special Interest  
The current list of a dverse events of special interest (AESIs) is located  in the rucaparib IB.  
3.4 Rationale for Study  
In vitro  studies have shown that cells deficient in BRCA1/2 as well as cells deficient in or 
depleted of homologous recombination proteins other than BRCA1/2 have been associated w ith 
PARP inhibitor sensitivity in vitro.18, 19, 27-30 Clinical data have shown that ovarian cancer 
patients with and without evidence of a gBRCA  mutation benefit from treatment with a PARP 
inhibitor20-24 and that maintenance treatment with a PARP inhibitor following a response to 
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  38 
 platinum- based treatment increases PFS in patients with ovarian cancer .31, 32 While p atients with 
a BRCA mutation derived the most benefit, patients without evidence of a BRCA mutation also 
derived significant benefit.23, 32 The purpose of this study is to evaluate PFS of patients with 
platinum- sensiti ve, high-grade serous or endometrioid epithelial ovarian, fallopian tube, or 
primary peritoneal cancer who receive rucaparib or placebo as switch maintenance therapy 
following a response to platinum -based chemotherapy  in order to identify the patients most 
likely to benefit from treatment with rucaparib . It is anticipated that rucaparib will provide 
therapeutic benefit and increase PFS in patients with HRD  associated with a BRCA gene 
mutation or other HR gene alteration . 
Patients will be  stratified into one of 3 HRD sub groups (tBRCA, nbHRD, and biomarker 
negative)  (Appendix A ) by Foundation Medicine’s ICTA, which will determine HRD status 
through analysis of homologous recombination gene mutations in tumor tissue. Tumor DNA will also be assessed to detect the presence of genomic scars.
35-38 Analysis of specific genomic 
scarring patterns may identify tumors with HRD regardless o f the underlying mechanism(s). 
Homologous recombination gene mutation analysis and genom ic scarring will also be assessed in 
a Phase 2 study (CO-338- 017) that will be initiated in parallel with this Phase 3 study. The 
insights from study CO-338- 017 will be applied prospectively to the analysis of this Phase 3 
trial. The Final Clinical Trial A ssay ( FCTA) analysis plan ( gene mutation and/or genomic 
scarring)  and classification  of HRD subgroups will be finalized and locked down prior to the 
completion of the Phase  3 study and applied prospectively to the analysis of this Phase 3 study. 
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  39 
 4 STUDY OBJECTIVES  
4.1 Objectives and Endpoints  
This is a double- blind  efficacy study of oral rucaparib in patients with platinum- sensitive, 
relapsed high -grade serous or endometrioid epithelial ovarian, fallopian tube, or primary 
peritoneal cancer  who receive rucaparib or placebo as switch maintenance therapy following a 
response to platinum -based chemotherapy . 
Primary , secondary, and exploratory objectives and endpoints are shown in Table  1. 
Table  1. Primary, Secondary,  and Exploratory Objectives and Endpoints  
Primary Objectives  Primary Endpoints  
1. To evaluate PFS by RECIST, as assessed by 
the investigator, in molecularly -defined 
HRD subgroups  1. Disease progression according to RECIST v1.1, as assessed by the investigator, 
or death from any cause (invPFS), in 
molecularly defined subgroups  
Secondary Objectives  Secondary Endpoints  
1. To evaluate patient -reported outcome (PRO) 
of disease related symptoms utilizing the disease-related symptoms – physical 
(DRS−P) subscale of the National 
Comprehensive Cancer Network -Functional 
Assessment of Cancer Therapy (NCCN-FACT) FACT -Ovarian Symptom 
Index 18 (F OSI-18) 1. Time to a 4 -point decrease in the DSR− P 
subscale of the FOSI -18 
2. To evaluate PRO utilizing the complete 
FOSI -18 2. Time to an 8 -point decrease in the total score of 
the FOSI -18 
3. To evaluate survival benefit  3. Overall survival ( OS) 
4. To evaluate PFS by RECIST , as assessed by 
independent radiology review (IRR), in 
molecularly -defined HRD subgroups  4. Disease progression according to RECIST v1.1, as assessed by IRR, or death from any cause 
(irrPFS), in molecularly defined subgroups  
5. To evaluate safety  5. Incidence of AEs, clinical laboratory 
abnormalities, and dose modifications  
6. To determine the population PK of rucaparib 6. Individual model parameter estimates of 
rucaparib and covariates identification  
Exploratory Objectives  Exploratory Endpoints  
1. To evaluate the relationship between CA-
125 levels and invPFS  1. Association between the change from baseline 
in CA -125 measurements and invPFS  
2. To evaluate PFS2 (PFS on the subsequent 
line of treatment)  2. Time to the next event of disease progression or 
death, as assessed by the investigator  
3. To evaluate ORR  3. ORR per RECIST v1.1 , as assessed by both 
investigator and IRR, in patients with 
measureable disease at study entry  
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  40 
 Table  1. Primary, Secondary,  and Exploratory Objectives and Endpoints  
4. To evaluate duration of response (DOR)  4. DOR per RECIST v 1.1, as assessed by both 
investigator  and IRR  
5. To evaluate PRO utilizing the Euro -Quality 
of Life 5D (EQ -5D) 5. PRO as measured by the total score on the 
EQ-5D 
6. To explore the relationship between 
rucaparib exposure, efficacy, and safety  6. Rucaparib PK, invPFS, irrPFS, CA-125, AEs, 
clinical laboratory abnormalities, and dose 
modifications  
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  41 
 5 STUDY DESIGN 
5.1 Overall Study Design and Plan  
This is a double- blind efficacy study of oral rucaparib in patients with platinum- sensitive, 
high- grade serous or endometrioid epithelial ov arian , fallopian tube, or primary peritoneal cancer 
who receive rucaparib or placebo as switch maintenance therapy following a response to 
platinum- based chemotherapy.  
5.1.1 Screening Phase  
All patients will undergo screening assessments within 120 days  prior to randomization.  
The study will enroll patients with platinum- sensitive (defined as disease with confirmed 
radiologic relapse >  6 months after the last dose of the penultimate platinum regimen received ), 
high- grade serous or endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer 
who achieved a response to  platinum- based chemotherapy administered for relapsed disease.  
Patients must have received ≥  2 prior platinum -based treatment regimens, inclusive of the 
regimen that must have been administered immediately prior to maintenance therapy in this trial. There is no limit on the number of prior platinum -regimens that may have been received , but the 
patient must have been sensitive to the penultimate platinum regimen received. In addition, up to 1 prior non-platinum chemotherapy regimen is permitted. Prior hormonal therapy is permitted; 
this treatment will not  be counted as a non- platinum regimen. Prior maintenance therapy may 
have been administered with any prior treatment , with the exception of the platinum regimen 
received immediately prior to maintenance in this study . For the last chemotherapy course prior 
to study entry, patients must have received a pl atinum-b ased doublet chemotherapy regimen  
(minimum 4 cycles) and have achieved a CR (defined as complete radiologic response by RECIST [ Appendix B ] or PR (def ined as partial response by RECIST [Appendix B ] and/or a 
GCIG CA -125 response [Appendix C] . All responses require that CA -125 be < ULN. The 
response must be maintained through the completion of chemotherapy and during the interval 
period between completion of chemotherapy and entry in the study.  
Screening assessments will include demographics and medical history, prior treatments for 
serous or endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer (and other malignancies, if applicable), prior and current medications and procedures, 12 lead electr ocardi ogram (ECG), ECOG performance status, central laboratory hematology, serum 
chemistry, and CA -125 measurement, serum pregnancy (for women of child-bearing potential 
only), urinalysis, physical examination, height, weight, and vi tal signs measurements, AEs, and 
radiologic assessment by CT or MRI. PRO will be collected using the FOSI-18 and EQ- 5D 
instruments.  
Germline BRCA mutation results should be obtained for all patients who are known to have been tested prior to enrollment  in order to determine whether any mutation was reported and if so, 
whether the mutation was classified as deleterious /pathogenic or other. Enrollment of patients 
with a gBRCA mutation classified as deleterious ( i.e. path ogenic), suspected deleterious,  or the 
equivalent, on the most recent assessment by a testing laboratory will be limited to 15 0. Patients 
with a BRCA mutation detected in tumor tissue ( tBRCA) will be limited to 200. Once this cap is 
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  42 
 reached, newly screened patients identified as having a BRCA mutation in tumor tissue will be 
offered treatment in another study. 
The complete results of the Foundation Medicine NGS test, which examines exons of 287 genes 
as well as introns of 19 genes, will be provided to all patients who opt to receive this information and provide appropriate consent. Results for the BRCA genes will be provided to patients who 
consent to r eceive this information upon availability. Results for the  remainder of the gene panel 
will be provided to consenting patients upon treatment discontinuation. All r esults are to be 
disclosed to consenting patients by the study physician as part of an overa ll clinical discussion.  
In the event a mutation associated with hereditary cancer or other syndrome is detected in tumor tissue, the patient will be referred by the investigator for genetic counseling and potential germline testing per institutional guidelines. If the patient chooses to have germline BRCA testing, this result will be entered into the clinical trial database. The sponsor will remain blinded to all NGS test results (including all t BRCA results ), as well as existing BRCA data,  until the 
primary efficacy analysis is conducted. 
Mutations detected in tumor tissue may be somatic or germline; however, the NGS test will not 
distinguish between the two. A blood sample will therefore be collected for all patients and 
stored. Prior to f inal efficacy analysis, genomic DNA may be subjected to exploratory analysis in 
order to determine whether any mutation identified is of germline or somatic origin . This data 
will be generated in a research setting and will not be provided to the investiga tor or patient.  
However, if an actionable mutation, as defined by the American C ollege of Medical Genetics 
and Genomics, is revealed that was not classified as deleterious on the tumor- based NGS test 
report , these  blood- based  incidental findings will be made available to the investigator, provided 
the results are generated from a Clinical Laboratory Improvement Amendment -certified 
laboratory.
53 
Enrollment will require Clovis (or designee) review of eligibility, including, but not limited to: 
• The number of prior therapies and the details for the penultimate and most recent platinum-based regimens, including dates administered;  
• documentation supporting platinum sensitivity; 
• documentation supporting a RECIST or GCIG CA-125 response to most recent 
platinum- based treatment;  
• confirmation if patient has had local gBRCA test ing;  
• confirmation that sufficient tumor tissue was submitted for HRD s tratification for 
randomization and storage for potential bridging to a validated companion 
diagnostic test and analysis results were successfully  transmitted to IXRS  
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  43 
 5.1.2 Randomization  
Randomization to study treatment must occur within 8 weeks following a patient’s last dose of 
platinum- based chemotherapy , and is described in more detail in Section  7.2. Study treatment 
must be initiated within 3 days of randomization . 
5.1.3 Double -Blind Treatment Phase  
For patients remaining on treatment as of implementation of Protocol Amendment 5, a more 
limited number of assessments will be performed during the treatment period as compared to previously; however, an appropriate level of safety monitoring will remain in place. A revised Schedule of Assessments, which replaces all prior schedules of assessments and should be 
followed for all patients who remain on treatment  or in long- term follow -up, is provided in 
Section  9.1. 
During the double-blind treatment phase  (continuous 28-day treatment cycles) , patients will be  
monitored for safety and efficacy. Assessm ents will include AEs ; serum pregnancy for women of 
child -bearing potential; complete blood count (monthly assessment advised); subsequent 
medications, therapies and  procedures; and study drug administration and accountability. In 
addition, clinical chemistry, urinalysis, and vital signs may be performed pe r local standard of 
care practices. 
 
Patients will be assessed for disease status per RECIST v1.1  every 12 calendar weeks (up to 
1 week prior is permitted) following initiation of study treatment on Day 1 of Cycle 1. Patients 
experiencing disease progression by RECIST v1.1, as assessed by the investigator, will be discontinued from treatment and enter follow -up. Disease progression will only be determined 
by RECIST  v1.1. Patients with a CR at study entry will only be considered to have disease 
progression if a new lesion is identified. Patients who meet GCIG CA -125 criteria for disease 
progression should have a radiologic assessment and be assessed by RECIST  v1.1. If the 
radiologic assessment does not confirm disease p rogression, patients should continue on 
treatment and  be assess ed by RECIST v1.1 per the protocol schedule of assessments.  Patients 
who have been on study at least 18 months may decrease the frequency of disease assessments to every 16 (±2) weeks.  Investig ator should consult with sponsor’s medical monitor before 
decreasing frequency.
  
Sites were previously  notified that a s of 06 December  2019, CT scans (and other imaging, as 
appropriate) performed during the treatment period and at treatment discontinuation  will no 
longer be collected for IRR.  
Patients were  continuously monitored for safety. An Independent Data Monitoring Committee 
(IDMC) with multidisciplinary representation evaluate d safety in compliance with a prospective 
charter.   
The IDMC was discontinu ed when the primary study endpoint of progression- free survival was 
reached .  
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  44 
 5.1.4 Treatment Discontinuation  
Upon treatment discontinuation, regardless of reason, patients will have a Tr eatment 
Discontinuation visit. Assessments at this visit will include AEs, serum pregnancy for women of 
child -bearing potential, disease status assessment, and study drug accountability; in addition, 
complete blood count, clinical chemistry, urinalysis, and vital signs may be performed per local standard of care practices.  An optional tumor biopsy will be collected from patients who 
experience disease progression and provide appropriate consent  prior to the start of any 
subsequent anticancer  treatment . If disease progression is caused by appearance of a new 
lesion(s),  the lesion(s) should be prioritized for the optional biopsy. A ll patients discontinued 
from treatment will be followed for 28  days following the last dose of study drug for the 
collection of AEs.  
5.1.5 Follow -Up Phase  
After the Treatment Discontinuation visit, all patients will be followed for AEs up to 28 days 
after last dose of study drug. All serious adverse events (SAEs) and AESIs are to be followed to 
resolution, stabilization, or lost to follow -up (refer to Section  10.7) even if the duration extends 
beyond the 28-day follow-up period. Patients will also be followed for survival, subsequent treatments, and monito ring for secondary malignancy approximately every 12 weeks (±  14 days) 
until death, loss to follow -up, withdrawal of consent, or study closure.  
Patients who discontinued treatment for reason other than disease progression or death should continue to have tumor scans performed at 12 week intervals from Cycle 1 Day 1 (a window of 
up to 7 days prior is permitted) until disease progression by RECIST v1.1, as assessed by the investigator, or death. Patients who have been on study at least 18 months may decrease the frequency of disease assessments to every 16 (±2) weeks. Investigator should consult with sponsor’s medical monitor before decreasing frequency.
  
5.2 Study Schema  
An overview of the study design is provided in Figure 2. 
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  45 
 Figure  2 Study Schema  
 
NOTE: With the  implementation of Protocol Amendment 4 , the collection of PRO data was no longer 
required . Other assessments have been revised w ith the implementation of Protocol Amendment 5. Please 
refer to the schedule of assessments ( Table  3). 

Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  46 
 5.3 End of Study  
The trial is monitored on an ongoing basis by an IDMC for the number of PFS events required 
for the primary endpoint and for safety signals. An unblinding of treatment assignment might be performed when the study is still ongoing if the IDMC recommends it. However, the study is not anticipated to close until all patients are off treatment and sufficient OS follow up has occurred , 
which could include patients being transferred to another study for OS follow up. Upon formal closure of the study, individual patients who are continuing to benefit from treatment with rucaparib at the time of study closure, and who do not meet any of the criteria for withdrawal, will have the option of receiving rucaparib via another access mechanism.  
The sponsor may discontinue the study early for any reason as noted in Section 13.7. 
5.4 Discussion of Study Design  
This is a multicenter, randomized, double -blind, placebo-controlled study. 
Sponsor personnel (with the exception of individuals responsible for clinical supply chain), 
investigator and clinical site staff, and patient will all be blinded to study tr eatment to avoid bias 
in the interpretation of the efficacy and safety results. To avoid bias between treatment groups, 
patients will be randomized to treatment with active drug or placebo with stratification  according 
to HRD classification, interval betwe en completion of penultimate platinum- based regimen and 
disease progression  by radiologic assessment , and best response to platinum regimen received 
immediately before initiation of maintenance therapy .  
PFS by RECIST will be assessed by the investigator f or the primary endpoint (invPFS)  and by a 
blinded independent radiologist for the secondary endpoint (irrPFS) . 
Ongoing benefit/r isk will be assessed regularly by an IDMC that will have access to unblinded 
datasets. The IDMC will hold meetings and continue to review data until the protocol specified primary endpoint collection is complete  (i.e., 
70% of the patients in the tBRCA subgroup have an 
event of PFS) and the IDMC recommend the sponsor to unblind the treatment assignments for 
assessment of pr imary efficacy. The treatment assignment was unblinded in June 2017 for the 
primary efficacy analysis and thus no further IDMC meetings are planned. Unless a patient is unblinded for safety reasons or following approval by Clovis Oncology, all study invest igators  
will remain blinded to patient treatment assignment until final study analysis . 
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  47 
 6 STUDY POPULATION  
6.1 Number of Patients and Sites  
Approximately 540 patients with platinum -sensitive, relapsed, high- grade serous or endometrioid 
epithelial ovarian, fallopian tube, or primary peritoneal cancer will be enrolled at approximately 
90 – 100 study sites. A minimum of 1 80 and a maximum of 200 patients with a deleterious 
tBRCA mutation will be enrolled. Enrollment of patients with a known deleterious gBRCA 
mutation documented in their medical record will not exceed 150. There is no minimum number 
of patients required for each of the nbHRD and biomarker negative subgroups; however, no 
more than 360 total patients will be randomized for stratification into these  subgroups combined.  
6.2 Inclusion Criteria  
All patients enrolling into the study must meet all of the following inclusion criteria:  
1. Have signed an Institutional Review Board/Independent Ethics Committee -approved 
informed consent form prior to any study- specif ic evaluation  
2. Be ≥ 18 years of age at the time the informed consent form is signed  
3. Have a histologically confirmed diagnosis of high- grade (Grade  2 or 3) serous or 
endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer  
− For mixed histology, >50% of the primary tumor must be confirmed to be high- grade 
serous or endometrioid  
− Grade  2 tumors classified under a 3- tier system should be re -reviewed by local pathology 
and confirmed as high- grade under the 2- tier system  
4. Received prior platinum -based therapy and have platinum -sensitive disease  (i.e. documented 
radiologic  disease progressio n >6 months following the last dose of the penultimate platinum 
administered) 
− Received ≥ 2 prior platinum- based treatment regimens, including platinum -based regimen 
that must have been administered  immediately prior to maintenance therapy in this trial . 
In addition, up to 1 non- platinum chemotherapy regimen is permitted.  Prior hormonal 
therapy is permitted; this treatment will not  be counted as a non -platinum regimen.  
− There is no  upper  limit on the number of prior platinum -based regim ens that may have 
been received, but the patient must have been sensitive to the penultimate platinum- based 
regimen administered . 
− If both neoadjuvant and adjuvant treatment were administered pre/post any debulking 
surger y, this will be considered 1 treatment regimen  
− Prior maintenance therapy following a prior treatment regimen  is permitted , with the 
exception of the regimen received immediately prior to maintenance in this study. No 
anticancer therapy is permitted to be a dministered as maintenance treatment in the 
interval period between completion of the most recent platinum -based therapy and 
initiation of study drug in this trial.  
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  48 
 5. Achieve d best response of either CR or PR to the most recent platinum -based regimen  
administered and is  randomized to study treatment within 8 weeks of the last dose of 
platinum received  
− The most recent platinum- based regimen must have been a chemotherapy doublet . The 
choice of the platinum and the 2nd chemotherapy agent is per investigator’ discretion.  
− A minimum of 4 cycles of platinum chemotherapy must have been administered.  There is 
no cap on the maximum number of cycles; however, additional cycles of treatment 
administered following completion  of therapy for the specific purpose of enabling patient 
eligibility and randomization within 8 weeks of the last platinum dose is not  permitted.  
− A CR is defined as a complete radiologic response per RECIST v1.1, i.e. absence of any 
detectable disease and CA -125 <ULN * 
− A PR is defined as either a partial response per RECIST v1.1 (if disease was measurable prior to chemotherapy) or a serologic response per GCIG CA -125 response criteria (if 
disease was not measurable according to RECIST v1.1) * 
− CA-125 must also be <ULN  for all responses classified as a PR  
− R0 surgery (no visible tumor) or R1 surgery ( residual disease <1 cm) as a component of 
the most recent treatment regimen is not permitted.  The response assessment must be 
determined solely in relation to the chemotherapy regimen adm inistered. The presence of 
measurable disease or CA -125 >2 x ULN immediately  prior to the chemotherapy regimen 
is required.  
− Responses must have been maintained through the completion of chemotherapy and during the interval period between completion of chem otherapy and entry in the study  
− All disease assessments performed prior to and during this chemotherapy regimen must be adequately documented in the patient’s medical record  
6. Have sufficient archival formalin -fixed paraffin -embedded (FFPE) tumor tissue ( 1 x 4 µ m 
section for hematoxylin and eosin [H&E] stain and approximately 8 – 12 x 10 µ m sections, 
or equivalent ) available for planned analyses.  
− The most recently  collected tumor tissue sample should be provided, if available  
− Submission of a tumor block is preferred; if sections are provided, these must all be from the same tumor sample  
− Sample must be received  at the central  laboratory at least 3 weeks prior to pl anned 
start of treatment in order to enable stratification for randomization  
7. Have CA- 125 measurement that is <  ULN  
8. Have ECOG performance status of 0 to 1 
9. Have adequate organ function confirmed by the following laboratory values obtained within 14 days of t he first dose of study drug:  
− Bone Marrow Function 
o Absolute neutrophil count (ANC) ≥  1.5 × 10
9/L 
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  49 
 o Platelets >  100 × 109/L  
o Hemoglobin ≥  9 g/dL  
− Hepatic Function  
o Aspartate aminotransferase (AST) and ALT ≤  3 × ULN; if liver metastases, then 
≤ 5 × ULN  
o Bilirubin ≤  1.5 × ULN  (< 2 x ULN if hyperbilirubinemia is due to Gilbert’s 
syndrome)  
− Renal Function  
o Serum creatinine ≤  1.5 × ULN or estimated glomerular filtration rate (GFR) 
≥ 45 mL /min using the Cockcroft Gault formula  
* Note : It is acceptable for sites to utilize local and contemporaneous  clinical imaging reports 
to record lesion measurement history and define a burden of disease according to RECIST; it 
is not a requirement to re -read radiologica l scans to collect this data.  
6.3 Exclusion Criteria  
Patients will be excluded from participation if any of the following criteria apply:  
1. History of a prior malignancy except:  
− Curatively treated non -melanoma skin cancer  
− Breast cancer treated curatively >3 year s ago, or other solid tumor treated curatively >5 
years ago, without evidence of recurrence  
− Synchronous endometrioid endometrial cancer (Stage 1A G1/G2)  
2. Prior treatment with any PARP inhibitor, including oral or intravenous rucaparib. Patients who previous ly received iniparib are eligible.  
3. Required drainage of ascites during the final 2 cycles of their last platinum- based regimen 
and/or during the period between the last dose of chemotherapy of that regimen and randomization to maintenance treatment in this  study  
4. Symptomatic and/or untreated central nervous system (CNS) metastases. Patients with asymptomatic previously treated CNS metastases are eligible provided they have been clinically stable for at least 4 weeks.  
5. Pre-existing duodenal stent and/or any gastrointestinal disorder or defect that would, in the 
opinion of the investigator, interfere with absorption of study drug 
6. Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) -related  illness, or history o f chronic hepatitis B or C  
7. Pregnant or breast feeding. Women of child- bearing potential must have a negative serum 
pregnancy test ≤ 3 days prior to first dose of study drug 
8. Received treatment with chemotherapy, radiation, antibody the rapy or other immunotherapy, 
gene therapy, vaccine therapy, angiogenesis inhibitors, or experimental drugs ≤  14 days prior 
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  50 
 to first dose of study drug and/or ongoing adverse effects from such treatment > 
NCI-CTCAE Grade  1, with the exception of Grade  2 non- hematologic toxicity such as 
alopecia, peripheral neuropathy, and related effects of prior chemotherapy that are unlikely to be exacerbated by treatment with study drug  
− Ongoing hormonal treatment for previously treated breast cancer is permitted 
− Refer also to inclusion criteria #4  for guidelines pertaining to prior maintenance therapy  
9. Received administration of strong CYP1A2 or CYP3A4 inhibitors ≤7 days prior to first dose 
of study drug or have on- going requirements for these medications  (Appendix F ) 
10. Non-study related minor surgical procedure ≤ 5 days, or major surgical procedure ≤21  days, 
prior to firs t dose of study drug; in all cases, the patient must be sufficiently recovered and 
stable before treatment administration  
11. Presence of any other condition that may increase the risk associated with study participation or may interfere with the interpretatio n of study results, and, in the opinion of the 
investigator, would make the patient inappropriate for entry into the study 
6.4 Patients or Partners of Patients of Reproductive Potential  
Pregnancy is an exclusion criterion and women of child-bearing potential m ust not be 
considering gett ing pregnant during the study. Female patients are considered to be of 
child -bearing potential unless 1 of the following applies: 
• Postmenopaus al, defined as no menses for at least 12  months without an alternative 
medical cause. A  high follicle-stimulating hormone (FSH) level consistently in the 
postmenopausal range (30  mIU/mL or higher) may be used to confirm a postmenopausal 
state in women not using hormonal contraception or hormonal replacement therapy; however, in the absenc e of 12 months of amenorrhea, a single FSH measurement is 
insufficient to confirm a postmenopausal state : or  
• Considered to be permanently sterile. Permanent sterilization includes hysterectomy , 
bilateral salpingectomy,  and/or bilateral oophorectomy.  
Female patients of child -bearing potential must have a negative serum pregnancy test result 
≤ 3 days prior to administ ration of the first dose of study drug . In addition, a serum pregnancy 
test must be performed within ≤ 3 days prior to Day 1 of every subsequent cycle during the 
treatment phase  and at the Treatment Discontinuation visit. All pregnancy testing will be 
performed by the local laboratory. 
Female p atients of reproductive potential must practice highly effective method s of 
contraception (failure rate <  1% per year) with their male partners during treatment and for 
6 months following the last dose of study drug. Highly effective contraception includes: 
• Ongoing use of progesterone- only injectable or implantable contraceptives (eg, Depo 
Provera, Implanon, Nexplanon); 
• Placement of an intrauterine device (IUD) or intrauterine system (IUS);  
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  51 
 • Bilateral tubal occlusion ;  
• Male sterilization, with appropriate post- vasectomy documentation of absence of sperm 
in ejaculate ; or 
• Sexual abstinence as defined as complete or true abstinence, acceptable only when it is 
the usual and preferred lifestyle of the pa tient; periodic abstinence (eg , calendar, 
symptothermal, post -ovulation methods) is not acceptable . 
Patients will be instr ucted to notify the investigator if pregnancy is disco vered either during or 
within 6  months of completing treatment with  study drug.  
6.5 Waivers of Inclusion/Exclusion Criteria  
No waivers of these inclusion or exclusion criteria will be granted by the invest igator and the 
sponsor or its designee for any pat ient enrolling into the study.  
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  52 
 7 DESCRIPTION OF STUDY TREATMENTS AND DOSE MODIFICATIONS  
7.1 Description of Investigational Product 
Rucaparib camsylate (also known as CO -338; previously known as PF-01367338- BW) is an oral 
formulation with a molec ular weight of 555.67 Daltons. Rucaparib tablets for oral administration  
and matched  placebo tablets will be supplied to the study sites by the sponsor. A brief 
description of the investigational product is provided below.  
Drug Name:  CO-338 
rINN:  rucaparib  
Formulation:  Tablet; film coated; 120 mg (salmon, oval), 200 mg (blue, round, 
debossed with C2) , 250  mg (white, rounded diamond shape, debossed 
with C25), 300  mg (yellow, oval, debossed with C3)  
How Supplied:  120, 200, 250, and 300 mg (as free base) strength tablets in high -density 
polyethylene bottles or equivalent with child-resistant caps. Patients may 
receive one or more strengths.  
Storage Conditions:  15–30 °C/ 59-86 ºF  
 
Placebo tablets will be identical in appearance to the rucaparib tablets , matched for each strength . 
Study drug containers containing rucaparib or p lacebo tablets will be labeled according to 
national regulations for investigational products  together with the batch expiry date. 
Exceptionally, w here accepted, the expiry date for the 120 mg strength tablets will not appear on 
the labels, but will be controlled by the use of an Interactive Voice Response System /Interactive 
Web Response System  (IVR S/IWRS).  
7.2 Method of Assigning Patients to Treatment Groups  
Following confirmation of eligibility in the screening phase, patients will be randomized 2:1 to 
receive rucaparib or placebo.  Randomization will occur by a central randomization procedure 
using IVRS/IWRS . The following will be included as randomization stratification factors at 
study entry to ensure treatment groups are balanced:  
• HRD classification ( tBRCA, nbHRD, or biomarker negative) by the ICTA  
(Appendix A ) 
• Interval between completion of the penultimate platinum- based regimen and 
disease progression (6 to 12 or >12 months) by radiologic assessment  
• Best response ( CR [defined as complete radiologic response by RECIST] or PR 
[defined as partial response by RECI ST and/or a GCIG CA-125 response] to 
platinum regimen received immediately prior to initiation of maintenance therapy. All responses require that CA -125 be <ULN. 
Randomization to study treatment must occur within 8 weeks following a patient’s last dose of platinum-based chemotherapy. Study treatment must be initiated within 3 days of random ization.  
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  53 
 7.3 Preparation and Administration of Protocol -Specified Treatment 
The investigator or designee will be responsible for distributing study drug to all patients. Study 
drug will be assigned by the IVRS/IWRS according to the patient’s randomization assignment. The system must be accessed at each dispensation in order to retrieve the bottle number appropriate to the patient’s treatment. Study sites should follow local guidelines for the handling of oral cytotoxic drugs. 
All patients will ingest study drug twice a day. Patients may take study drug on an empty 
stomach or with food (with a regular meal or within 30  minutes  after a regular meal) . Each dose 
should be taken with at least 8 oz (240 mL ) of room temperature water. Tablets should be 
swallowed whole.  
Patients should take study drug doses as close to 12  hours apart as possible , preferably at the 
same times every day . If a patient misses a dose ( i.e. does not take it within 4  hours of the 
scheduled time ), she should skip the missed dose and resume taking study drug with their next 
scheduled dose. Missed or vomited doses should not be made up. A sufficient number of tablets will be provided to the patient to last until the next scheduled visit. 
Patients will be instructed to bring their study drug tablets  and all containers (empty, partially 
used, and/or unopened) to the next scheduled visit for reconciliation by site personnel. A 
compliance check and t ablet count will be performed by study personnel during clinic visits and 
the dose dispensation will be entered in the eCRF.  
• Once available supplies of 120 mg tablets /matching placebo are exhausted or the expiry 
date is reached, patients receiving this dose strength will be transitioned to 200  mg, 
250 mg or 300  mg tablets /matching placebo, or combination of dose strengths. If/when 
patients are transitioned from 120  mg to 200 mg, 250 mg , or 300 mg strength tablets, the 
investigator has the discretion to select the dose most appropriate for the patient, 
rounding up or down as necessary. 
• The dose that a patient will receive upon transition from 120  mg to 200 mg, 250 mg or 
300 mg tablets /matching placebo  will be agreed upon between the investigator and 
sponsor (or designee) in advance of any dosing change. 
7.3.1 Dietary Restrictions  
All patients participating  in the study should be instructed not to consume any grapefruit 
products or any of the CYP1A2 or CYP3A4 inhibitors noted in Appendix F  for 7 days prior to 
their first scheduled dose of oral rucaparib or placebo. 
7.4 Starting Dose and Dose Modifications of Pro tocol -Specified Treatment  
7.4.1 Starting Dose  
The starting dose in this study will be 600 mg  rucaparib or matched placebo, BID. 
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  54 
 7.4.2 Dose Modification Criteria  
Treatment with study drug should be held if any of the following are observed and a dose 
reduction should be considered or implemented:  
• Grade  3 or 4 hematologic toxicity  
Grade  3 or 4 non- hematologic toxicity (except for nausea, vomiting, or diarrhea 
adequately controlled with sys temic antiemetic/antidiarrheal medication administered in 
standard doses accordin g to the study center routines) . Grade 3 or Grade 4 ALT/AST 
elevations should be managed as de scribed below .  
• In addition, and at the discretion of the investigator, the dose of study drug may  be held 
and/or reduced for Grade  2 toxicity not adequately controlled by concomitant 
medications and/or supportive care.  
MANAGEMENT OF STUDY DRUG  TREATMENT- EMERGENT ALT/AST 
ELEVATIONS  
• Grade 4 ALT/AST elevations : hold study drug until values have returned to Grade 2 or 
better, then resume study drug with a dose reduction. Monitor liver function tests weekly 
for 3 weeks after study drug has been restarted.  
• Grade 3 ALT/AST elevations, in the absence of other signs of liver dysfunction, should be managed as follows:  
– Monitor liver function tests weekly until resolution to ≤  Grade 2. 
– Continuation of study drug with elevation of ALT/AST up to Grade  3 is permitte d 
provided bilirubin is <  ULN and alkaline phosphatase is <  3 x ULN.  
– If patient has Grade 3 ALT/AST and continues on study drug , and levels do not 
decline within 2 weeks or they continue to rise, treatment interruption and resolution to ≤  Grade 2 will be required before  study drug can be resumed, either 
at the current dose or at a reduced dose. 
Treatment with study drug should be held until the toxicity resolves to ≤  CTCAE Grade  2. Twice 
daily dosing may then be resumed at either the same dose or a lower dose,  per investigator 
discretion.  If treatment is resumed at the same dose, and the patient experiences the same 
toxicity, the dose should be reduced following resolution of the event  to ≤ CTCAE Grade  2. If a 
patient continues to experience toxicity despit e dose reduction to 240 mg/300 mg BID rucaparib 
or placebo , or if dosing with study drug is interrupted for >  14 consecutive days due to toxicity, 
treatment discontinuation or further dose reduction should be discussed and agreed between the investigator and the s ponsor.  
MANAGEMENT OF NEW OR WORSENING PULMONARY SYMPTOMS  
If new or worsening unexplained pulmonary symptoms suggestive of pneumonitis (including, but not limited to, dyspnea) occur, or a deterioration of pulmonary function is observe d, and/or 
radiologic abnormality is detected in the lungs, and this occurs in the absence of any clear diagnosis, a diagnostic workup (including high- resolution CT scan) in consultation with a 
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  55 
 pulmonologist should be performed in order to rule out pneumoni tis. During this time, treatment 
with study drug may be interrupted or continued per investigator discretion. If study drug is 
given in combination with another agent, the contribution of the other agent should also be assessed independently.  
Following investigation, if pneumonitis is not confirmed, treatment with study drug may be resumed/continued as deemed appropriate by the investigator and in accordance with the study protocol directions for management of AEs. All confirmed events of pneumonitis should be treated as appropriate per medical judgement and institutional guidelines. If the event resolves and retreatment with study drug is being considered, please consult the study Medical Monitor. Retreatment with study drug may be resumed at the current or a reduced dose, if appropriate.  
Refer to Section  10.3 and Section  10.8 of the protocol for additional information regarding 
classification and reporting of pneumonitis (and related events) as an AESI. Dose reduction steps are presented in  Table 2.  
Dose re- escalation upon resolution of toxicity to ≤  CTCAE Grade 1 is permitted at the discretion 
of the investigator. 
Table 2. Dose Reduction Steps  
Tablets  120 mg  200/250/300 mg  
Starting Dose  600 mg BID  
Dose Level -1 480 mg BID  500 mg BID  
Dose Level -2 360 mg BID  400 mg BID   
Dose Level -3* 240 mg BID  300 mg BID  
*Additional dose reduction steps should be discussed with the medical monitor. 
7.4.3 Criteria for Re -Treatment 
A new cycle of treatment may begin if: 
• ANC ≥1.0 x 109/L 
• Platelet count ≥ 75 x 109/L 
• Non-hematologic toxicities  have returned to baseline or ≤  CTCAE  Grade  1 
severity (or, at the investigator’s discretion, ≤  CTC AE Grade  2 severity if not 
considered a safety risk for the patient) . Grade 3 or Grade 4 ALT/AST elevations 
should be managed as described above. 
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  56 
 7.5 Accountability of Protocol -Specified Treatment  
Study personnel will maintain accurate records of study drug receipt, disp ensation, use, return, 
destruction, and reconciliation. A n IVRS/IWRS will be used to manage study drug inventory at 
all sites. In order to function properly , and to ensure patients receive the correct study drug 
according to the treatment assigned at rando mization , the system will require real -time entry of 
study drug receipt, dispensation, or destruction, etc. by study personnel at the study center.  
The site is responsible for the return or destruction of study drug as required . Authorization to 
destroy st udy drug at the site that has not been dispensed to a patient (eg, expired study drug), 
must be requested from the sponsor prior to destruction. Any study drug accidentally or 
deliberately destroyed must be accounted for. All study drug containers  must be accounted for 
prior to their destruction at the study center, according to institutional procedures for disposal of 
cytotoxic drugs. Unused study drug containers  should be destroyed on- site if possible. 
Destruction of damaged or expired study drug at the s ite requires prior approval by the sponsor. 
If destruction on site is not possible, supply should be returned to the drug depot.  
During the course of the study and at  completion of the study, the number of study drug 
containers received, dispensed, returned, and destroyed must be reconciled.  
7.6 Blinding/Masking of Treatment  
Active and matching placebo tablets of  the same dose strength will be identical in appearance 
and supplied in identical containers. The medication labeling  will ensure th at no staff member or 
patient will be able to identify whether the tablets are placebo or contain active medication.  
Patients will take the equivalent number of active or placebo tablets according to the treatment 
assignment and scheduled dose.  
In the even t of a medical emergency, an individual patient’s treatment assignment may be 
unblinded using IVRS/IWRS. The module to unblind treatment assignment is accessible only to specific authorized study personnel. AEs per se are not a reason to break the treatmen t code. 
Unblinding should only occur for  medical emergencies that require explicit knowledg e of the 
treatment administered in order to dete rmine the next course of action. The IVRS/IWRS vendor 
operates a 24 -hour/365 -day helpline as a back -up in the rare ev ent the electronic system is  
unavailable when unblinding is required.  
The study will not be unblinded for overall safety evaluation. 
7.7 Treatment Compliance  
Study site personnel will review dosing information with the patient (or legally authorized representative) on scheduled clinic visit days, providing instructions regarding  dose , dose 
frequency  and the number of tablets to be taken for each dose  as well as requirements to return 
all containers at next clinic visits for accountability purposes . A compliance check and tablet 
count will be performed by study personnel  during clinic visits  and the dose dispensation will be 
entered in the eCRF . 
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  57 
 8 PRIOR AND CONCOMITANT THERAPIES  
Patients who have received prior treatment with a PARP inhibitor including IV  or oral rucaparib , 
are not eligible to participate in this study. Patients having received prior treatment with iniparib 
are eligible.  
During the study, supportive care ( eg, antiemetics; analgesics for pain control) may be used at 
the investigator’s discretion and in accordance with institutional procedures.  
All procedures performed (eg , thoracentesis, etc.) and medications used during the study must be 
documented on the eCRF.  
8.1 Anticancer or Experimental Therapy  
No anticancer therapy is permitted to have be en administered as maintenance treatment in the 
interval period between completion of the most recent platinum- based chemotherapy and 
initiation of maintenance treatment in this study. 
No other anticancer therapies (including chemotherapy, radiation, hormonal treatment, antibody 
or other immunotherapy, gene therapy, vaccine therapy, angiogenesis inhibitors, or other experimental drugs) of any kind will be permitted while the patient is participating in the study , 
with the exception of ongoing hormonal treatment for previously treated breast cancer.  
8.2 Hematopoietic Growth Factors and Blood Products  
Erythropoietin, darbepoetin alfa, and/or hematopoietic colony- stimulating factors for treatment 
of cytopenias should be administered according to institutional guidelines. Transfusion thresholds for blood product support will be in accordance with institutional guidelines. 
8.3 CYP450 Isoenzyme Inhibitor s, Inducers , and Substrates  
Based on the results from the in vivo CYP -interaction clinical study CO -338-044, rucaparib is a 
moderate inhibitor of CYP1A2, a weak inhibitor of CYP2C9, CYP2C19, and CYP3A, and shows no clinically significant effect on P -gp. Caution should be used in patients taking 
concomitant medicines that are substrates of CYP1A2, CYP2C9, CYP2C19, and/or CYP3A with 
narrow therapeutic windows; dose adjustments may be considered, if clinically indicated (Appendix F ). Please refer to current IB for further information.  
Although in vitro  rucaparib metabolism mediated by CYP3A4 was slow, a significant 
contribution of CYP3A4 in vivo cannot be excluded. Caution should be used for concomitant use of strong CYP3A4 inhibitors or inducers. 
8.4 Bisphosphonates  
Bisphosphonates are permitted. 
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  58 
 8.5 Anticoagulants  
Rucaparib is a weak inhibitor of CYP2C9 in vivo. Caution should be exercised in patients 
receiving study drug and concomitant warfarin (C oumadin). Patients taking warfarin should have 
international normalized ratio (INR)  monitored regularly per standard institutional practice.  
8.6 Other Concomitant Medications  
Therapies considered necessary for the patient’s well -being may be given at the discretion of the 
investigator and should be documented on the eCRF. Other concomitant medications, except for analgesics, chronic treatments for concomitant medical conditio ns, or agents required for 
life-threatening medical problems, should be avoided. H erbal and complementary therapies 
should not be encouraged because of unknown side effects and potential DDIs, but any taken by 
the patient should be documented appropriately on the eCRF. 
Rucaparib marginally increased digoxin area under the plasma concent ration -time curve (AUC) 
by 20%. Caution should be exercised for patients receiving rucaparib and requiring concomitant 
medication with digoxin. Patients taking digoxin should have their digoxin levels monitored after starting rucaparib and then regularly per standard clinical practice.  
In vitro , rucapari b is a potent inhibitor of MATE 1 and MATE2- K, a moderate inhibitor of OCT1, 
and a weak inhibitor of OCT2. As inhibition of these transporters could increase metformin renal elimination and decrease liver uptake of metformin, caution is advised when metformin is co -
administered with rucaparib. In addition, rucaparib is an inhibitor of the BCRP with IC
50 value 
suggesting potential BCRP inhibition and increased exposures of medicinal products that are BCRP substrate (eg, rosuvastatin).   
8.7 General Restrictions  
Photosensitivity has been observed in patients treated with rucaparib. Patients should avoid spending time in direct sunlight because they burn more easily during treatment with rucaparib. When outdoors, patients should use typical precautions such as applying sunscreen (sun protection factor 50 or greater) and/or covering exposed skin with clothing and wearing a hat and sunglasses.  
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  59 
 9 STUDY PROCEDURES 
9.1 Schedule of Assessments  
Table  3 summarizes the procedures and assessments to be performed for all patients 
remaining on treatment or in follow  up as of implementation of Protocol Amendment 5. 
The revised evaluations should commence immediately after the patient has provided 
appropriate informed consent, maintaining previous treatment cycle and day sequence . 
The revised Schedule of Assessments replaces all prior schedules of assessment . 
All procedur es and assessments are to be completed within ± 3 days of the scheduled time point 
unless otherwise stated .  
The purpose of the revised schedule of assessment is to allow patients who continue to benefit 
from treatment with rucaparib to continue on treatment and follow -up but to reduce the number 
of assessments required at study visits (including at the end of treatment and follow -up 
assessments), while maintaining an appropriate level of safety monitoring.
Clovis Oncology, Inc.  Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  60 
 Table  3. Schedule of Assessments  After Implementation of Amendment 5  
Procedurea Blinded Treatment Phase  
(±3 days)  
Cycle X Day 1 Post-Treatment Phase 
Treatment 
Discontinuation  28-day 
Follow -up Long -term 
Follow -up 
Adverse Eventsb The investigator should monitor and educate patients on possible 
AEs observed with rucaparib  X  
Complete Blood Count  Monthly assessments advised    
Clinical Chemistry, Urinalysis, Vital Signs  Local standard of care practices per investigator    
Serum Pregnancy Test (WOCBP only)c X X   
Disease Assessment (Tumor Scans/CA -125)d Xe X Xf Xf 
Study Drug Dispensation/Administration/Accountability  X X   
Tumor Tissue Biopsy (optional)g  
X  
 
Subsequent Treatments, Secondary Malignancy 
Monitoring, and Overall Survivalh   
X X 
Abbreviations: AE  = Adverse event; AESI = adverse event of special interest; CA -125 = cancer antigen 125;  CR = complete response; CT = computed 
tomography; GCIG  = Gynecologic Cancer InterGroup; MRI  = magnetic resonance imaging; PET  = positron emission tomography; RECIST  = Response 
Evaluation Criteria in Solid Tumors; SAE  = serious adverse event; WOCBP  = women of child -bearing potential.  
a The study visit window in the double -blind treatment phase is ± 3 days, unless noted otherwise for a particular assessment. Study visits should take into 
account the subject’s investigational product supply. Study drug should be dispensed as applicable . 
b AEs will be monitored but only SAEs/AESIs are recorded through 28 days after last dose of rucaparib. Only treatment -related SAEs and all AESIs, 
regardless of causality, need to be reported after the 28 -day window.  Ongoing SAEs and AESIs will be followed unt il resolution, stabilization, or lost to 
follow -up.  
c Women of child -bearing potential must have a negative serum pregnancy test result ≤  3 days prior to the first dose of study drug. A serum pregnancy test 
must also be performed ≤  3 days prior to Day 1 of every cycle during the treatment phase and at the treatment discontinuation visit. All tests will be 
performed by a local laboratory.  
d Disease assessments to consist of clinical examination and appropriate imaging techniques (preferably CT scans of the chest, abdomen and pelvis, with 
appropriate slice thickness per RECIST); other assessment techniques (MRI, X- ray, PET, and ultrasound) may be performed if required. The same 
methods used to detect lesions at baseline are to be used to follow the same lesions throughout the clinical study. CT /MRI scans of the chest, abdomen, 
and pelvis performed to determine the extent of disease at baseline should also be performed at each time of disease assessme nt, even if the scans were 
negative at baseline.  
e Tumor scans to be performed every 12 calendar weeks (a 7 -day window prior is permitted) after start of treatment on Day 1 of Cycle 1. Disease 
progression will only be determined by RECIST v1.1. Patients with a CR at study entry will only be considered to have disease  progression if a new 
Clovis Oncology, Inc.  Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  61 
 lesion is identified. Patients who meet GCIG CA -125 criteria for disease progression should have a radiologic assessment and be assessed by RECIST 
v1.1. If the radiologic assessment does not confirm disease progression, patients should co ntinue on treatment and continue to be assessed by RECIST 
v1.1 per the protocol schedule of assessments. Patients who have been on study at least 18 months may decrease the frequency of disease assessments to 
every 16 (±2) weeks. Investigator should consul t with sponsor’s medical monitor before decreasing frequency.  
f To be performed every 12 calendar weeks (up to 7 days prior is permitted) through to investigator -assessed radiologic disease progression by RECIST 
v1.1 for any patient who discontinued from study treatment for reason other than disease progression or death. Patients who have been on study at least 
18 months may decrease the frequency of disease assessments to every 16 (±2) weeks. Investigator should consult with sponsor’s medical monitor before decreasing frequency.  
g An optional tumor biopsy may be collected from patients from time of radiographic disease progression until the start of the subsequent anticancer 
treatment. Additional consent is required. Refer to the Pathology Charter for detailed sample handling instru ctions. If disease progression is caused by 
appearance of a new lesion(s), the lesion(s) should be prioritized for the optional biopsy.  
h All patients discontinued from treatment, regardless of reason, should be followed for subsequent treatments, secondary malignancy, and survival 
approximately every 12  weeks (±  14 days) from Cycle 1 Day 1 until death, loss to follow -up, withdrawal of consent from study, or closure of the study. 
Follow -up can be performed via the telephone. Diagnosis of any secondary malignancy requires appropriate documentation (i.e. , laboratory and/or 
pathology reports) and should be reported as specified in Section  10.  
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  62 
 9.2 Screening Phase  
Following written informed consent, and unless otherwise specified, the following assessments 
will be performed prior to randomization. Assessments performed within the specified  window s, 
but prior to patient signing informed consent , are acceptable only i f confirmed to have been 
standard of care.  
Up to 120 days prior to randomization:  
• Medical history, including demographic information (birth date, race, gender, etc.) and smoking status, and oncology history, including date of diagnosis for ovarian, primary peritoneal, or FTC  (and other malignancy, if applicable), prior treatments receiv ed, dates of 
administration, best response achieved, date of progression and how assessed, radiology reports, and gBRCA mutation status (if known)  
• FFPE archival tumor tissue sample. Sufficient archival FFPE tumor tissue (enough for  
1 x 4 µ m section for H&E and approximately 8 to 12 x 10 µ m sections, or equivalent) for 
planned analyses should be provided. Refer to the Pathology Charter for detailed sample handling instructions.  
o The most recently collected tumor tissue sample should be provided, if availa ble.  
o Submission of a tumor block preferred; if sections are provided, these must all be 
from the same tumor sample.  
o Tumor content ≥30% is strongly preferred for successful genomic scarring/ LOH 
analysis  
o Sample must be submitted to the central laboratory at  least 3 weeks prior to 
planned start of treatment  in order to enable stratification for randomization  
• AE monitoring (only if related to screening procedure ) 
Up to 28 days prior to randomization:  
• PRO collected using the FOSI -18 and EQ -5D instruments  
• Physic al examination by body system, including height  and weight  
• Vital signs (blood pressure, pulse, and temperature)  
• 12-lead ECG  
• Prior and concomitant medications and any surgical procedures   
• Disease assessment/tumor scans: t umor assessments should consist of clinical examination 
and appropriate imaging techniques ( including CT  scans of the chest, abdomen, and pelvis 
with appropriate slice thickness per RECIST; other studies ( magnetic resonance imaging  
[MRI ], X-ray, positron emission tomography [PET], and ultrasound) may be performed if 
required. The same methods used to detect lesions at baseline are to be used to follow lesion s 
throughout the clinical study. If a patient has known brain metastases, this disease should be evaluated at each required assessm ent. CT/MRI scans of the chest, abdomen, and pelvis 
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  63 
 performed to determine the extent of disease at baseline should also be performed at each 
time of disease assessment, even if the scans were negative at baseline.  
• ECOG performance status  (Appendix D ) 
• AE monitoring (only if related to screening procedure) 
Up to 14 days prior to randomization: 
• Hematology (RBC and parameters [Hgb, Hct, MCH, MCV, and MCHC] and reticulocyte 
count, white blood cell [ WBC] and differential [with ANC], and platelet count  
• Serum chemistry (total protein, albumin, creatinine, or estimated GFR using the Cockcroft Gault formula, blood urea nitrogen [BUN] or urea, total bilirubin, alkaline phosphatase (ALP), ALT, AST, glucose, sodium, potassium, chloride, CO
2, calcium, and phosphorus) and 
lipid panel ( total cholesterol, low density lipoprotein [LDL], high density lipoprotein [HDL], 
and triglycerides). Note: f asting is not required.  
• Urinalysis performed on freshly voided clean sample (dipstick for protein, glucose, blood, 
pH, and ketones) ≤14 days prior to the first dose of study drug. If dipstick findings are 
abnormal based on investigator judgment, then a microscopic evaluation will be performed to 
assess the abnormal findings 
• CA-125 measurement  
• AE monitoring (only if related to screening procedure) 
Up to 3 days prior to first dose of study drug: 
• Serum pregnancy test for w omen of child -bearing potential 
• AE monitoring (only if related to screening procedure) 
9.3 Treatment Phase  
9.3.1 Day 1 of Cycle s 1 and 2 
The following procedures /assessments will be completed before study drug is administered:  
• PRO using the FOSI-18 and EQ-5D instruments 
• Physical examination  
• Weight 
• Vital Signs  
• Concomitant medicatio ns and procedures 
• ECOG performance status  (Appendix D) 
• Hematology  
• Serum chemistry  (fasting is not required) 
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  64 
 • Serum pregnancy for women of child-bearing potential (Cycle 2 only) 
• CA-125 measurement (Cycle  1 only)  
• Blood sample for storage (Cycle 1 only; i f sample is not collected on Day  1 of Cycle 1, it 
should be collected as soon as possible thereafter ) 
• Study drug dispensation  
• AE monitoring 
• Plasma PK sample ( prior to first dose taken that day) (Cycle 2 only; see Section  9.5.1 ) 
• Serum sample for alpha-1 acid glycoprotein ( AAG) sample (Cycle 2 only) 
Study drug will be dispensed to the patient in sufficient quantity to last until the next treatment 
cycle.  Patients will ingest study drug twice daily  at about the same time s every day , as close to 
12 hours apart as possible. Each dose of study drug should be taken with at least  8 oz (240 mL) 
of room temperature water. Patients may take study drug on an empty stomach or with food 
(with a regular meal or within 30  minutes  after a regular meal). Patients will record dosing 
information  in their electronic dosing diary. 
Patients will be instructed to refrain from taking their first dose of study drug at home on the day 
of their clinic visits because certain assessments must be performed prior to dosing.  
9.3.2 Day 15 of Cycle s 1 and 2  
The following procedures will be completed:  
• Concomitant medications and procedures  
• Hematology 
• Serum chemistry  (fasting is not required) 
• AE monitoring 
• Plasma PK sample (in morning or afternoon following the first dose of study drug taken this day; see Section  9.5.1) 
• Serum sample for AAG  analysis ( note: sample can be collected at the same time as 
hematology and serum chemistry and/or with the PK sample)   
Patients will ingest study drug twice daily  at about the same time s every day , at close to 12 hours 
apart as possible. Each dose of study drug should be taken with at least  8 oz (240 mL) of room 
temperature water. Patients may take study drug on an empty stomach or with food (with a 
regular meal or within 30  minutes after a regular meal). Patients will record dosing information 
in their electronic dosing diary. 
9.3.3 Cycles 3 and Beyond  
The revised Schedule of Assessments shown in Table  3 replaces all prior schedules of 
assessments as of implementation of Protocol Amendment 5.  
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  65 
 Disease assessment/tumor scans will be performed every 12 calendar weeks (within 7 days prior 
is permitted) after start of treatment on Day 1 of Cycle 1. Patients who have been on study at 
least 18 months may decrease the frequency of disease assessments to every 16 (±2) weeks. Investigator should consult with sponsor’s medical monitor before decreasing frequency. 
The following procedures are advised : 
• Hematology (complete blood count); monthly assessments advis ed 
• Clinical chemistry, urinalysis, and vital signs according to local standard of care per 
investigator 
• Serum pregnancy for women of child-bearing potential 
• CA-125 measurement  (Day 1 of Cycles 4, 7, 10, etc.)  
• AE monitoring 
• Study drug accountability 
Study drug will be dispensed to the patient in sufficient quantity to last until the next clinic visit. 
A single dose of study drug will be administered during the current clinic visit with at least 8 oz 
(240 mL) of room temperature water. P atients may take study drug on an empty stomach or with 
food (with a regular meal or within 30  minutes after a regular meal).  
Patients will continue dosing with study drug at home on an empty stomach or with food (with a 
regular meal or within 30  minutes after a regular meal) , taking doses twice daily  at about the 
same times every day. Study drug should be taken with at least 8 oz (240 mL) of room 
temperature water.  
9.4 Post-Treatment Phase  
9.4.1 Treatment Discontinuation  
The revised Schedule of Assessments shown in Table  3 replaces all prior schedules of 
assessments as of implementa tion of Protocol Amendment 5.  
Upon treatment discontinuation, regardless of the reason, patients will have a Treatment Discontinuation visit. The following procedures will be performed: 
• Tumor scans (using the same methodology as was used at screening) if r eason for treatment 
discontinuation was other than disease progression based on radiologic assessment  
• CA-125 measurement  
• Study drug accountability 
 
The following procedures are advised: 
• ECOG performance status  (Appendix D) 
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  66 
 • Hematology (complete blood count) 
• Clinical chemistry, urinalysis, and vital signs according to local standard of care per 
investigator 
• Serum chemistry  (fasting is not required) 
• Serum pregnanc y test for women of child -bearing potential 
• AE monitoring 
• Optional tumor tissue biopsy collection at time of disease progression/treatment 
discontinuation until the start of the subsequent anticancer  treatment (requires additional 
consent). If disease progression is caused by appearance of a new lesion(s), the lesion(s) 
should be prioritized for the optional biopsy. Tumor tissue will be processed locally as FFPE 
tissue. Refer to the Pathology Charter for detaile d sample handling instructions.  
9.4.2 28-day Follow -up 
The following procedures will be performed for all patients at 28 (±3) days after the last dose of study drug: 
• Disease assessment for patients who discontinued treatment for reason other than disease 
progression or death. Tumor scans should continue to be performed at 12- week  intervals (up 
to 7 days prior permitted) until radiologic disease progression by RECIST v1.1, as assessed by the investigator. Patients who have been on study at least 18 months may decrease the frequency of disease assessments to every 16 (±2) weeks. Investigator should consult with sponsor’s medical monitor before decreasing frequency.
  
• AE mo nitoring (only SAEs/AESIs are recorded through 28 days after last dose of rucaparib. 
Ongoing SAEs and AESIs will be followed until resolution, stabilization, or lost to follow-up). 
• Subsequent treatments, secondary malignancy monitoring, and overall survival ( OS) 
9.4.3 Long -term Follow -up 
• Disease assessment for patients who discontinued treatment for reason other than disease progression or death. Tumor scans should continue to be performed at 12- week  intervals (up 
to 7 days prior permitted) until radiologi c disease progression by RECIST v1.1, as assessed 
by the investigator. Patients who have been on study at least 18 months may decrease the frequency of disease assessments to every 16 (±2) weeks. Investigator should consult with sponsor’s medical monitor before decreasing frequency.
  
• Subsequent treatments, secondary malignancy monitoring, and OS  information will be 
collected for all patients approximately every 12 weeks  (± 14 days) until death, loss to 
follow -up, withdrawal of consent from study, or closure of the study. Follow- up can be 
performed via the telephone. Diagnosis of any secondary malignancy requires appropriate documentation (i.e., laboratory and/or pathology reports)  and should be reported as indicated 
in Section  10.8. 
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  67 
 • SAEs related to study drug and all AESIs, irrespective of causality, are to be reported as 
specified in Section  10.8 . 
9.5 Methods of Data Collection  
Hem atology, clinical chemistry,  urinalysis, serum CA-125, and serum pregnancy in women of 
child -bearing potential will be performed locally .  
9.5.1 Pharmacokinetic Evaluations  and AAG Measurement  
As of implementation of Protocol Amendment 5, samples will no longer be collected for PK and AAG analyses.  
9.5.2 Biomarker Analysis – FFPE Tumor Tissue  
Archival tumor tissue must be located during the screening process and submitted to the central 
laboratory directly  as soon as possible for determination of HRD status . Archival tumor tissue 
is required for HRD stratification for randomization and for storage for potential bridging to a 
validated companion diagnostic test.  
9.5.3 Biomarker Analysis – Blood 
As of implementation of Protocol Amendment 5, blood samples will no longer be collected for biomarker analyses. 
9.5.4 Safety Evaluations  
9.5.4.1 Adverse Event Assessment  
The investigator is responsible for  assessing the safety of the patients and for compliance with 
the protocol to ensure study integrity. Patients will be monitored for AEs during study participation, beginning after the first dose of study drug and until 28 days after the last dose of 
study drug. Any ongoing SAEs and AESI s will be recorded and followed until resolution , 
stabilization , or loss to follow-up. Only treatment -related SAEs and all AESIs, regardless of 
causality, need to be reported after the 28-day window. SAEs will be graded according to the NCI-CTCAE grading system (v4.03) and recorded on the eCRF. 
Complete details for monitoring AEs, including the definition of drug -related AEs, are provided 
in Section  10. 
9.5.4.2 Prior and concomitant medications  
Prior concomitant medications will be recorded during screening and concomitant medications will be collected from study entry until the Treatment Discontinuation visit.  
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  68 
 9.5.4.3 Clinical Laboratory Investigations  
Certified local laboratories will perform study -related clinical laboratory tests according to 
institutional procedures, and the results will be reviewed by the investigator. The panels of 
laboratory tests to be performed are shown below:  
Hematology: As of implementation of Protocol Amendment  5, monthly hematology assessment, 
consisting of a complete blood count, is advised.  
Clinical Chemistry: As of implementation of Protocol Amendment  5, clinical chemistry 
assessments may be performed according to local standard of care per i nvestigator.  
Urinalysis: As of implementation of Protocol Amendment 5, urinalysis may be performed 
according to local standard of care per i nvestigator.  
Laboratory reports should be reviewed by the investigator or delegated physician who will assess clinical significance.  
Serum Pr egnancy:  For women of child -bearing potential only. Serum pregnancy testing is to be 
performed ≤  3 days prior to first dose of study drug, ≤  3 days  prior to the start of every cycle 
during the treatment phase , and at the Treatment Discontinuation v isit. 
9.5.4.4 Vital Signs  
As of implementation of Protocol Amendment 5 , vital signs may be performed according to local 
standard of care per i nvestigator.   
9.5.4.5 12-Lead Electrocardiograms  
As of implementation of Protocol Amendment 5 , ECGs will no longer be  a required procedure 
for this protocol.  
9.5.4.6 Body Weight and Height  
As of implementation of Protocol Amendment 5, body height and weight assessments will no longer be a required procedure for this protocol.   
9.5.4.7 Physical Examinations  
As of implementation of Protoc ol Amendment  5, physical examinations  will no longer be a 
required procedure for this protocol.   
9.5.4.8 ECOG Performance Status 
As of implementation of Protocol Amendment 5 , ECOG performance status assessments will no 
longer be a required procedure for this proto col. 
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  69 
 9.5.5 Efficacy Evaluations  
9.5.5.1 Disease Assessments  
Tumor assessment measurements will be performed at screening, at the end of every 12  weeks of 
treatment (up to 1 week prior permitted) relative to Cycle 1 Day 1, at discontinuation of 
treatment, and as clinically indicated. Patients who have been on study at least 18 months may decrease the frequency of disease assessments to every 16 (±2) weeks. Investigator should consult with sponsor’s medical monitor before decreasing frequency.  
Disease assessment will comprise clinical examination and appropriate imaging techniques (CT 
scans of the chest, abdomen, and pelvis with appropriate slice thickness per RECIST); other 
studies (MRI, X -ray, PET, and ultrasound) may be performed if required. If a patient has known 
brain metastases, this disease should be evaluated at each required assessment. The same 
methods used to detect lesions at baseline are to be used to follow the same lesions throughout the clinical study. CT /MRI scans of the chest, abdomen, and pelvis performed to determine the 
extent of disease at baseline should also be performed at each time of disease assessment, even if the scans were negative at baseline. Investigators should perform scans of other anatomical sites 
that, in their judgment, are appropriate to assess based on each patient’s tumor status. Imaging 
guidelines provided in the Bioclinica Site Manual should be followed for the collection of images and the radiological assessment of disease.   
Tumor response will be interpreted using RECIST v1.1 ( Appendix B ). Disease progression will 
only be determined by RECIST v1.1. Patients with a CR at study entry will only be considered to have disease progression if a new lesion is identified. Patients who meet GCIG CA -125 criteria 
for disease progression should have a radiologic assessment and be assessed by RECIST. If the radiologic assessment does no t confirm disease progression, patients should continue on 
treatment and continue to be assessed by RECIST v1.1 per the protocol schedule of assessments.  
Patients who discontinued treatment for reason other than disease progression or death should continue to have tumor scans performed at 12- week  intervals (up to 7 days prior permitted) until 
radiologic disease progression  by RECIST  v1.1, as assessed by the investigator.  Patients who 
have been on study at least 18 months may decrease the frequency of disease assessments to every 16 (±2) weeks. Investigator should consult with sponsor’s medical monitor before decreasing frequency. 
9.5.5.2 Tumor Markers  
CA-125 measurement will be performed at screening, on Day 1 of Cycle 1, at the start of every 
3rd cycle thereafter (i.e., Day 1 of Cycle 4, Cycle 7, Cycle 10, etc.), at discontinuation of treatment, and as clinically indicated . 
9.5.6 Patient- Reported Outcomes  
With the implementation of Protocol Amendment 4, t he collection of patient -reported outcomes 
was no longer required .   
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  70 
 9.5.7 Appropriateness of Measurements  
The assessments planned in the protocol are widely used and recognized as reliable, accurate and 
relevant.  
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  71 
 10 ADVERSE EVENT MANAGEMENT  
10.1 Definition of an Adverse Event  
An AE is any untoward medical occurrence, including the exacerbation of a pre -existing 
condition, in a patient administered a pharmaceutical product. The pharmaceutical product does 
not necessarily have a causal relationship with the AE. Anticipated fluctuations of pre -existing 
conditions, including the  disease under study, that do not represent a clinically significant 
exacerbation or worsening are not considered AEs.  
For the purposes of this study, disease progression of the patient’s tumor with new or worsening symptoms must be documented as an AE. However, disease progression documented solely by radiographic evidence with no new or worsening symptoms will not require reporting as an AE.  
It is the responsibility of the investigator to document all AEs that occur during the study. AEs 
should be elicit ed by asking the patient a nonleading question (eg, “Have you experienced any 
new or changed symptoms since we last asked/since your last visit?”). The existence of an AE may be concluded from a spontaneous report of the patient; from the physical examinat ion; or 
from special tests such as the ECG, laboratory assessments, or other study -specified procedure 
(source of AE). AEs will be reported on the AE eCRF. Symptoms reported spontaneously by the patient during the physical examination will also be document ed on the AE eCRF.  
10.2 Definition of a Serious Adverse Event 
An SAE is any untoward medical occurrence that occurs at any dose that:  
• Results in death.  
• Is immediately life -threatening (i.e. the patient is at risk of death at the time of the event; it 
does not r efer to an event that hypothetically might have caused death if it were more 
severe).  
• Requires in -patient hospitalization or prolongation of existing hospitalization.  
• Results in a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions.  
• Results in a congenital anomaly or birth defect.  
• Important medical events that may not result in death, are not life -threatening, or do not 
require hospitalization may be considered SAEs when, based on appropriate medica l 
judgment, they may jeopardize the patient and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. Examples of such events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, or the 
development of drug dependency or drug abuse.  
10.3 Definition of an Adverse Event of Special Interest  
An AESI (serious or nonserious) is one of scientific and medical concern specific to the sponsor’s product or program, for which ongoing monitoring and rapid communication by the 
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  72 
 investigator to the sponsor can be appropriate. Such an event might warrant further investigation 
in order to characterize and understand it. Depending on the nature of the event, rapid communication by the trial sponsor to other parties (eg, health authorities or ethics committees) might also be warranted.  
Details on the sponsor’s currently agreed list of AESIs for rucaparib can be found in the current rucaparib IB. These AESIs are to be reported to the sponsor expeditiously (see Section  10.8 for 
reporting instructions).  
Report any AE of pneumonitis, or any of the following AEs, irrespective of causality assessment and severity, as an AESI within 24 hours using the study Serious Adverse Event Form and the applicable procedures as outlined in Section 10.8 :  
•
 pneumonitis  
• interstitial lung disease  
• pulmonary fibrosis  
• acute interstitial pneumonitis  • alveolitis necrotizing  
• alveolitis  
• hypersensitivity pneumonitis  
• organizing pneumonia  
 
10.4 Exceptions to Serious Adverse Event Reporting  
The fol lowing are not considered SAEs and therefore are not required to be reported to the 
sponsor : 
• Pre-planned or elective hospitalization, including social and/or convenience situations ( eg, 
respite care).  
• Hospital visits of less than 24  hours duration (eg, patient presents to the emergency room, but 
is not admitted to a ward) .  
• Overdose of either study drug or concomitant medication, unless associated with an SAE . If 
the event does not meet SAE criteria , it should still be captured as a non -serious AE on the 
appropriate eCRF.  
• Events of disease progression of the patient’s underlying cancer as well as events clearly related to disease progression (i.e., signs and symptoms) should not be reported as a SAE unless the outcome is fatal and occurs during the safety reporting period. If the event has a 
fatal outcome during the safety reporting period, then the event of Progression of Disease must be recorded as an AE/SAE with C TC Grade 5 (fatal outcome) indicated . 
• Diagnosis of progression of disease or hospitalization due to signs and symptoms of disease 
progression alone should not be reported as a SAE. 
10.5 Clinical Laboratory Assessments and Other Abnormal Assessments as 
Adverse Events and Serious Adverse Events  
It is the responsibility of the investigator to assess the clinical significance of all abnormal 
laboratory values as defined by the list of reference ranges from the local laboratory. In some 
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  73 
 cases, significant change in laboratory values within the normal range may require similar 
assessment.  
An abnormal value that is not already associated with an AE is to be recorded as an AE only if one of the foll owing criteria is met:  
• It resulted in treatment modification (reduction of dose, interruption of dosing, or permanent discontinuation of study drug)  
• It required intervention /management  
• It is suggestive of organ toxicity  
• The i nvestigator considers it to be clinically significant  
10.6 Pregnancy  or Drug Exposure during Pregnancy  
If a patient becomes pregnant during the course of the study, study drug dosing should be held immediately.  
Pregnancy is not considered to be an AE or SAE; however, all pregnancies occurrin g during 
study participation or within 6 months of last dosing must be reported to the sponsor using the Clinical Pregnancy Report form within the same timelines as for as SAE.  
All pregnancies should be followed through to outcome whenever possible. Once t he outcome of 
a pregnancy is known, the Clinical Pregnancy Outcome Report form should be completed and submitted to the sponsor.  
AEs, SAEs, or AESIs that occur during pregnancy will be assessed and processed according to the AE or SAE /AESI processes using the appropriate AE or SAE /AESI forms .  
10.7 Recording of Adverse Events , Serious Adverse Events , and Adverse Events 
of Special Interest  
As of the implementation of Amendment 5, only  SAEs/AESIs  will be fully documented on the 
appropriate eCRF. For each S AE/AESI , the i nvestigator must provide duration (start and end 
dates or ongoing), intensity, relationship to study drug, and indicate whether specific action or therapy was required.  
Any SAE /AESI  that occurs after the first d ose of study drug until  28 days after last dose of study 
drug administration will be collected, documented and reported to the sponsor by the investigator 
according to the specific definitions and instructions detailed within this protocol, whether dosing has occurred or not. In addition, any AE/SAE that occurs after informed consent is obtained and is deemed related to a screening procedure for the study should also be reported on the AE eCRF and, if applicable, the SAE report form. Events that occur after signing of informed consent but prior to initiation of study drug, unless due to a protocol -mandated procedure, should 
be recorded on the Medical History eCRF. In order to avoid vague, ambiguous, or colloquial expressions, the AE should be recorded in standard medical terminology rather than the patient’s own words. Whenever possible, the investigator should combine signs and symptoms that 
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  74 
 constitute a single disease entity or syndrome into a final diagnosis. For example, fever, cough, 
and shortness of breath may be reported as pneumonia, if that is a reasonable diagnosis.  
All SAEs /AESIs that occur during the study or within 28 days after receiving the last dose of 
study drug, regardless of relationship to study drug, must be reported to the sponsor/designated safety contact imme diately (i.e., within 24 hours of the investigator’s knowledge of the event). 
This should be done by faxing or emailing the completed SAE/ AESI report to the 
sponsor/designee contact provided on the SAE/ AESI report form. After the 28 -day window after 
treatment discontinuation, only SAEs assessed as related to study drug and all AESIs, irrespective of causality, should be reported. If a patient is determined to be a screen failure, no further AEs /SAEs are required to be reported once that determination has been made, with the 
exception of AEs/ SAEs deemed related to a protocol -specified procedure. Information on the 
follow -up of AEs, SAEs, and AESIs is provided in Section  10.7.4.  
10.7.1  Intensity of Adverse Events  
Severity refers to the intensity of an AE. The severity of each AE will be categorized using the NCI-CTCAE, v4.03.
54 
For any term that is not specifically listed in the CTCAE, intensity should be assigned a grade of 1-5 using the following CTCAE guidelines:  
• Mild (Grade 1): mild or asymptomatic symptoms; clinical or diagnostic observations only; 
intervention not indicated 
• Moderate (Grade 2): limiting age -appropriate instrumental activities of daily living; minimal, 
local or noninvasive intervention indicated 
• Severe (Grade 3): limiting self -care activities of daily living; hospitalization indicated  
• Life threatening (Grade 4): life -threatening consequences; urgent intervention indicated 
• Fatal (Grade 5): results in death  
10.7.2  Causal Relationship of Adve rse Events to Study Drug   
Medical judgment should be used to determine the cause of the AE considering all relevant factors such as, but not limited to , the disease under study, concurrent disease, concomitant 
medication, relevant history, pattern of the AE, temporal relationship to the study medication, dechallenge or rechallenge with the study drug.  
Not Related 
To Study Drug  An AE that is clearly due to extraneous causes (eg, concurrent disease, concomitant medication, disease under study, etc.)  
An AE that does not follow a reasonable temporal sequence from administration of the study drug.  
An AE that does not follow a known pattern of response to study drug.  
An AE that does not reappear or worsen when study drug is restarted.  
An AE for which an alternati ve explanation is likely, but not clearly identifiable.  
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  75 
 Related to 
Study Drug  An AE that is difficult to assign to alternative causes.  
An AE that follows a  strong or reasonable temporal sequence from  administration of 
study drug.  
An AE that could not be reasonably explained by the patient’s clinical state, 
concurrent disease, or other concomitant therapy administered to the patient.  
An AE that  follows a known response pattern to study drug.  
An AE that is  confirmed with a positive rechallenge or supporting laboratory data.  
10.7.3  Outcome   
The investigator will record the outcome for each AE according to the following criteria:  
• Recovered/Resolved  
• Recovered/Resolved with sequelae  
• Improved  
• Ongoing 
• Death  
• Unknown/Lost to follow -up 
10.7.4  Follow -up of Adverse Events, Serious Adverse Events, and Adverse Events of 
Special Interest   
All AEs (including SAEs and AESIs) occurring during the study are to be followed up in 
accordance with good medical practice until resolved; judged no longer clinically significant; or, if a chronic condition, until fully characterized until 28 days after the last dose of study treatment. Any SAE /AESI must be followed until the event has resolved, the condition has 
stabilized, or the patient is lost to follow up. If the patient is lost to follow -up with an ongoing 
SAE /AESI, this should be captured accordingly on a follow -up SAE /AESI report.  
10.8 Regulatory Aspects of Adverse Event Reporting  
All SAEs and AESIs, irrespective of relationship to study treatment, as well as all pregnancies, must be repor ted to the s ponsor’s SAE designee within 24 hours  of knowledge of the event, 
occurring during the study through 28 days after receiving the last dose of study treatment, according to the procedures below. After the 28 -day specified window, SAEs considered to be 
treatment related and all AESIs, regardless of treatment relationship, should be reported if occurring. Pregnancies that occur within 6 months of the last dose of study drug should be reported. It is important that the investigator provide an assessm ent of relationship of the 
SAE /AESI to study treatment at the time of the initial report. The SAE /AESI Report form must 
be used for reporting SAEs /AESIs. The contact information for reporting of SAEs /AESIs can be 
found on the SAE /AESI Reporting Form and Pregnancy Report Forms . 
Clovis Oncology, Inc. (Clovis Oncology), or its designee is responsible for submitting reports of AEs associated with the use of the drug that are both serious and unexpected to the Food and Drug Administration ( FDA), according to 21 Code of Federal Regulations (CFR)  312.32;  to the 
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  76 
 European regulatory authorities according to the European Commission Clinical Trials Directive 
(2001/20/EC); and to other regulatory authorities, according to national law and/or local regulations. All inv estigators participating in ongoing clinical studies with the study medication 
will receive copies of these reports for prompt submission to their IRB  or IEC. In accordance 
with the European Commission Clinical Trials Directive (2001/20/EC), Clovis Oncology or its designee will notify the relevant ethics committees in concerned member states of applicable suspected unexpected serious adverse reactions (SUSARs) as individual notifications or through periodic line listings.  
Clovis Oncology or its designee wil l submit all safety updates and periodic reports to the 
regulatory authorities as required by applicable regulatory requirements.  
10.9 Independent Data Monitoring Committee  
No formal efficacy interim analyses are planned.  
An IDMC will be established to review safety and efficacy data in complian ce with a prospective 
charter and will be involved until the primary endpoint has been met and the study unblinded. 
The I DMC will be comprised of medical oncologists with experience in treating women with 
ovarian cancer  and a statistician, all of whom are not otherwise involved in the study as 
investigators. The IDMC responsibilities, authorities, and procedures will be documented in the IDMC charter, which will be endorsed and signed by the IDMC prior to the first data re view 
meeting.  
The IDMC will:  
• Review safety and efficacy  of rucaparib compared with placebo to ensure the study is 
beneficial to patients  
• Ensure the study is conducted in a high quality manner  
• Monitor the size of the t BRCA subgroup and the known gBRCA group 
Following data review, the IDMC will recommend continuation, revision, or termination of the study and/or continuing or halting enrollment into a particular subgroup. The I DMC wi ll meet at 
least semi -annually after  sufficient dat a has been collected.  The IDMC chairperson may convene 
formal IDMC meeting if there are safety concerns. The sponsor can also request an IDMC 
review of safety data.  
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  77 
 11 STATISTICAL METHODS  
11.1 Analysis Populations  
The following analysis populations are defined for  the study:  
Safety Table  Population – The safety population will consist of all patients who received at 
least one dose of protocol -specified treatment.  
Intent -to-treat (ITT) Population  − The ITT population will consist  of all randomized patients.  
11.2 Statistical Methods  
11.2.1  General Considerations  
Variables r egistered on a continuous scale  will be presented  using the following descriptive 
statistics : N, mean, standard deviation, median, minimum and maximum. Continuous variables 
may also be presented using frequencies  and percentages among appropriate categorizations. 
Categorical variables will be presented using frequencies and percentages. The Kapla n-Meier 
methodology will be used to summarize time -to-event variables. The number of patients with 
events and the number of censored patients will also be presented. The stratified logrank test will 
be used to compare the time -to-event distributions betwee n the randomized treatment groups. In 
addition, the Cox proportional hazards model will be used to estimate the HR between the 
randomized treatment groups. 
The primary and key secondary endpoints will be tested among the tBRCA and all HRD 
subgroups, and al l randomized patients, using an ordered step- down multiple comparisons 
procedure. Investigator determined PFS (invPFS) in the tBRCA subgroup will be tested first at a 
one-sided 0.025 significance level. If invPFS in the tBRCA subgroup is statistically sign ificant , 
then invPFS will be tested in the all HRD subgroup followed by invPFS in all randomized 
patients. Continuing in an ordered step- down manner, the PRO  of disease symptoms utilizing the 
FOSI -18 DRS -P subscale will be tested at the one -sided 0.025 significance level in the tBRCA, 
all HRD, and all randomized patients subgroups and then for the remaining key secondary 
endpoints of PRO utilizing the FOSI- 18 total score and OS. Once statistical significance is not 
achieved for one test the statistical sign ificance will not be declared for all subsequent analyses 
in the ordered step -down procedure.  
PFS by IRR will be evaluated as a stand -alone secondary endpoint.  
All data will be used to their maximum possible extent but without any imputations for missing data.  
All statistical analyses will be conducted with the SAS
® System, v9.1 or higher.  
Unless otherwise specified, baseline is defined as the last measurement on or prior to the first day of study drug administration.  
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  78 
 11.2.2  Patient Disposition  
Patient disposition (analysis population allocation, entered, discontinued, along with primary 
reason for discontinuation) will be summarized using frequency counts, and the corresponding percentages.  
11.2.3  Baseline Characteristics  
All demographic and baseline characte ristics will be summarized for the safety population.  
The following variables will be summarized with frequency tabulations:  
• Time since diagnosis (months): > 12-24, > 24 
• Baseline laboratory par ameters: graded based on CTCAE  
• HRD status  for stratification at randomization: tBRCA,  nbHRD, biomarker 
negative 
• Interval between completion of penultimate platinum regimen and disease 
progression (6 to 12 months of >12 months) by radiologic assessment  
• Best response to most recent platinum- based regimen  (CR [defined as complete 
radiologic response by RECIST v1.1 with normalization of CA-125] or PR 
[defined as partial radiologic response by RECIST v1.1 and/or a GCIG CA-125 
response]). All responses require that CA -125 be <ULN. 
Descriptive statistics may also be used to summar ize the continuous variables.  
11.2.4  Efficacy Analyses  
All efficacy evaluations will be conducted using the ITT population. 
11.2.4.1 Primary Efficacy Analysis 
The primary efficacy endpoint for the study is invPFS by RECIST  v1.1. Investigator-determined 
PFS is defined as the time from randomization to disease progression, according to RECIST v1.1 
criteria ( Appendix B ), as assessed by the investigator, or death due to any cause, in molecularly 
defined subgroups . The stratification factors included in the primary analysis of invPFS will be 
as follows:  
• HRD c lassification ( tBRCA or nbHRD or biomarker negative) 
• Interval between completion of penultimate platinum regimen and disease progression (6 to 12 months or >12 months) by radiologic assessment  
• Best response to the most recent platinum- based regimen  (CR [de fined as 
complete radiologic response by RECIST v1.1 with normalization of CA-125] or PR [defined as partial response by RECIST v1.1 and/or a GCIG CA-125 response]). All responses required that CA-125 be <ULN. 
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  79 
 Tumor HRD status by the FCTA  will be determined after randomization, but before the final 
efficacy analysis, so that the prima ry endpoint (PFS in molecularly -defined HRD subgroups) can 
be assessed prospectively.  
11.2.4.2 Secondary Efficacy Analyses 
Secondary efficacy endpoints are: 
• Time to a 4 -point decrease i n the FOSI -18 DSR− P subscale  
• Time to an 8 -point decrease in the FOSI -18 total score  
• OS 
• PFS by RECIST v1.1 as assessed by IRR (irrPFS) 
PRO of disease- related symptoms as measured by the FOSI-18 DRS −P subscale  
The time to an event in PRO of worsening of disease symptoms will be defined as the time from 
randomization to a 4-point reduction in the FOSI-18 DRS -P subscale. Patients without a 4 -point 
reduction will be censored on the date of their last PRO evaluation.  
PRO as measured by the t otal score of the FOSI-18 
An event in worsening of PRO utilizing the complete FOSI- 18 instrument will be defined as the 
time from randomization to an 8 -point reduction in the total score.  Patients without an 8-point 
reduction will be censored on the date of their last PRO evaluation.  
Overall survival  
Overall survival (OS) is defined as the number of days from the date of randomization to the dat e 
of death (due to any cause) . Patients without a known date of death will be censored on the date 
the patient was last known to be alive.  
An interim OS was determined  at the time of the primary endpoint unblinding ( Section  11.3). 
The final OS  analysis will be performed at the time of the study close. See S ection  11.3 for 
further details.  
irrPFS PFS for secondary efficacy analysis is defined as the time from randomization to disease 
progression, according to RECIST v1.1 criteria as assessed by IRR, or death due to any cause, whichever occurs first.  
11.2.5  Safety Analyses  
Safety endpoints are incidence o f AEs, clinical laboratory abnormalities, and dose modifications.  
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  80 
 Data from all patients who receive at least one dose of study drug will be included in the safety 
analyses. AEs, clinical laboratory information, vital signs, ECG results, ECOG performance 
status, body weight, and concomitant medications/ procedures will be tabulated and summarized.  
11.2.5.1 Adverse Events  
AEs will be classified using the Medical Dictionary for Drug Regulatory Activities (MedDRA) 
classification system. The severity of the toxicities wi ll be graded according to the NCI -CTCAE 
whenever possible. Only treatment- emergent adverse events ( TEAEs ) will be collected: TEAEs 
are defined as AEs with onset date on or after the date of first dose of study medication until the date of the last study me dication dose plus 28 days.  
The number and percentage of patients who experienced TEAEs for each system organ class (SOC) and preferred term will be presented. Multiple  instances of the TEAE in each SOC and 
multiple occurrences of the same preferred term are counted only once per patient. The number and percentage of patients with at least one TEAE will also be summarized.  
Separate tables will be presented as follows:  
• All TEAEs  
• TEAEs by CTCAE gra de 
• Grade  3 or greater TEAEs  
• Serious TEAEs  
• TEAEs with an outcome of death  
• TEAEs leading to disc ontinuation of study medication  
• TEAEs resulting in inter ruption /delay  of study medication  
• TEAEs resulting in dose reduction of study medication  
If a patient experiences multiple occurrences of the same AE with different toxicity grades, the 
patient will be counted once for the maximum (most severe) toxicity grade. AEs with a missing toxicity grade will be presented in the summary table with a toxicity grade of “Missing.” For each toxicity grade, the number and percentage of patients with at least one TEAE of the given grade will be summarized.  
11.2.5.2 Clinical Laboratory Evaluations  
Clinical laboratory evaluations include the continuous variables for hema tology, serum 
chemistry, and urinalysis. The laboratory values will be presented in SI units. The on -treatment 
period will be defined as the time from the first dose of study drug to 28 days after the last dose 
of study drug. Laboratory values collected du ring the on- treatment period will be included in the 
summary tables. The laboratory values collected after the on- treatment period will only be 
presented in the data listings.  
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  81 
 The summary of laboratory data will include shift tables based on CTCAE for shi fts in grade 
from baseline to maximum, minimum and last value during the on -treatment period.   
Supporting laboratory data including normal ranges and abnormal laboratory flags will be 
provided using by- patient  listings. Separate listings will be produced for clinically significant 
laboratory abnormalities (i.e. those that meet Grade  3 or 4 criteria according to CTCAE).  
11.2.5.3 Vital Sign Measurements 
The on- treatment period will be defined as the time from the first dose of study drug to 28 days 
after the last dose  of study drug. Vital sign measurements collected during the on- treatment 
period will be included in the summary tables. The vital sign measurements collected after the on-treatment period will only be presented in the data listings.  
The summary of vital sign data will include descriptive statistics (N, mean, SD, minimum, median, third quartile and maximum) of the maximum, minimum and last value during the on -
treatment period. Summaries using descriptive statistics (N, mean, SD, minimum, median and maximum ) of the change from baseline to the maximum, minimum, and last value during the 
on-treatment period will also be given.  
11.2.6  Population  PK Analysis  
The PK endpoint is individual model parameter estimates of rucaparib a nd covariates 
identific ation.  
A specific population PK data analysis plan will be developed that will outline the detailed approach to data handling, model development and diagnostics, individual model parameter estimation, exploration of covariate effects, and final model evaluation tec hniques.  
11.2.7  Exploratory Analyses  
The endpoints for the exploratory analyses are:  
• Change from baseline in CA- 125 measurements by the central laboratory  
• PFS2 ( PFS on the subsequent line of treatment) defined as the time  from randomization  
to the second event of  disease progression or death, as assessed by the investigator  
• ORR per RECIST v1.1, as assessed by both the  investigator and IRR , in patients with 
measureable disease at study entry  
• DOR per RECIST v1.1, as assessed by both the  investigator  and IRR   
• PRO as measured by the EQ -5D total score  
• Rucaparib PK, invPFS, irrPFS, CA- 125, AEs, clinical laboratory abnormalities, and dose 
modifications  
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  82 
 11.2.7.1 Change from Baseline in CA -125 
Analyses of changes and/or percent changes from baseline will be analyzed for each scheduled 
post- baseline visit and for the final visit for the CA -125 measurements from the central 
laboratory. Patients that do not have both a baseline measurement and at least one post- baseline 
measurement will not be included.  
At a given visit, the change and/or percent change from baseline will be compared between the randomized treatment groups using an ANCOVA using the treatment as a categorical factor and baseline measurement for the parameter as a continuous covariate.  
The association between the change from baseline in CA -125 measurements and invPFS will be 
evaluated using a Cox proportional hazards model. A measure of CA -125 kinetics such as the 
rate of change from baseline in CA -125 may also be associated with invPFS using a Cox model. 
11.2.7.2 Progression F ree Survival 2 ( PFS2) 
The second event of PFS, PFS2, is defined as the time from randomization to the second event of disease progression as assessed by the investigator, or death due to any cause. The first event of disease progression will be captu red as the primary endpoint in this study and thus the second 
event will be the next event of disease progression as assessed by the investigator. This second event of PFS may be a documented event per RECIST guidelines or may be an event of symptomatic progression.  
11.2.7.3 Overall Response R ate 
ORR is defined as a best response of CR or PR using the RECIST v1.1 criteria ( Appendix B ), as 
assessed by both inves tigator and IRR, in patients with measurable disease at study entry. ORR 
will be summarized with frequencies and percent ages in the safety population.  
11.2.7.4 Duration of R esponse 
The DOR is measured from the time measurement criteria are met for CR/PR per RECIST v1.1 
criteria  (Appendix B ), as assessed by both the investigator and IRR, until the first date that 
recurrent or  progressive disease ( PD) is objectively documented. The DOR will be summarized 
with descriptive statistics. Only patients with a response will be included in the summary . 
11.2.7.5 Patient Reported O utcome EQ-5D 
Analyses of ch anges and/or percent changes from baseline will be analyzed for each scheduled 
post- baseline visit and for the final visit for the EQ -5D instrument. Patients that do not have both 
a baseline measurement and at least one post -baseline measurement will not be included. 
At a given visit, the change and/or percent change from baseline will be compared between the randomized treatment groups using an ANCOVA using the treatment as a categorical factor and baseline measurement for the parameter as a continuous covariate.  
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  83 
 11.2.7.6 Relationship between Rucaparib Exposure and Efficacy and Safety  
The primary endpoint of invPFS will be presented for subgroups of patients defined by levels of 
rucaparib exposure. These analyses are exploratory in nature so the definition of relevant subgroups may be data-driven.  
11.3 Interim Analysis  
No formal interim efficacy analyses will be performed.  
All endpoints were summarized at the time the primary endpoint (invPFS) was unblinded in April 2017; however, the following efficacy endpoints ar e still being collected and will be 
summarized at the time of the study closing:  
• Secondary Endpoint of Final OS  
• Post-progression exploratory endpoints (PFS2, time to first subsequent anticancer 
treatment, time to second subsequent anticancer treatment, an d chemotherapy- free interval)  
The OS  data were heavily censored at the time of the primary endpoint analysis. In order to 
adjust for multiple analyses of OS at a later stage, a stopping rule will be applied. The Haybittle-
Peto
55, 56 stopping rule will be applied, where an OS result with a p -value < 0.001 can be used to 
claim superiority of rucaparib compared to placebo. This means that a p -value < 0.05 can be 
utilized at the final analysis , which is projected to occur once 70% of the death events have been 
collected.  
11.4 Sample Size Cons iderations  
The total enrollment planned is 540 patients. A minimum of 1 80 and a maximum of 200 patients 
with a deleterious t BRCA mutation will be enrolled. Enrollment of patients with a known 
deleterious gBRCA mutation documented in their medical record will not exceed 150. There is 
no minimum number of patients required for each of the nbHRD and biomarker negative subgroups; however, no more than 360 total patients will be randomized for stratification into these subgroups combined. Prior to final efficacy analysis, HRD classif ication will be 
determined by the FCTA, which will evaluate homologous recombination gene mutations and/or 
extent of genomic scarring in tumor tissue.  
Table  4 below provides estimated sample sizes and power calculations.  
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  84 
 Table  4. Estimated Sample Sizes and Power Calculations  
Group  Hazard 
Ratio  Cumulative 
N  Minimum 
Number of 
Events 
(70%)  Median PFS 
Placebo vs 
Rucaparib 
(months)  Power  One-
sided 
Alpha  
BRCA HRD  0.50 180 126 6 vs 12  90% 0.025  
All HRD 
(BRCA + 
nbHRD)  0.60 300 210 6 vs 10  90% 0.025  
ITT Population  
(BRCA + 
nbHRD + 
Biomarker 
Negative)  0.70 540 378 6 vs 8.5  90% 0.025  
 
The study will end after 70% of the patients in the t BRCA subgroup have an observed event of 
investigator -determined disease progression or death. If the minimum number of t BRCA patients 
are enrolled , then the study will end following the 126th event of investigator -determined disease 
progression or death. Similarly, if the maximum number of t BRCA patients are enrolled , then the 
study will end following the 140th event of investigator -determined diseas e progression or death. 
The IDMC will inform the s ponsor when the required number of PFS events have been observed 
in order to ensure the sponsor remains blinded to which patients are in the t BRCA subgroup. If 
the nbHRD and/or biomarker negative subgroups have observed events of invPFS in fewer than 
60% of the patients, the IDMC may recommend that the study continue for up to 6 more months if it is likely that the nbHRD and biomarker negative subgroups will observe enough additional events of PFS to reach 60%.  
Following the collection of the required number of PFS events, the outstanding queries for all 
visits and events prior to the data cutoff date will be resolved and the database will be locked before the blind break and subsequent primary ana lysis.  
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  85 
 12 PATIENT DISPOSITION  
12.1 Removal of patients from therapy or assessment 
A patient must be discontinued from treatment with study drug if any of the following apply: 
• Consent withdrawal at the patient’s own request or at the request of their legally 
authorized representative 
• Progression of patient’s underlying disease  by RECIST v1.1 as assessed by the 
investigator 
• Any event, adverse or otherwise, that, in the opinion of the investigator, would pose an 
unacceptable safety risk to the patient  
• An intercurrent illness that, in the opinion of the investigator, would affect assessments of 
the clinical status to a significant degree and requires discontinuation of therapy  
• A positive pregnancy test at any time during the study. 
The sponsor may discontinue the trial early for any of the reasons noted in Section  13.7. 
12.2 Procedures for discontinuation  
The sponsor (or designee) should be notified of all study terminations as soon as possible. The 
date and reason for cessation of study drug must be documented in the eCRF and source documents. To the extent possible, end-of-study procedures should be performed on all patients who receive study drug. The Treatment Discontinuation  visit should occur 28 (±3) days 
following the last dose of study drug. Patients will be followed for 28 days after the last dose of study drug for safety; those with ongoing SAEs/ AESIs will be followed until either resolution or 
stabilization has been determined.  
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  86 
 13 STUDY ADMINISTRATION  
13.1 Regulatory and Ethical Considerations  
The study will be conducted in accordance with the protocol and applicable standard operating 
procedures (SOPs); and in compliance with applicable guidelines  and regulations.  
The investigator will assure that no amendments to the protocol will take place without prior agreement from the sponsor and documented approval from the IRB/IEC, and local health authority (whe re applicable), except where necessary to eliminate an immediate hazard(s) to the 
study participants.  
Significant noncompliance with the protocol, SOPs, Good Clinical Practice (GCP), and/or applicable regulatory requirement(s) by an investigator/institutio n, or by member(s) of the 
sponsor staff or its representatives will lead to prompt action by the sponsor to secure compliance. If monitoring and/or auditing identifies serious noncompliance on the part of an investigator/institution, the sponsor will take steps to secure compliance or terminate the investigator's/institution’s participation in the study. When an investigator's/institution’s participation is terminated because of significant noncompliance, the sponsor will promptly notify the regulatory authority(ies) and other appropriate parties (eg, IRB/IEC).  
All potential serious breaches of GCP must be reported to the sponsor or designee within 24 hours. A serious breach is a breach of the conditions and principles of GCP in connection with the study or the protocol, which is likely to affect, to a significant degree, the safety or physical or mental integrity of the participants of the study or the scientific value of the study.  
Personnel involved in conducting this study will be qualified by education, training, and experience to perform their respective tasks.  
This study will not use the services of study site personnel where sanctions have been invoked or 
where there has been scientific misconduct (eg, debarment).  
13.2 Regulatory Authority Approvals  
The sponsor or designee will submit the study protocol plus all relevant study documents to concerned regulatory agencies for approval prior to the study start. No patient will begin study- specific screening until appropriate regulatory approval of the study prot ocol has been 
received.  
Each investigator must complete a Form FDA 1572 (or equivalent, when participating in a US Investigational New Drug Application [IND] study). In addition, local statement of investigator documents must be provided where required. Ea ch investigator must submit to the sponsor (or 
designee) financial disclosure information for studies under a US IND or if required by national law and/or local regulations. 
The study will be registered on regionally -relevant registries, including www.clin icaltrials.gov , 
EU Clinical Trials Register, and other applicable trial registry sy stems as appropriate.  Data 
generated from this study must be handled in accordance with any laws, rules, and regulations 
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  87 
 related to the privacy of personal data or medical information applicable in the jurisdiction where 
the data is processed, including without limitation, the US  Health Information Portability and 
Accountability Act of 1996 (HIPAA), and its implementing regulations, and the European Union General Data Protection Regulation 2016/679
 (GDPR).  
13.2.1  Institutional Review Board or Independent Ethics Committee  Approval  
The p rotocol, all protocol amendments, and any material to be provided to the patient (such as 
the ICF, Patient Information Sheets (PIS), advertisements, drug dosing diaries, or descriptions of the study used to obtain informed consent) must be reviewed and approved by an IRB/IEC before study start, according to national law and/or local regulations. There must be proof of submission of the Investigator’s Brochure (IB) to the IRB/IEC. The sponsor will supply relevant information to the investigator to use for su bmission of the study protocol and additional study 
documents to the IRB/IEC. Verification of the IEC’s/IRB’s unconditional approval of the study protocol and the written ICF will be transmitted to Clovis Oncology by the investigator or by 
other means as d etermined between the investigator and the sponsor.  
No patient will begin study specific screening  until appropriate IEC/IRB approval of the study 
protocol  and ICF/PIS  have  been received  and the investigator has obtained the patient’s legally 
effective ICF .  
The investigator will submit appropriate reports on the progress of the study to the IEC/IRB at least annually in accordance with applicable national law and/or local regulations and in agreement with the policy established by the IEC/IRB.  
The IEC/IRB must be informed by the investigator of all SAEs or SUSARs occurring during the 
study that are likely to affect the safety of the patients or the conduct of the study, according to IRB/IEC policies.  
13.3 Patient Information and Informed Consent  
13.3.1  General Aspects of Informed Consent  
All information about the clinical study, including the patient information sheet and the ICF, is prepared and used for the protection of the human rights of the patient according to ICH GCP guidelines, the Declaration of Helsin ki, and local requirements. 
The ICF, prepared by the investigator with the assistance of the sponsor, must comply with all applicable regulations, be approved along with the study protocol by the IRB/IEC, and be acceptable to the sponsor.  
It is the respons ibility of the investigator to obtain legally effective informed consent from each 
patient participating in this study after adequate explanation of the aims, methods, objectives, and potential hazards of the study, answering all questions from the patient  regarding the study, 
and prior to undertaking any study- related procedures.  
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  88 
 13.3.2  Informed Consent Process  
The patient must be provided with the patient information, if applicable, and the most current 
IRB/IEC approved ICF. The investigator or their designee sh all discuss with each patient the 
nature of the study, its requirements, and that participation is voluntary and may be terminated at any time by the investigator or participant. To participate in the study, informed consent must be obtained from each pros pective patient prior to any protocol specific activities.  
The ICF must be in language fully comprehensible to the prospective patient  or legally 
authorized representative. Patients or legally authorized representatives (where acceptable according to nati onal law and/or local regulations) must be given sufficient time and opportunity 
to inquire about the details of the study and to discuss and decide on their participation in the study with the investigator. The patient or legally authorized representative and the person 
conducting the informed consent discussion for the study will personally sign and date the ICF in 
addition to any other required signatures (if applicable). A copy of the signed ICF will be 
provided to the patient or legally authorized repr esentative and the original will be filed in the 
investigator’s file. The process of obtaining informed consent will be documented in the patient’s source documents. The date when a patient’s informed consent was obtained will be captured in the patient’s source documents and eCRF. The patient or legally authorized representative will need to re -consent if the ICF is updated during the study, such as after an amendment to the 
protocol, if mandated by the IRB/IEC.  
13.3.3  Additional Informed Consent Documentation  
Patients providing an optional tumor tissue biopsy sample at the time of radiographic disease 
progression/treatment discontinuation must consent to this procedure. A separate consent form may be used for tissue testing.  
13.4 Patient Confidentiality  
The investiga tor must assure that patients’ anonymity is strictly maintained and that their 
identities are protected from unauthorized parties. Only patient initials and an identification  
code ( i.e., no names or, in some regions, initials or date of birth)  according to country 
regulations will be recorded on any form submitted to the sponsor and the IEC/ IRB. T he 
investigator must have a list where the identity of all treated patients can be found , but not 
intended for use by the sponsor . 
13.5 Study Monitoring  
The sponsor, or contract research organization (CRO) or contract monitor acting on the sponsor’s behalf, will contact or visit the investigator at the study center prior to the entry of the first patient (unless the sponsor or the CRO has worked with the cente r recently in the same or 
comparable indication, the site location and facilities have not changed significantly since after the last visit by the sponsor or CRO, and the potential investigator/site are currently in good standing with respect to regulatory compliance, in which case this initial visit may be waived) and at predetermined appropriate intervals during the study until after the last patient is completed. The monitor will also perform a study closure visit.  
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  89 
 In accordance with ICH GCP and local regulations, the clinical monitor will periodically review, 
via direct access, all eCRFs, study documents, medical records (office, clinic, or hospital) for patients in this study (anonymity is to be preserved), research facilities, and clinical laboratory facilities associated with the study at mutually convenient times until completion of the study. If 
these requirements are in conflict with local regulatory restrictions or institutional requirements, the investigator must inform the sponsor of these restrictions before initiation of the study. 
The investigator must ensure provision of sufficient time, reasonable space, and adequate 
qualified personnel for the monitoring visits. The visits are for the purpose of the monitor to verify adherence to the study protocol and the completeness, consistency, and accuracy of data recorded on the eCRF and other documents; however, the investigator retains ultimate responsibility for the quality and integrity of data generated by the site. Aspects of the study that are essential for human patient protection and safety and the reliability of study data shall be confirmed. The investigator will make all source data (ie, the various study records, laboratory test reports, other patient records, drug accountability forms, and other pertinent data) and eCRFs for the entire study period available to the monitor. Monitoring is done by comparing the relevant site records of the patients with the entries on the eCRF (ie, source data verification).  
By agreeing to participate in the  study, the investigator agrees to cooperate with the monitor to 
ensure that any issues detected in the course of the monitoring visits are resolved. Contact information for the study monitor is located in the investigator file.  
13.6 Case Report Form   
The data  will be collected using an electronic data capture (EDC) system by remote data entry on 
eCRFs. Sites will receive training on the EDC system. All users will be supplied with unique login credentials.  
Data collection is the responsibility of the clinical trial staff at the site under the supervision of the 
site investigator. The investigator is responsible for ensuring the accuracy, completeness, legibility, 
and timeliness of the data reported.  
All source documents should be completed in a neat, legible ma nner a ccording to the principles of 
Attributable, Legible, Contemporaneous, Original or Certified Copy, Accurate, and ‘Plus’ (+) Complete, Consistent, Enduring, and Available (ALCOA+), to ensure accurate interpretation of data. 
Data recorded in the eCRF should be consistent with the data recorded on the source documents.  
Prior to study start, the investigator will prepare a list showing the all individuals delegated 
responsibility on this study. This “study site personnel and delegation list” must be kept current throughout the study.  
Full information regarding electronic data capture and completing eCRFs is included in the investigator files. All questions or comments related to electronic capture should be directed to the assigned monitor.  
Data collection  will be decreased at the time of implementation of Protocol Amendment  5, as all 
endpoints except those associated with long- term follow up have been met and reported. As of 
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  90 
 the implementation of Protocol Amendment 5, the assessments required to be entered  into the 
study eCRFs/eCRF modules for patients are as follows:  
• Log Forms  
− Adverse Events (SAE/AESIs only)  
− Subsequent Anticancer Therapy (SAT)  
• TA_Scan  
• EOT  
• 28-Day Post  
• Long- Term Follow -Up 
• Death  
• PI_Sign  
Updated eCRF Completion Guidelines will be provided to the sites for further detail regarding 
what should be entered for patients that are ongoing on treatment or in long- term follow -up at the 
time Protocol Amendment  5 is implemented . 
13.7 Study Termination and Site Closure  
The sponsor, the investigator /institution, or IRB/IEC reserve the right to terminate the study at 
any time. Should this be necessary, the sponsor and investigator will arrange discontinuation procedures. In terminating the study, the sponsor and the investigator will assure that adequate consideration is given to the protection of the patients’ interests.  
The sponsor reserves the right to terminate the study at any time for medical or administrative reasons. When feasible, a 30 -day written notification will be given.  
The entire study w ill be stopped if any of the following applies:  
• The protocol -specified treatment is considered too toxic to continue the study;  
• Evidence has emerged that, in the opinion of the sponsor or the investigator(s), makes the 
continuation of the  study unnecessary or unethical ; 
• The stated objectives of the study are achieved ; or 
• The sponsor discontinues the development of oral rucaparib  
Regardless of the reason for termination, all data available for the patient at the time of 
discontinuation of follow -up must be r ecorded in source documents and on the eCRF. All 
reasons for discontinuation of treatment must be documented. 
If the study is terminated prematurely the sponsor will promptly inform the 
investigators/institutions, and the regulatory authority(ies) of the termination or suspension and the reason(s) for the termination or suspension. The investigators will promptly inform their 
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  91 
 IRB/IEC, providing the reason(s) for the termination or suspension by the sponsor or by the 
investigator/institution, as specified by the applicable regulatory requirement(s).  
13.8 Study Protocol Amendments  
Protocol amendments must be made only with the prior approval of Clovis Oncology. Agreement from the investigator must be obtained for all protocol modifications  and changes to 
the informed consent document. The IEC/IRB must be informed of all amendments a nd give 
approval prior to their implementation. The sponsor will submit any study protocol amendments to the applicable  regulatory authorities for approval and keep the investigator(s) updated as 
detailed in the ICH GCP guidelines. Management of protocol deviations is described in  
Section  13.10.1. 
13.9 Retention of Study Documents  
The study site will maintain a study file, which will contain all documents defined in the ICH E6(R2) Guideline for Good Clinical Practice. The investigator will have control of all essential documents generated by the site. Source documents must be maintained and ALCOA+ documentation practice used. Any changes to source data will be traceable, will not obscure the original entry, and will be explained if necessary  (via an audit trail). The investigator must 
implement procedures to ensure the integrity of any data generated.  
The sponsor and investigator will maintain a record of the location(s) of their respective essential 
documents including source documents. The storage systems used during the study and for archiving (irrespective of media used) must provide for documentation identification, version, history, search, and retrieval. The investigator agrees to keep records and those documents that include (but are not limited to) the identification of all participating patients, medical records, 
study specific source documents, all original signed and dated ICFs, copies of all eCRFs, query responses, and detailed records of drug disposition to enable inspections or audits from regulatory authorities, the IRB/IEC, and the sponsor or its designees. The investigator shall retain records and documents, including signed ICFs, pertaining to the conduct of the study for a period of 25 years after study completion or, if no application is to be filed or if the application is not approved for such indication, until at least 5 years after the investigation is discontinued. However, these documents will be retained for a longer period if required by the applicable regulatory requirement(s), institutional policies,  or if needed by Clovis Oncology. In addition, 
the investigator must make provision for the patients’ medical records to be kept for the same period of time.  
No data should be destroyed without the agreement of Clovis On cology. Copies of original 
documents will fulfill the ICH E6(R2) requirements for certified copies. Should the investigator 
wish to assign the study records to another party or move them to another location, Clovis Oncology must be notified in writing of the new responsible person and/or the new location. Clovis Oncology will inform the investigator, in writing, when the trial- related records are no 
longer needed. 
All clinical study information will be recorded, handled, and stored in a way that allows accurate 
reporting, interpretation, and verification, irrespective of the media used. 
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  92 
 Patients’ medical records and other original data will be archived in accordance with the 
archiving regulations or facilities of the investigational site ; but at a minimum, for the period 
defined by the applicable regulatory requirements . 
13.10 Quality Control and Assurance  
The sponsor will implement and maintain quality control and quality assurance procedures with written SOPs to ensure that the study is conducted, and data are generated, documented, and reported in compliance with the protocol, GCP, and applicable regulatory requirements.  
13.10.1  Protocol Deviations  
The investigator may not deviate from the protocol unless necessary to eliminate immediate 
hazards to the patient. A deviation may result in the patient having to be withdrawn from the 
study and rendering that patient’ s data nonevaluable. Any deviation must be documented in the 
source documents and reported to the sponsor and to the IRB/IEC according to institutional and 
sponsor requirements.  
13.10.2  Study Site Training  
Each investigator and the site personnel for this study w ill be trained by the sponsor and/or a 
designee (ie, a CRO) on GCP and on the design, conduct, procedures, and administrative aspects of this study. This training may include, but is not limited to, on- site training, Investigator 
Meeting(s), and/or tele/videoconferencing. Training may be ongoing as refresher, to address specific items, or to introduce changes in the study. When site staff join after study training has been conducted, the investigator is responsible for ensuring that the new staff member is trained.  
13.10.3  Quality Assurance Audits and Inspections  
An audit of a clinical center may be conducted by a quality assurance auditor appointed by the sponsor. The purpose of an audit, which is independent of and separate from routine monitoring or quality cont rol functions, is to evaluate study conduct and compliance with the protocol, 
SOPs, ICH GCPs, and the applicable regulatory requirements. The investigator will be informed if an audit is to take place and advised as to the scope of the audit. IRB/IEC repre sentatives may 
also conduct an audit of the study at any time.  
Representatives of the FDA, EMA, or other regulatory agencies may conduct an inspection of the study at any time. If informed of such an inspection, the investigator will notify the sponsor immediately.  
13.10.4  Direct Access to Source Data/Documents for Audits and Inspections  
The investigator will ensure that the auditors or inspectors have access to the clinical supplies, study site facilities, and laboratory, and that all data (including original source documentation) and all paper and electronic study files and audit trails are available, if requested. It is important that the investigator(s) and their staff cooperate with the quality assurance auditor or regulatory authority inspector during the audi t or inspection.  
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  93 
 13.11 Clinical Study Report 
A clinical study report (CSR)  will be prepared under the responsibility and supervision of Clovis 
Oncology and signed by the sponsor’s chief medical officer, head of biostatistics, and head of 
regulatory affairs; thereby indicating their agreement with the analyses, results, and conclusions 
of the clinical study report. The CSR will be provided to the clinical investigator(s) and regulatory agency(ies) as required by the applicable regulatory requirements. 
13.12 Study Public ation  and Disclosure Policy  
All information for the study provided by the sponsor or designee to the investigator, including, but not limited to, the IB, this protocol, eCRFs, the protocol- specified treatment, and any other 
study information, will remain the sole and exclusive property of the sponsor during the conduct of the study and thereafter. This information is not to be disclosed to any third party (except employees or agents directly involved in the conduct of the study or as required by law) without prior written consent from the sponsor. The investigator further agrees to take all reasonable precautions to prevent the disclosure by any employee or agent of the study center to any third party or otherwise into the public domain.  
All data generated f rom this study will be maintained by the sponsor. All data generated from 
this study, and all information furnished by the sponsor, the investigators, and other participating study groups shall be held in strict confidence. Independent analysis and/or publication of study data by the investigator(s) or any member of their staff are not permitted without the prior written consent of the sponsor. Any collaborative publications will be authored in accordance with the applicable guidelines (eg, International Committee of Medical Journal Editors [ICMJE]).
57 Written permission to the investigator will be co ntingent on the review of the 
statistical analysis and manuscript/abstract by the sponsor and participating cooperative groups, and will provide for nondisclosure of the confidential or proprietary information. In all cases, the parties agree to provide al l manuscripts or abstracts to all other parties 60 days prior to 
submission. This timeframe will enable all parties to protect proprietary information and to provide comments based on information that may not yet be available to other parties.  
13.13 Investigato r Oversight 
The investigator has full responsibility for supervising any individual or party to whom they delegate study -related duties and functions conducted at the study site, including satellite 
locations. The responsibility for supervision includes the services of any party or individual retained by the investigator for this purpose, regardless of location. All staff-delegated study responsibilities must be documented on an approved study site personnel and delegation log for the study and this log filed with the essential documents. In addition, the investigator must ensure that delegated staff are qualified by documented education, training, experience and licensure (as applicable). The investigator will implement procedures to ensure integrity of the  
study related duties, functions performed, and any data generated.  
Clovis Oncology, Inc.  Clinical Protocol CO-338-014 
Oral rucaparib (CO-338) 06 July 2020 
Amendment 5 94 
 14 REFERENCES  
1. Rubraca (rucaparib) tablets [prescribing info rmation]. Boulder, CO: Clovis Oncology, Inc.; 
2018. 
2. Clovis Oncology UK Ltd. RUBRACA (rucap arib) SmPC May 2018. Available from: 
http://www.ema.europa.eu/docs/ en_GB/document_library/EPAR_-
_Product_Information/human/004272/WC500249806.pdf. 
3. TCGA. Integrated genomic analyses of  ovarian carcinoma. Nature. 2011;474(7353):609-
15. 
4. Alsop K, Fereday S, Meldrum C, deFazio A,  Emmanuel C, George J, et al. BRCA mutation 
frequency and patterns of treatment respons e in BRCA mutation-positive women with 
ovarian cancer: a report from  the Australian Ovarian Cancer Study Group. J Clin Oncol. 
2012;30(21):2654-63. 
5. Pruthi S, Gostout BS, Lindor NM. Identifi cation and Management of Women With BRCA 
Mutations or Hereditary Predisposition for Breast and Ovarian Cancer. Mayo Clin Proc. 
2010;85(12):1111-20. 
6. Hennessy BTJ, Timms KM, Carey MS, Gutin A, Meyer LA, Flake DD, et al. Somatic 
Mutations in BRCA1 and BRCA2 Could Expand  the Number of Patients That Benefit 
From Poly (ADP Ribose) Polymerase Inhib itors in Ovarian Cancer. J Clin Oncol. 
2010;28(22):3570-6. 
7. Shinohara A, Ogawa H, Ogawa T. Rad51 protei n involved in repair and recombination in 
S. cerevisiae is a RecA-like protein. Cell. 1992;69(3):457-70. 
8. Kurumizaka H, Ikawa S, Nakada M, Eda K,  Kagawa W, Takata M, et al. Homologous-
pairing activity of th e human DNA-repair proteins Xr cc3.Rad51C. Proceedings of the 
National Academy of Sciences of the Un ited States of America. 2001;98(10):5538-43. 
9. Lisby M, Rothstein R, Mortensen UH. Rad52 forms DNA repair and recombination centers 
during S phase. Proceedings of the National Acad emy of Sciences of the United States of 
America. 2001;98(15):8276-82. 
10. Sigurdsson S, Van Komen S, Petukhova G,  Sung P. Homologous DNA pairing by human 
recombination factors Rad51 and Rad54. Th e Journal of biological chemistry. 
2002;277(45):42790-4. 
11. Yang YG, Herceg Z, Nakanishi K, Demuth I,  Piccoli C, Michelon J, et al. The Fanconi 
anemia group A protein m odulates homologous repair of DNA double-strand breaks in 
mammalian cells. Carcinoge nesis. 2005;26(10):1731-40. 
12. Niedzwiedz W, Mosedale G, Johnson M, O ng CY, Pace P, Patel KJ. The Fanconi anaemia 
gene FANCC promotes homologous  recombination and error-prone DNA repair. Mol Cell. 
2004;15(4):607-20. 
13. Ohashi A, Zdzienicka MZ, Chen J, Couch FJ. Fanconi anemia complementation group D2 
(FANCD2) functions independently of BRCA2- and RAD51-associated homologous 
recombination in response to DNA da mage. J Biol Chem. 2005;280(15):14877-83. 
14. Beucher A, Birraux J, Tchouandong L, Barton O,  Shibata A, Conrad S, et al. ATM and 
Artemis promote homologous recombinati on of radiation-induced DNA double-strand 
breaks in G2. The EMBO journal. 2009;28(21):3413-27. 
Clovis Oncology, Inc.  Clinical Protocol CO-338-014 
Oral rucaparib (CO-338) 06 July 2020 
Amendment 5 95 
 15. Chanoux RA, Yin B, Urtishak KA, Asare A, Bassing CH, Brown EJ. ATR and H2AX 
cooperate in maintaining ge nome stability under replicati on stress. The Journal of 
biological chemistr y. 2009;284(9):5994-6003. 
16. Sorensen CS, Hansen LT, Dziegielewski J, Sy ljuasen RG, Lundin C, Bartek J, et al. The 
cell-cycle checkpoint kinase Chk1 is required for mammal ian homologous recombination 
repair. Nature cell biology. 2005;7(2):195-201. 
17. Zhang J, Willers H, Feng Z, Ghosh JC, Kim S, Weaver DT, et al. Chk2 Phosphorylation of 
BRCA1 Regulates DNA Double-Strand Break Re pair. Molecular and Cellular Biology. 
2003;24(2):708-18. 
18. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing 
of BRCA2-deficient tumours w ith inhibitors of poly(ADP-ri bose) polymerase. Nature. 
2005;434(7035):913-7. 
19. Farmer H, McCabe N, Lord CJ, Tutt AN, J ohnson DA, Richardson TB, et al. Targeting the 
DNA repair defect in BRCA mutant cells  as a therapeutic strategy. Nature. 
2005;434(7035):917-21. 
20. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of 
poly(ADP-ribose) polymerase in  tumors from BRCA mutation carriers. N Engl J Med. 
2009;361(2):123-34. 
21. Audeh MW, Carmichael J, Penson RT, Friedlan der M, Powell B, Bell-McGuinn KM, et al. 
Oral poly(ADP-ribose) polymeras e inhibitor olaparib in pa tients with BRCA1 or BRCA2 
mutations and recurrent ovarian cance r: a proof-of-concept trial. Lancet. 
2010;376(9737):245-51. 
22. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, et al. Oral 
poly(ADP-ribose) polymerase i nhibitor olaparib in pa tients with BRCA1 or BRCA2 
mutations and advanced breast cancer:  a proof-of-concept trial. Lancet. 
2010;376(9737):235-44. 
23. Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, et al. 
Olaparib in patients with r ecurrent high-grade serous or poorly differentiated ovarian 
carcinoma or triple-negative breast cancer : a phase 2, multicentre, open-label, non-
randomised study. Lancet Oncol. 2011;12(9):852-61. 
24. Kaye SB, Lubinski J, Matulonis U, Ang JE, Gourley C, Karlan BY, et al. Phase II, Open-
Label, Randomized, Multicente r Study Comparing the Efficacy and Safety of Olaparib, a 
Poly (ADP-Ribose) Polymerase Inhibitor,  and Pegylated Liposomal Doxorubicin in 
Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer. J Clin Oncol. 
2012;30(4):372-9. 
25. Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, et al. The 
poly(ADP-ribose) polymerase inhibitor nira parib (MK4827) in BRC A mutation carriers 
and patients with sporadic cancer: a phas e 1 dose-escalation tria l. Lancet Oncol. 
2013;14(9):882-92. 
26. De Bono JS, Mina LA, Gonzalez M, Curtin NJ, Wang E, Henshaw JW, et al. First-in-
human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors. J Clin 
Oncol. 2013;31 (suppl; abstr 2580). 
Clovis Oncology, Inc.  Clinical Protocol CO-338-014 
Oral rucaparib (CO-338) 06 July 2020 
Amendment 5 96 
 27. McCabe N, Turner NC, Lord CJ, Kluzek K, Bi alkowska A, Swift S, et al. Deficiency in the 
repair of DNA damage by homologous recomb ination and sensitivity to poly(ADP-ribose) 
polymerase inhibition. Can cer Res. 2006;66(16):8109-15. 
28. Murai J, Huang SY, Das BB, Renaud A, Zha ng Y, Doroshow JH, et al. Trapping of PARP1 
and PARP2 by Clinical PARP Inhib itors. Cancer Res. 2012;72(21):5588-99. 
29. Min A, Im SA, Yoon YK, Song SH, Nam HJ, Hur HS, et al. RAD51C-Deficient Cancer 
Cells Are Highly Sensitive to the PARP Inhibitor Olaparib. Mol Cancer Ther. 
2013;12(6):865-77. 
30. Gottipati P, Vischioni B, Schultz N, Solom ons J, Bryant HE, Djureinovic T, et al. 
Poly(ADP-ribose) polymerase is hyperactivated  in homologous recombination-defective 
cells. Cancer Res. 2010;70(13):5389-98. 
31. Ledermann J, Harter P, Gourle y C, Friedlander M, Vergote I,  Rustin G, et al. Olaparib 
Maintenance Therapy in Platinum-Sensitive  Relapsed Ovarian Cancer. N Engl J Med. 
2012. 
32. Ledermann J, Harter P, Gourle y C, Friedlander M, Vergote I, Rustin GJS, et al. Olaparib 
maintenance therapy in patients with plati num-sensitive relapsed serous ovarian cancer 
(SOC) and a BRCA mutation (BRCAm). J C lin Oncol. 2013:31(15_suppl):abstract 5505. 
33. Eisenhauer EA, Therasse P, Bogaerts J, Sc hwartz LH, Sargent D, Ford R, et al. New 
response evaluation criteria in solid tumour s: Revised RECIST guideline (version 1.1). 
European Journal of Ca ncer. 2009;45(2):228-47. 
34. Rustin GJS, Vergote I, Eisenhauer E, Puja de-Lauraine E, Quinn M, Thigpen T, et al. 
Definitions for Response and Pr ogression in Ovarian Cancer C linical Trials Incorporating 
RECIST 1.1 and CA 125 Agreed by the Gyn ecological Cancer Intergroup (GCIG). Int J 
Gynecol Cancer. 2011;21(2):419-23. 
35. Abkevich V, Timms KM, Hennessy BT, Potter J, Carey MS, Meyer LA, et al. Patterns of 
genomic loss of heterozygosity  predict homologous recomb ination repair defects in 
epithelial ovarian cancer. Br J Cancer. 2012;107(10):1776-82. 
36. Birkbak NJ, Wang ZC, Kim JY, Eklund AC, Li  Q, Tian R, et al . Telomeric allelic 
imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer 
Discovery. 2012;2(4):366-75. 
37. Popova T, Manie E, Rieunier G, Caux-Moncoutie r V, Tirapo C, Dubois T, et al. Ploidy and 
Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with 
BRCA1/2 Inactivation. Cancer Research. 2012;72(21):5454-62. 
38. Wang ZC, Birkbak NJ, Culhane AC, Drapkin R,  Fatima A, Tian R, et al. Profiles of 
genomic instability in high-grade serous ova rian cancer predict treatment outcome. Clin 
Cancer Res. 2012;18(20):5806-15. 
39. US Cancer Statistics Working Group. United States Cancer Statistics: 1999–2009 
Incidence and Mortality Web-based Report: At lanta (GA): Department of Health and 
Human Services, Centers for Disease Cont rol and Prevention, and National Cancer 
Institute; 2013. Available from: http://www.cdc.gov/uscs. 
40. Morgan RJ, Jr., Alvarez RD, Armstrong DK, Boston B, Burger RA, Chen LM, et al. 
NCCN Clinical Practice Guidelines in Onco logy: epithelial ovaria n cancer. J Natl Compr 
Canc Netw. 2011;9(1):82-113. 
Clovis Oncology, Inc.  Clinical Protocol CO-338-014 
Oral rucaparib (CO-338) 06 July 2020 
Amendment 5 97 
 41. Cannistra SA. Cancer of the ova ry. N Engl J Med. 2004;351(24):2519-29. 
42. Salvador S, Rempel A, Soslow RA, Gilk s B, Huntsman D, Miller D. Chromosomal 
instability in fallopian tube  precursor lesions of ser ous carcinoma and frequent 
monoclonality of synchronous ovarian and fa llopian tube mucosal serous carcinoma. 
Gynecol Oncol. 2008;110(3):408-17. 
43. Levanon K, Crum C, Drapkin R. New insights into the pathogenesis of serous ovarian 
cancer and its clinical impact. J Clin Oncol. 2008;26(32):5284-93. 
44. Flesken-Nikitin A, Hwang CI, Cheng CY, Michurina TV, Enikolopov G, Nikitin AY. 
Ovarian surface epithelium at the junction ar ea contains a cancer-prone stem cell niche. 
Nature. 2013;495(7440):241-5. 
45. Reed E, Dabholkar M, Chabner BA. Pla tinum Analogues. In: Chabner BA, Longo DL, 
editors. Cancer Chemotherapy and Biotherapy. Philadelphia: Lippincot t-Raven Publishers; 
1996. p. 357-78. 
46. Parkinson CA, Brenton JD. Predictive Biol ogy of Ovarian Cancer. In: Kehoe S, editor. 
Gynaecological Cancers: Biology and Therapeutics. London: RCOG; 2011. p. 41-54. 
47. Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, et al. OCEANS: 
a randomized, double-blind, placebo-controlled ph ase III trial of chemotherapy with or 
without bevacizumab in patient s with platinum-sensitive r ecurrent epithelial ovarian, 
primary peritoneal, or fallopian tube  cancer. J Clin Oncol. 2012;30(17):2039-45. 
48. Burger RA, Brady MF, Bookman MA, Fl eming GF, Monk BJ, Huang H, et al. 
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer. N Engl J Med. 
2011;365(26):2473-83. 
49. Perren TJ, Swart AM, Pfisterer J, Ledermann JA , Pujade-Lauraine E, Kristensen G, et al. A 
phase 3 trial of bevacizumab in ovarian  cancer. N Engl J Med. 2011;365(26):2484-96. 
50. US Department of Health andHuman Se rvices, Food and Drug Administration, CDER. 
Draft Guidance for Industry: Drug Interacti on Studies - Study Design, Data Analysis, 
Implications for Dosing, and Labeling Recommendations Febr uary 2012. Available from: 
https://www.xenotech.com/regulator y-documents/2012/2012_guidance.aspx. 
51. Fahmi OA, Hurst S, Plowchalk D, Cook J, Guo F, Youdim K, et al. Comparison of 
different algorithms for predicting clinical drug-drug interactions, based on the use of 
CYP3A4 in vitro data: predictions of compounds  as precipitants of interaction. Drug Metab 
Dispos. 2009;37(8):1658-66. 
52. US Department of Health and Human Se rvices, Food and Drug Administration, CDER, 
CBER. Guidance for Industry: Drug-Induced Liver Injury: Premarketing Clinical Evaluation 2009 [15 December 2014]. Available from: http://www.fda.gov/downloads/Drugs/.../Guidances/UCM174090.pdf. 
53. Kalia SS, Adelman K, Bale SJ, Chung WK, Eng C, Evans JP, et al. Recommendations for 
reporting of secondary findi ngs in clinical exome a nd genome sequencing, 2016 update 
(ACMG SF v2.0): a policy statement of the Am erican College of Medical Genetics and 
Genomics. Genetics in Me dicine. 2017;19(2):249-55. 
54. National Cancer Institute. Common Terminol ogy Criteria fo r Adverse Events, Version 4.03 
14 June 2010 [cited 19 Novemb er 2014]. Available from: 
http://www.eortc.be/services/doc/ctc /CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. 
Clovis Oncology, Inc.  Clinical Protocol CO-338-014 
Oral rucaparib (CO-338) 06 July 2020 
Amendment 5 98 
 55. Haybittle JL. Repeated assessment of results in clinical trials of  cancer treatment. Br J 
Radiol. 1971;44(526):793-7. 
56. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and 
analysis of randomized clinical  trials requiring prolonged obser vation of each patient. I. 
Introduction and design. British jour nal of cancer. 1976;34(6):585-612. 
57. International Committee of Medical Journa l Editors. Recommendations for the Conduct, 
Reporting, Editing, and Publication of Scholarly  Work in Medical Journals December 
2017. Available from: http:// www.icmje.org/reco mmendations/. 
 
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  99 
 15 APPENDICES  
Appendix A. List of Homologous Recombination Genes for HRD Stratification  by the  ICTA  
Appendix B. Response Evaluation Criteria in Solid Tumors Criteria  
Appendix C. Gynecological Cancer Intergroup (GCIG) Guidelines   
Appendix D. Eastern Cooperative Oncology Group (ECOG) Performance Status Scale  
Appendix E. Quality of Life Questionnaires  
Appendix F. Examples of CYP Substrates with Narrow Therapeutic Range  
  
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  100 
 15.1 Appendix A 
List of Homologous Recombination Genes for HRD Stratification  by the ICTA  
tBRCA  nbHRD  Biomarker -negative  
BRCA1  
BRCA2  ATM  
ATR  
ATRX  
BARD1  
BLM  
BRIP1  
CHEK1  
CHEK2  
FANCA  
FANCC  
FANCD2  
FANCE  
FANCF  
FANCG  FANCI  
FANCL  
FANCM  
MRE11A  
NBN  
PALB2  
RAD50  
RAD51  
RAD51B  
RAD51C  
RAD51D  
RAD52  
RAD54L  
RPA1  Genes not included in 
the tBRCA or nbHRD 
groups  
 
  
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  101 
 15.2 Appendix B 
Response Evaluation Criteria in Solid Tumors Criteria  
The RECIST guidelines (v1.1) are described in Eisenhauer (2009)33 and at 
http://www.eortc.be/Recist/Default.htm. A short summary is given below.  
Measurable Disease:  
Tumor lesions: measurable lesions are defined as those that can be accurately measured in at 
least one dimension (longest diameter to be recorded) with the following: 
• A minimum size of 10 mm by CT scan (CT scan thickness no greater than 5 mm). 
• A minimum size of 10 mm caliper measurement by clinical exam (lesions that cannot be 
accurately measured with calipers should be recorded as nonmeasurable).  
• A minimum size of 20 mm by chest X -ray. 
All tumor measurements must be recorded n millimeters (or decimal fractions of centimeters).  
Malignant lymph nodes: to be considered pathologically enlarged and measurable, a lymph node 
must be ≥15 mm in short axis when assessed by CT scan (CT scan slice thickness recommended 
to be not greater than 5 mm). At baseline and in follow -up, only the short axis will be measured 
and followed.  
Nonmeasurable Disease:  
All other lesions (or sites of disease), including small lesions (longest diameter <  10 mm or 
pathological lymph nodes with ≥ 10 to <15 mm short axis), as well as truly nonmeasurable 
lesions, are considered nonmeasurable disease. Lesions considered truly nonmeasurable include 
leptomeningeal disease, ascites, pleural/pericardial effusions, inflammatory breast disease, lymphangitic involvement of skin and lung, and abdominal masses/abdominal organomegaly identified by physical exam that is not measurable by reproducible imaging techniques.  
Bone Le sions  
Bone lesions, cystic lesion, and lesions previously treated with local therapy require particular 
comment. Bone scan, PET scan, or plain films are not considered adequate imaging techniques to measure bone lesions. However, these techniques can be us ed to confirm the presence or 
disappearance of bone lesions.  
Lytic bone lesions or mixed lytic–blastic lesions with identifiable soft tissue components that can be evaluated by cross- sectional imaging techniques such as CT or MRI can be considered as 
measurable lesions if the soft tissue component meets the definition of measurability described above. 
Blastic bone lesions are nonmeasurable.  
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  102 
 Cystic Lesions 
Lesions that meet the criteria for radiographically defined simple cysts should not be considered 
as ma lignant lesions (neither measurable nor nonmeasurable) because they are, by definition, 
simple cysts.  
Cystic lesions thought to represent cystic metastases can be considered as measurable lesions if they meet the definition of measurability described above . However, if noncystic lesions are 
present in the same patient, these are preferred as target lesions.  
Lesions with Prior Local Treatment  
Tumor lesions situated in a previous irradiated area or in an area subjected to other locoregional therapy are usuall y not considered measurable unless there has been demonstrated progression in 
the lesion.  
Target Lesions 
All measurable lesions up to a maximum of two lesions per organ and five lesions in total, 
representative of all involved organs, should be identified as target lesions and recorded and measured at baseline. Target lesions should be selected on the basis of their size (lesions with the longest diameter) and their suitability for accurate repeated measurements (either by imaging techniques or clinically).  A sum of the longest diameter (LD) for all target lesions will be 
calculated and reported as the baseline sum LD. The baseline sum LD will be used as reference by which to characterize the objective tumor response.  
Non target Lesions 
RECIST criteria requ ire unequivocal quantification of the changes in tumor size for adequate 
interpretation of the sum of target lesions. Consequently, when the boundaries of the primary are difficult to delineate, this tumor should not be considered a target lesion.  
Guidelin es for Evaluation of Measurable Disease  
The same method of assessment and the same technique should be used to characterize each 
identified and reported lesion at baseline and during follow -up. Imaging- based evaluation is 
preferred to evaluation by clinica l examination when both methods have been used to assess the 
antitumor effect of a treatment.  
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  103 
 Evaluation of Target Lesions  
Complete Response  Disappearance of all target lesions. Any pathological lymph nodes 
(whether target or nontarget) must have reduction in short axis to <10 
mm. 
Partial Response At least a 30% decrease in the sum of the LD of target lesions, taking as 
reference the baseline sum LD.  
Stable Disease Neither sufficient shrinkage to qualify for partial response nor sufficient 
increase to qualify for progressive disease ( PD), taking as reference the 
smallest sum LD since the treatment started.  
Progressive Disease  At least a 20% increase in the sum of th e LD of target lesions, taking as 
reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, 
the sum must also demonstrate an absolute increase of at least 5 mm. 
The appearance of one or more new lesions is also considered progression.
 
Evaluation of Nontarget Lesions  
Complete Response  Disappearance of all nontarget lesions and normalization of tumor marker level.  
Stable Disease/Incomplete 
Response  Persistence of one or more nontarget lesion(s) or/and maintenance of tumor marker level above the normal limits.
 
Progressive Disease  Appearance of one or more new lesions and/or unequivocal progression of existing nontarget lesions.  
If tumor markers are initially above the institutional ULN, they must normalize for a patient to 
be considered a complete responder.  
Evaluation of Best Overall Response  
The best overall response is the best response recorded from the start of the treatment until disease progr ession/recurrence (taking as reference for PD the smallest measurements recorded 
since the treatment started). The patient’s best response assignment will depend on the achievement of both measurement and confirmation criteria.  
Evaluation of Best Overall Response  
Target Lesions  Nontarget Lesions  New Lesions  Overall Response  
CR CR No CR 
CR Non-CR/non -PD No PR 
CR Not evaluated  No PR 
PR Non-PD or not 
evaluated  No PR 
SD Non-PD or not 
evaluated  No SD 
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  104 
 Evaluation of Best Overall Response  
Target Lesions Nontarget Lesions  New Lesions  Overall Response 
Not Evaluated  Non-PD No NE 
PD Any Yes or No  PD 
Any PD Yes or No  PD 
Any Any Yes PD 
NE = Not evaluable.  
Patients with a global deterioration of health status requiring discontinuation of treatment 
without objective evidence of disease progression at that time should be classified as hav ing 
symptomatic deterioration. Every effort should be made to document the objective progression, even after discontinuation of treatment.  
In some circumstances, it may be difficult to distinguish residual disease from normal tissue. When the evaluation of  complete response ( CR) depends on this determination, it is 
recommended that the residual lesion be investigated (fine needle aspiration/biopsy) prior to confirming the CR status.  
Confirmatory Measurement/Duration of Response 
Confirmation  
CT scans are req uired at screening and at the end of every 3rd cycle of treatment . 
Duration of Overall Response  
The duration of overall response is measured from the time measurement criteria are met for CR 
or PR (whichever is first recorded) until the first date that recurrent or PD is objectively documented (taking as reference for PD the smallest measurements recorded since the treatment started).  
The duration of overall CR is measured from the time measurement criteria are first met for CR until the first date that recurrent disease is objectively documented.  
Duration of Stable Disease  
SD is measured from the start of the treatment until the criteria for progression are met, taking as reference the smallest measurements recorded since the treatment started.  
 
 
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  105 
 15.3 Appendi x C 
Modified Gynecological Cancer Intergroup (GCIG) Guidelines  
GCIG Guide lines for Response Using CA -12534 (adapted for use in this trial)  
GCIG CA- 125 definitions are available at http://gcig.igcs.org/CA-125.html.  
To be evaluable for response by CA-125 requires at least one pre-treatment sample  >2 x ULN  
and two post-treatment samples confirming a response 
A response to CA- 125 has occurred if there is at least a 50% decrease as the result of the 
treatment. The pre  / post treatment samples must satisfy the following criteria:  
1. There must be at least one sample that is  >2 x ULN  prior to initiation of treatment  
2. The second sample (post- treatment) must be ≤ 50% of the pre -treatment sample;  
3. The confirmatory third  sample must  be ≥21 days after the second sample  and ≤ 110% of 
the second sample; 
4. Any intervening samples between samples 2 and 3 must be ≤  110% of the previous 
sample unless considered to be increasing because of tumor lysis. 
Per inclusion criteria #5, CA -125 must =be <ULN prior to study entry. This requirement applies 
to all patients, including those who achieved a best response of PR by serologic CA-125 
response criteria. Thus, patients must have achieved a >50% reduction in CA-125 level and also 
have CA-125 <ULN. 
Patients are not evaluable by CA -125 if they have received mouse antibodies or if there has been 
medical or surgical interference with their peritoneum or pleura during the previous 28  days.  
  
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  106 
 15.4 Appendix D 
Eastern Cooperative Oncology Group (ECOG) Performance Status Scale  
ECOG Performance Status  
0 Fully active, able to carry on all predisease performance without restriction.  
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a 
light or sedentary nature ( eg, light house work or office work).  
2 Ambulatory and capable of all self care but unable to carry out any work activities. Up and 
about more than 50% of waking hours . 
3 Capable of only limited self care; confined to bed or chair more than 50% of waking  hours . 
4 Completely disabled. Cannot carry on any self care. Totally confined to bed or chair.  
5 Dead.  
 
In the event performance status is assessed by the Karnofsky Performance Status scale, the 
following conversion chart applies.  
Karnofsky Performance Status  ECOG Performance 
Status  
General Description  Score  Specific Description  Score  
Able to carry on 
normal activity and to 
work; no special care 
needed  100 Normal; no complaints; no 
evidence of disease  0 
90 Able to carry on normal activity; 
minor signs or symptoms of disease  1 
80 Normal activity with effort; 
some signs or symptoms of disease  
Unable to work; able 
to live at home and 
care for most personal 
needs; varying 
amount of assistance 
needed  70 Cares for self, unable to carry on 
normal activity or to do active 
work  2 
60 Requires occasional assistance, 
but is able to care for most of personal needs 
50 Requires considerable assistance 
and frequent medical care 3 
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  107 
 Karnofsky Performance Status  ECOG Performance 
Status  
General Description  Score  Specific Description  Score  
Unable to care for 
self; requires 
equivalent of 
institutional or 
hospital care; disease 
may be progressing 
rapidly  40 Disabled; requires special care 
and assistance 
30 Severely disabled; hospital 
admission is indicated although 
death not  imminent 4 
20 Very sick; hospital admission 
necessary; active supportive 
treatment necessary  
10 Moribund; fatal processes 
progressing rapidly  
0 Dead  5 
 
  
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  108 
 15.5 Appendix E  
National Comprehensive Cancer Network – Functional Assessment of Cancer Therapy 
(NCCN- FACT) FACT - Ovarian  Symptom Index ( FOSI -18) instrument (NCCN -FACT 
FOSI -18) – English Version  
Sample form and background available at:  http://www.facit.org/FACITOrg/Questionnaires .  
Patients will complete the instrument on an electronic device. This device is a Class 1 listed ( i.e., 
approved) device.  
Below is a list of statements that other people with your illness have said are important.  
Please circle or mark one number per line to indicate your response as it applies to  
the past 7 days. 
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  109 
   
 Not at 
all A little 
bit Some -
what  Quite  
a bit  Very 
much  
       GP1 I have a lack of energy
 ................................ ................................ .....  0 1 2 3 4 
GP4 I have pain
 ................................ ................................ .....  0 1 2 3 4 
GP6 I feel ill
 ................................ ................................ .....  0 1 2 3 4 
O3 I have cramps in my stomach area
 ................................ ................................ .....  0 1 2 3 4 
HI7 I feel fatigued
 ................................ ................................ .....  0 1 2 3 4 
Cx6 I am bothered by constipation
 ................................ ................................ .....  0 1 2 3 4 
O1 I have swelling in my stomach area
 ................................ ................................ .....  0 1 2 3 4 
C3 I have control of my bowels
 ................................ ................................ .....  0 1 2 3 4 
GF5 I am sleeping well
 ................................ ................................ .....  0 1 2 3 4 
GE6 I worry that my condition will get worse
 ................................ ................................ .....  0 1 2 3 4 
GP2 I have nausea
 ................................ ................................ .....  0 1 2 3 4 
B5 I am bothered by hair loss
 ................................ ................................ .....  0 1 2 3 4 
GP5 I am bothered by side effects of treatment
 ................................ ................................ .....  0 1 2 3 4 
O2 I have been vomiting
 ................................ ................................ .....  0 1 2 3 4 
BMT15  I am bothered by skin problems
 ................................ ................................ .....  0 1 2 3 4 
BMT5  I am able to get around by myself
 ................................ ................................ .....  0 1 2 3 4 
GF3 I am able to enjoy life
 ................................ ................................ .....  0 1 2 3 4 D
R
S-
P 
T
S
E 
F 
W 
B D
R
S-
E 
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  110 
 GF7 I am content with the quality of my life 
right now
 ................................ ................................ .....   
0  
1  
2  
3  
4 
 
Euro -QoL5D (EQ -5D) – English Version for the US  
By placing a checkmark in one box in each group below, please indicate which statements best 
describe your own health state today.  
Mobility  
I have no problems in walking about    
I have some problems in walking about    
I am confined to bed   
Self-Care  
I have no problems with self -care   
I have some problems washing or dressing myself    
I am unable to wash or dress myself    
Usual Activities ( e.g. work, study, housework, family or  leisure activities)  
I have no problems with performing my usual activities    
I have some problems with performing my usual activities    
I am unable to perform my usual activities    
Pain/Discomfort  
I have no pain or discomfort    
I have moderate pain or discomfort    
I have extreme pain or discomfort    
Anxiety/Depression  
I am not anxious or depressed   
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  111 
 I am moderately anxious or depressed   
I am extremely anxious or depressed   
 
Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  112 
   

Clovis Oncology, Inc.   Clinical Protocol  CO-338-014 
Oral rucaparib (CO -338) 06 July 2020  
Amendment 5  113 
 15.6 Appendix F 
Examples of CYP Substrates with Narrow Therapeutic Range  
CYP Enzyme  Substrates with Narrow Therapeutic Rangea 
CYP1A2  Tizanidine, theophylline  
CYP2C9 Warfarin, phenytoin  
CYP3A  Alfentanil, astemizole, cisapride, cyclosporine, dihydroergotamine, 
ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, terfenadine 
The table is based on the Draft FDA Guidance on Drug Interaction Studies — Study Design, Data Analysis, 
Implications for Dosing, and Labeling Recommendations, 2012.50  
a CYP substrates with narrow therapeutic range refers to drugs whose exposure -response relationship indicates that 
small increases in their exposure levels by the concomitant use of CYP inhibitors may lead to serious safety 
concerns (eg, Torsades de Pointes).  